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Abstract
Biophysical tools are becoming more useful in approaching human genetic
disease. The pathogenic mechanisms behind many disorders have been attributed to protein loss of function or gain in toxic function. For example,
changes in the protein Adenylosuccinate Lyase (ADSL) lead to ADSL deficiency, a disorder that causes symptoms ranging from epilepsy to expression
of autistic features. Biophysics offers different tools to study intrinsic properties of proteins. We have applied such tools to study the enzyme kinetics and
protein stability of ADSL and two mutations (R426H and R303C) to formulate
better hypotheses regarding the pathogenic mechanism. Enzyme kinetic findings indicate a) non-linear dependences of the activities on the substrate ratios
due to competitive binding and b) distinct differences in the behaviors of the
different mutations. Preliminary stability measurements indicate a) there is
an intermediate state in the folding pathway and a fourth state is necessary for
modeling, b) R426H, a mutation that causes severe phenotypes, is less stable,
c) there is no evidence of a gain in toxic function for either mutation. This
complete work supports our hypothesis that there are multiple mechanisms of
pathogenesis of ADSL deficiency including instability of the functional ADSL
tetramer, aggregation of ADSL, or diminution of enzyme activity. The signif-
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icance of this is that development of an effective therapy may depend upon
which mechanism is active in a particular patient.
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Chapter 1
Introduction
1.1

ADSL Deficiency

All living organisms either make purines themselves via the de novo purine
biosynthesis pathway (Figure 1.1) or obtain them from their environment.
Purines are vital components of all living cells, fulfilling a wide range of diverse biological functions. They are the building blocks of DNA and RNA, the
basic elements of the cell programming machinery [40]. In addition they fulfill a
variety of functions in the metabolism of the cell, of which the most important
are regulation of cell metabolism and function, energy conservation and transport, intracellular signaling and regulation of gene transcription, formation
of coenzymes and of active intermediates of phospholipid and carbohydrate
metabolism [40, 85]. Purine metabolism is highly conserved, especially from
yeast to mammalian species. This is likely due to the fact purine metabolism
is the first known metabolic pathway to develop (Figure 1.1). It is believed the
pathway was developed so early because prebiotic chemistry was insufficient to
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keep up with the early demand for purines. Evolution of the pathway required
the recruitment of multifunctional enzymes that are closely related in their
folding structure [14]. The recruitment for the purine biosynthesis pathway
was the first completed pathway that interestingly has not furthered evolved
(see Figure 1.1), further depicting the importance of completing the pathway
as soon as possible for life to progress.

Figure 1.1: Purine pathway

Because of the critical nature of purine metabolism, disturbances within
the pathway lead to human inborn errors of metabolism (A recent summary
of these can be found in Knox et al [45]). For example, point mutations of the
protein Adenylosuccinate Lyase (ADSL), an enzyme involved in two steps of
the de novo purine biosynthesis pathway and the purine nucleotide cycle, lead
to ADSL deficiency, an autosomal recessive disorder first reported in 1984 [36].
Since then many other patients in different ethnic groups have been detected
with this disorder characterized by a spectrum of neurological and physio-
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Figure 1.2: Metabolism evolution

logical symptoms such as psychomotor retardation, epilepsy, and expression
of autistic features such as lack of eye contact, language and aggressive attitude [17]. Other phenotypes also include axial hypotonia, peripheral hypertonicity, ataxia, muscle wasting, growth retardation and strabismus [30,58,78].
One of these phenotypes, expression of autistic features, raises interest because
it is estimated to affect more than 1 in 200 individuals in the United States.
Since autistic features are common in ADSL deficiency [17], occurring in about
40 to 50% of cases, the study of ADSL deficiency, a single gene disorder, may
reveal significant information regarding biomarkers for or possible pathogenic
mechanisms leading to Autism Spectrum Disorder (ASD).
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Figure 1.3: Early development of biochemical pathways

The leading hypothesis for the manifestation of ADSL deficiency is by
elevated levels of ADSL substrates, 5-aminoimidazole-4-(N succinylaminoimidazolecarboxamide ribonucleotide) (SAICAR) and adenylosuccinate (SAMP),
intracellularly. As SAICAR and SAMP accumulate, they are consequently dephosphorylated into succinylaminoimidazolecarboxamide riboside (SAICAr)
and succinyladenosine (S-Ado) respectively and are transported out of the cell
into urine, plasma and cerebrospinal fluid (CSF). The expected concentration
of these dephosphorylated derivatives for a normal individual is < 1µM, or
below detectable limits. Those with the deficiency accumulate a concentration of 150-500 µM [78]. The initial diagnosis is made by detection of SAICAr
in urine using the Bratton-Marshall reaction for diazotizable amines followed
by confirmatory analysis by other methods such as high performance liquid
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chromatography (HPLC) with ultraviolet detection or liquid chromatographytandem mass spectrometry (LC-MS/MS).

Three distinct phenotypic groups of ADSL deficiency have been distinguished: 1) neonatal fatal form, 2) severe childhood form (Type I), 3) moderate
or mild form (Type II). A summary of these groups can be found in Table 1.1.
The neonatal fatal form exhibits prenatal hyperkinesis, pulmonary hypoplasia and prenatal growth restriction, resulting in fatal neonatal encephalopathy [98]. The severe childhood form displays within the first months of life,
encompassing the whole spectrum of disease symptoms and resulting in severe psychomotor retardation, developmental arrest, coma vigil, and often
early death [98]. The moderate or mild form displays within the first years
of life either with psychomotor retardation or hypotonia [98]. The first correlation found between biochemical diagnosis and phenotype expression has
been the ratio of S-Ado to SAICAr. Patients with neonatal fatal form have a
S-Ado:SAICAr ratio of <1. Patients with Type I have a S-Ado:SAICAr ratio
of ∼1. Patients with Type II have a S-Ado:SAICAr ratio of >1.

Currently, the mechanism by which ADSL deficiency directly causes the
phenotypes of the disorder is not known. Consequently there is no effective
treatment for ADSL deficiency either. Heterogeneity in disease phenotype has
made it harder to attribute one single pathogenic mechanism behind the disease. Studies have not reported significant irregularities in most aspects of
purine synthesis. The rate of synthesis is roughly normal as are growth rates
of fibroblasts [86, 87]. Regular concentrations of purine nucleotides and ATP
5

Table 1.1: Phenotypic Groups, and Characteristics
Phenotypic Group

Phenotype Level

S-Ado:SAICAr

Neonatal
Type I

Fatal Neonatal
Severe

<1
∼1

Type 2

Moderate

>1

Symptoms
In utero death
PMR, developmental arrest,
often death
PMR, hypotonia, expression
of
Autistic
features

are also reported [86, 87]. These findings seem to suggest that ADSL deficiency may not lead to the disorder by disruption of de novo purine synthesis.
However, a significant weakness of many of these studies is that they do not
adequately control for the presence of purines in the environment and purine
salvage pathways, nor do they take into account the possibilities that de novo
purine synthesis may be altered during particular stages of development or in
particular tissues. Furthermore, the increased level of metabolites of ADSL
substrates in urine, plasma and CSF points towards the critical role the enzyme defects may play in disease pathogenesis. Perhaps the most convincing
evidence of enzyme defects involved in disease onset is the identification of few
alterations in mutants of ADSL that are directly related to the severities of
the symptom. These observations offer few possible scenarios about the disease mechanism. The resulting hypotheses regarding the pathogenesis include:
1) toxicity of high levels of SAICAR, AMPS, or their metabolites; 2) lack of
ability to synthesize sufficient purines using the de novo purine biosynthetic
pathway; 3) lack of a completely functional purine nucleotide cycle in muscle
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and brain; 4) improper regulation of energy metabolism; or 5) inhibiting formation of a fully functional multi-enzyme purinosome complex [2, 57, 78, 98].
We hypothesize that there are multiple mechanisms of pathogenesis of ADSL
deficiency including diminution of enzyme activity, instability of the functional
ADSL tetramer, or aggregation of ADSL. The significance of this is that development of an effective therapy may depend upon which mechanism is active
and the mechanism will depend on the patient’s ADSL mutation.

Although metabolites of the substrates SAICAR and SAMP are what are
usually detected in patients, it has been shown that SAICAR is toxic when it
accumulates in yeast cells [34, 64, 71, 72, 80]. In a recent study [55], the affects
of defects in the de novo purine pathway on chronological life span (CLS) in
yeast cells was tested. The results showed when any one protein in the pathway
was absent, with the exception of ADSL, the CLS of the yeast was expanded.
Cells missing ADSL could not survive even in the presence of adenine. This
suggests ADSL is an essential enzyme at least for yeast. This study further
demonstrates the importance of ADSL to be functional in the pathway and
the toxic consequences of accumulating SAICAR.

Substrate accumulation can happen either by simple loss of enzymatic activity due to subtle changes in structure of ADSL or by drastic changes in
the stability of the enzyme itself. Decrease in stability will result in fewer
functional protein molecules or an increase in unfolded/misfolded proteins
that may promote aggregation and/or degradation. If ADSL mutants have
a higher propensity to aggregate, it is possible these aggregates could be
7

toxic. This is in accordance with the idea of mutations in proteins that can
cause disease by Loss of Function or by Gain in Toxic Function [5, 33, 52].
The role of protein mis-aggregation/misfolding in human disorders is widely
recognized, and a number of inborn errors of metabolism may fall into this
class of disorder, for example phenylketonuria (PKU), a classic inborn error
of metabolism [8, 46, 81, 94, 95]. Recent studies have also alluded to a novel
idea of formation of the purinosome, a multi-enzyme complex, crucial in the
de novo purine synthesis pathway [2, 89]. It is possible that the mutations in
ADSL alter the purine metabolic pathway by inhibiting formation of a fully
functional multi-enzyme purinosome complex leading to altered purine synthesis during selected phases of the cell cycle or during times of particularly
high purine demand. There could also be a more profound effect of ADSL
deficiency during fetal development when excess purines are unavailable and
the embryo is likely to require the de novo pathway.

The unusual behavior of different mutants of human ADSL and their direct
relevance to disease pathogenesis requires careful investigation. The proposed
research is to study the enzyme activity, conformation, stability, and aggregation propensity of wild-type human ADSL as well as 4 mutants associated with
ADSL deficiency (E80D, D87E, R303C, R426H) and A291V, a unique mutation that eliminates all detectable activity. These disease associated mutants
were chosen because they represent missense mutations that cause different
phenotypes on the ADSL Deficiency spectrum. Thus, we believe this study of
the structure-function-stability relationship of the wild type (WT) and disease
mutants of ADSL will advance our understanding of the mechanistic aspects of
8

ADSL deficiency and its relation to disease pathogenesis and therefore suggest
new approaches towards therapy.

1.2

Disease Associated Mutations

Single site mutations in the amino acid sequence can be useful in evolution for protein structure or could be detrimental and cause disease. Whether
a mutation is favorable or unfavorable depends on chemical factors such as
composition, polarity, and molecular volume, which have been quantified by
the Grantham Score (the higher the number the greater the difference). The
work in this thesis will focus on two unfavorable missense mutations that are
the standards for the extreme cases of ADSL deficiency: a substitution of a
histidine for an arginine at amino acid position 426 (R426H) and a substitution of a cysteine for an arginine at amino acid position 303 (R303C). The
R426H mutation is the most common occurring in 30% (see Table 1.3) of reported cases of ADSL deficiency and when homozygous is characterized by
severe symptoms. R303C has been identified as a homozygous mutation in
two patients with the mildest phenotypes and highest S-Ado/SAICAr ratios
reported [78, 98]. Two other mutations of interest are a substitution of an
aspartate for a glutamate at position 80 (E80D), and substitution of a glutamate for an aspartate at position 87 (D87E). These mutations are found in
one heterozygous patient. These are of particular interest because the patient
was initially diagnosed with Autism [76]. We have also investigated a substitution of a valine for an alanine at amino acid position 291 (A291V). This is
a mutation that causes complete loss of activity and could provide informa-
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Table 1.2: Grantham Score and Frequency in Disease and Evolution
∆A.A.

Grantham Score

Frequency
in Disease (%)

R→H
R→C
D→E
E→D
A→V
**G → V

29
180
45
45
64
121

2.5 - 12.5
2.5 - 12.5
12.5 - 100
12.5 - 100
2.5 - 12.5
12.5 - 100

Frequency
in Evolution (%)
*Has not been recorded
12.5 - 100
2.5 - 12.5
2.5 - 12.5
2.5 - 12.5
12.5 - 100

*H → R substitution is in the top 2.5% of substitutions in evolution
**G → V is the mutation that causes sickle cell anemia
Grantham, 1974 [31]; Wu et al, 2007 [93]

Table 1.3: Number of Cases Reported of Mutations in ADSL Deficiency
Mutation

Homozygote

Heterozygote

Total

%) Reported

E80D*
D87E*
A291V
R303C
R426H

2
12

1
1
6

1
1
18

1.6
1.6
3.3
30

*Found in same patient

tion regarding a highly conserved loop in the enzyme structure. The general
location of these mutations on the monomer is depicted in Figure 1.4.

1.2.1

R426H (Arginine to Histidine)

The amino acid R426 is located at the surface of the substrate channel and
is important for mediating the interaction of Q409 and D422. When histidine
replaces the arginine, it disrupts the arginine-mediated interaction and causes
instability [98]. The mutation of arginine to histidine has a Grantham score of
10

Figure 1.4: Human ADSL monomer with labeled clinically associated mutations in this study

29, meaning the two amino acids are very similar on a chemical level. However,
this particular mutation is frequently associated with human genetic disease
(2.5-12.5%) and has never been recorded in evolution (Figure 1.2) [31, 93].
Interestingly, the histidine to arginine mutation is one of the most frequent
amino acid substitutions in evolution [93]. This may be due to the difference
in pKa values. Arginine has a pKa value of 12.5 compared to histidine pKa
value of 6.5. This means that histidine is more susceptible to losing its positive
charge when small shifts in physiological pH levels occur.
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(a)

(b)

Figure 1.5: Amino acid structures for arginine (a) and histidine (b)

1.2.2

R303C (Arginine to Cysteine)

The R303 amino acid is located directly in the active site. Its function in
the active site is to use its positive charge for binding the phosphate group
of the substrate. Cysteine is a non-polar, hydrophobic, residue that usually
plays an important structural role. Because of these differences the Grantham
score for arginine and cysteine is 180. If a cysteine is substituted for arginine, the positive charge is lost and the ability to bind the phosphate group
of the substrates is lost. Interestingly, this mutation shows a more severe loss
in activity with SAMP than with SAICAR, although the extent of disproportionality varies from study to study, perhaps reflecting differences in how
the enzyme assays were carried out. Some investigators were unable to detect
activity with SAMP in extracts from fibroblasts [53], while others found 3%
of normal activity (8). In other cases using different recombinant ADSL constructs, 7% and 18% of wild-type (WT) activity was observed with SAMP and
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44% with SAICAR [53, 67]. The reason for the non-parallel loss of activity is
not yet understood.

	
  

	
  

(a)

(b)

Figure 1.6: Amino acid structures for arginine (a) and cysteine (b)

1.2.3

E80D (Glutamic Acid to Aspartic Acid) and D87E
(Aspartic Acid to Glutamic Acid)

The E80D and D87E mutations, which these laboratories collaborated in
identifying, lead to relatively mild disease [76]. Both mutations are highly
conserved on the basis of evolutionary considerations for mammals and the
locations of the two mutations relative to the active site histidine residue at
position 86. This is surprising because the Grantham Score (45) and the
frequency of the D to E and E to D mutations in evolution are high (Table
1.2). This would lead one to think the two are very interchangeable, but that
is not the case for residue D87.
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(a)

(b)

Figure 1.7: Amino acid structures for aspartic acid (a) and glumatic acid (b)

1.2.4

A291V (Alanine to Valine)

All of the solved crystal structures for ADSL have a non-solvable region
from amino acid 284 to 292. It is believed this region is a flexible loop that
encloses the active site upon substrate binding. The mutation A291V was
recently identified in our laboratory as the mutation in the ADSL deficient
AdeI mutation of Chinese hamster ovary (CHO) cells. This mutation results
in loss of detectable enzyme activity. Alanine and Valine are both non-polar
amino acids that differ slightly in their structure with valine having two extra
carbon bonds leading to a Grantham score of 64. Yet, the frequency of the
substitution is the same for causing disease and for evolutionary purposes.
These findings suggest that our current understanding of the functions of these
amino acid residues in ADSL is incomplete.
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(a)

(b)

Figure 1.8: Amino acid structures for alanine (a) and valine (b)

1.2.5

Comments on Using B. Subtilis for Studying Disease Mutations

The use of Bacillus subtilis ADSL in particular as a model to study properties of mutant enzymes in some cases involved modification of additional
amino acid residues in the B. subtilis ADSL to more closely resemble human
ADSL [11, 76]. However, attempts to make use of a B. subtilis model system
to replicate the ADSL mutations have proven difficult because B. subtilis and
H. sapiens only have a sequence identity of 30% and a similarity of 63% (Table
1.4). Specifically, to replicate the R303C mutation, the sequence diversity of
B. subtilis and H. sapiens results in multiple alterations within the active site
to include but not limited to an asparagine residue in place of the corresponding R303 in human ADSL as well as an arginine residue in place of human
corresponding T354. Not surprisingly, the removal of B. subtilis’s asparagine
at the corresponding human ADSL R303 position for cysteine did not gener15

Table 1.4: Sequence Comparison of Different Species with H. Sapien
Type

Identity (%)

Similarity (%)

E. coli
T. Maritima
B. subtilis
M. Musulus

23.3
24.6
30.3
94.0

57.7
57.2
62.6
98.1

www.dbi.ac.uk/Tools/psa/lalign

ate a disproportional reduction in catalytic ability [76]. This observation as
well as others suggest that the study of the bacterial enzyme, while useful for
understanding some of the basic features of ADSL, may not be as useful for
understanding the effects of various disease causing mutations on the human
enzyme. On the basis of studies with the homologous B. subtilis enzyme, the
E80D mutation severely affects the activity of ADSL, while the D87E mutation has a more mild effect on enzyme activity. Recent vitro studies of the
human E80D and D87E ADSL mutants expressed in E. coli suggest that the
homomeric D87E or the E80D mutations result in relatively active and stable
enzyme and that the heteromeric form is also quite stable and active [98].
The conclusion regarding the mutations in the B. subtilis enzyme is that the
mutation equivalent to E80D is more deleterious than the mutation equivalent
to the D87E mutation in humans.

The use of B. subtilis was often employed prior to having a stable human
ADSL construct to perform in vitro studies on fundamental properties such
as function and stability. These studies contributed to initial understanding
of ADSL, but since the development of a stable ADSL construct, it has been
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seen that studies characterizing clinical mutations using B. subtilis do not
match with the human protein. This is most likely due to the difference in
sequence identity and similarity where a humanized B. subtilis would have
to be constructed using multiple mutations besides the clinically associated
mutation. These results emphasize the importance of using the human stain
of any enzyme when attempting to characterize how mutations affect inherent
properties of the enzyme.

1.3

Introduction to Enzymes

The discovery of enzymes began with Louis Pasteur in the 1850s when
he observed that fermentation of sugar into alcohol by yeast is catalyzed by
what he called “ferments”. It was initially thought that these ferments were
inseparable from the cell structure until Edward Buchner showed yeast cell
extracts could also ferment sugar in 1897. This proved that these “ferments”
were molecules that continued to have function outside of the cellular environment. Frederick W. Kühne later gave the name enzymes to these molecules
responsible for the fermentation of sugar. The isolation and crystallization of
one enzyme, urease, by James Sumner in 1926 determined the enzyme consisted of protein. He postulated all enzymes are proteins, a theory that wasn’t
accepted until after other known digestive enzymes such as trypsin and pepsin,
were also proven to be proteins. Since them, thousands of enzymes have been
purified and with the exception of a small group of catalytic RNA molecules,
all enzymes are proteins.
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1.4

How Enzymes Work

Most chemical reactions are not favorable to occur within the cellular environment. The reaction must overcome a large energy barrier to spontaneously
occur as depicted by the black line in Figure 1.9. To circumvent this issue,
enzymes provide a specific environment to make a reaction occur more rapidly
by lowering the energy barrier to enhance the reaction rates. The enzyme provides free energy by creating a favorable environment for catalysis; the active
site binds the substrate in an advantageous orientation for catalysis. Catalysis is still the rate limiting step since it has the highest energy barrier than
either the enzyme substrate or enzyme product complexes which are reaction
intermediates in the reaction pathway with a finite lifetime.

∆G‡ shows the activation energy for the forward and reverse reactions
between the substrate ground state and the transition state. ∆G‘◦ is the biochemical standard free energy change. Reaction equilibria are linked to ∆G‘◦
and the reaction rate to ∆G‡ . From thermodynamics, the relationship between the equilibrium constant, Kd and ∆G‘◦ is ∆G‘◦ = -RTlnKd where R is
the gas constant and T is absolute temperature. From transition state theory
an expression that relates the magnitude of a rate constant to the activation
‡

energy can be derived: k =

kT −∆G
e RT
h

. Since enzymes do not alter the position

and direction of equilibrium, they do not change the Kd of the reaction.

Specificity of enzyme substrate pairs is a crucial advantage for the physiological context because it allows regulation of a myriad of cellular process
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in the same space and time. Specificity results from the active site being
both geometrically and chemically suited for binding a certain substrate and
performing a certain type of chemical catalysis. Formation of these small interactions is accompanied by the release of small amounts of free energy that
is used to lower the activation barrier of the reaction. These weak interactions
provide a substantial driving force for enzyme catalysis and are optimized in
the transition state.

Figure 1.9: Free energy diagram of a chemical reaction with an enzyme. Figure
from Principles of Biochemistry, 5th edition

1.5

ADSL Method of Catalysis

There are 5 main types of catalysis: substrate confinement, non-covalent
stabilization of the transition state, covalent catalysis, metal-ion catalysis, and
19

general acid/base catalysis. ADSL uses the general acid/base catalysis where
the transition state stabilization can sometimes be carried out by transferring
a proton to the substrate or from it. When the transition state is negatively
charged, protonation may stabilize it in a hydrophobic or negatively charged
binding site. Protonation of the transition state requires an acid, whereas
de-protonation requires a base. Enzymes often use the own chemical groups
for such processes, mainly imidazole, and to a lesser extent carboxylate. In
many cases, the transfer of hydrogen species occurs despite an impeding energy barrier. The transfer is made possible thanks to a quantum-mechanical
phenomenon referred to as tunneling. The hydrogen atom tunnels through the
barrier as opposed to crossing it using kinetic energy.

ADSL is a member of a metabolic enzyme superfamily known as the fumarase enzymes. Members of this family catalyze reactions with fumarate as
one of the products. Though there are differences among the catalytic mechanisms, there is a highly conserved sequence found by all members of this family,
corresponding to residues 284 - 303 in human ADSL, that is in close proximity
of the active site [11, 44]. The ADSL catalyzed conversion of SAMP to AMP
and fumarate proceeds via a uni-bi mechanism, where fumarate is released
from the active site prior to AMP [10, 75]. The proposed chemical mechanism
is β-elimination where one of the hydrogens attached to the β carbon of the
succinyl moiety is abstracted by a general base; a double bond forms between
the β and α carbon of the succinyl moiety; the leaving group is protonated at
either the N1 of N6 position by a general acid, and the bond between the α
carbon an N6 of the adenosine ring system of the leaving group is cleaved [75].
20

Site directed mutagenesis of Bacillus subtilis ADSL has revealed three histidines as critical residues of the intersubunit catalytic site, His68 , His89 , and
His141 [11,48–50], and it has been proposed that His68 and His141 form the acid
base pair [49]. Since the catalytic mechanism of the fumarase family is highly
conserved, the human analogues to His68 and His141 are also proposed to play
the same role in catalysis.

1.6
1.6.1

Review of Elementary Reaction Kinetics
First Order Reaction
k

1
[A] −
→
[P ]

d[P]
dt

= - d[A]
= k 1 [A]1 = k 1 [A]
dt
= k 1 [A]
- d[A]
dt
- d[A]
= k 1 dt
[A]
-

RA d[A]

Ao

[A]

Rt
= k 1 dt
0

t
Ln[A] |A
Ao = k 1 dt |0

Ln[A] - Ln[Ao ] = k 1 t
Ln[ [AAo ] = k 1 t
[A] = [Ao ]ek1 t
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1.6.2

Pseudo First Order Reaction
k

1
[A] + [B] −
→
[P ]

d[P]
dt

0

= - d[A]
= - d[B]
= k 1 [A][B] = k 1 [A]
dt
dt

0

where = k1 [B ] = k1 if [B ] >> [A] ([A] would be the limiting concentration)

1.6.3

Second Order Reaction
k

1
→
[P ]
[A] + [A] −

d[P]
dt

= - d[A]
= = k 1 [A][A] = k 1 [A]2
dt
- d[A]
= k 1 [A]2
dt
d[A]
[A]2

RA d[A]
[A]2

Ao

= -k 1 dt
Rt
= - k 1 dt
0

t
- A1 |A
Ao = -k 1 dt |0

- A1 - - A10 = -k 1 t
1
A

1.6.4

=

1
A0

+ k 1t

Reversible First Order Reactions
k

1
−
*
[A] −
)
−
− [P ]

k −1

1
Keq = [P]eq
= kk−1
[A]eq

[A]o - [A]t = [P ]o + [P ]t
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Where o and t represent concentration of A or P at time 0 and any time t.
Assuming there is no initial concentration of P
[P ]t = [A]o - [A]t
At t = ∞, the system has reached equilibrium
[P ]eq = [A]o - [A]eq
Using the definition of Keq
·k1
[P ]eq = [A]keq
= [A]o - [A]eq
−1

Solving for [A]eq
[A]eq =

[A]o ·k−1
k−1 +k1

Using the principle of mass action to write the differential equation for the
change in [A] at time = t’
d[P]t0
dt0

=-

d[A]t0
dt0

= k 1 [A]t0 - k −1 [P ]t0

-

d[A]t0
dt0

= k 1 [A]t0 - k −1 ([A]o - [A]t0 )

-

d[A]t0
dt0

= (k 1 + k −1 )[A]t0 - k −1 [A]o

-

d[A]t0
dt0

=

d[A]t0
dt0
d[A]t0
dt0

R [A]t
0

=

k−1 [A]o
[A]t0
[A]eq

=

- k −1 [A]o

k−1 [A]o
(Aeq
[A]eq

- At0 )

(k−1 +k1 )[A]eq
(Aeq
[A]eq

d[A]t0
[A]eq −[A]t0

=

Rt
0

- At0 )

(k −1 + k 1 )dt’

Which results in the final solution
o −[A]eq
ln( [A]
) = (k −1 + k 1 )t
[A]t −[A]eq
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1.7
1.7.1

Introduction to Enzyme Kinetics
Rate Law

The rate of a process depends in some way on the concentrations or amounts
involved. Substances can either change concentration with time (reactant,
products, intermediates) or stay constant (catalysts, intermediates (steadystate), solvent. The concentration of the catalyst will not change during a
single experiment, but may change from one experiment to the next which
may alter the rates of reactions. The general enzyme reaction is given by:
k

k

k

k −1

k −2

k −3

1
2
3
−−
*
−
*
−
*
[E ] + [S ] )
−
− [ES ] −
)
−
− [EP ] −
)
−
− [E ] + [P ]

Assuming that [ES ] breaks down directly to [E ] + [P ]
k

k

k −1

k −3

1
3
−−
*
−
*
[E ] + [S ] )
−
− [ES ] −
)
−
− [E ] + [P ]

k−3

Assuming the reverse reaction [E ] + [P ] −−→ [ES ] is negligible

k1

k

cat
−−
*
[E] + [S] )
→ [E] + [P]
−
− [ES] −−

k −1

(1.7.1)

The formation of [ES ] is a second order process and the breakdown of [ES ] is
a first order process. The units for the rate constants are: k −1 = k cat = s −1
and k 1 = M −1 s −1

1.7.2

Michaelis-Menten Kinetics Derivation
d[ES]
dt

= k 1 ·[E ][S ] - k −1 ·[ES ] - k cat ·[ES ]
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Steady-state approximation;

d[ES]
dt

=0

k 1 ·[E ][S ] = k −1 ·[ES ] + k cat ·[ES ]
[Etotal ] = [E ] + [ES ] ; [E ] = [Etotal ] - [ES ]
k 1 ·([Etotal ] - [ES ])[S ] = k −1 ·[ES ] + k cat ·[ES ]
k 1 ·[Etotal ]·[S ] = k 1 ·[ES ]·[S ] + k −1 ·[ES ] + k cat ·[ES ]
[ES ] =

[Etotal ]·[S]
[S]+

Km =

k−1 +kcat
k1

k−1 +kcat
k1

Note that K m is not a binding constant that measures the strength of
binding between the enzyme and substrate. Its values include the affinity of
the substrate for enzyme, but also the rate at which the substrate bound to the
enzyme is converted to product. The Michaelis-Menten model is too simple
for many purposes.
[ES ] =
k cat · [ES ] =

[Etotal ]·[S]
[S]+Km
kcat ·[Etotal ]·[S]
[S]+Km

V max = k cat ·[Etotal ]
ν=

Vmax ·[S]
[S]+Km

At [S ] = K m ; ν =
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Vmax
2

Assumptions of Michaelis-Menten
• The production of product is linear with time during the time interval used.
• The concentration of substrate vastly exceeds the concentration of enzyme.
This means that the free concentration of substrate is very close to the concentration added, and that substrate concentration is constant throughout the
assay.
• A single enzyme forms the product.
• There is negligible spontaneous creation of product without enzyme.
• No cooperativity. Binding of substrate to one enzyme binding site doesn’t
influence the affinity or activity of an adjacent site.
• Neither substrate nor product acts an an allosteric modulator to alter the
enzyme velocity.

1.7.3

Allosteric Enzymes

Enzymes comprised of multi-subunit proteins and that have multiple active sites are commonly allosteric, where the conformation of one active site
is altered due to the binding of the substrate in another active site. These
allosteric interactions can be positive or negative. A positive (negative) cooperativity means a favorable (unfavorable) conformation change that increases
(decreases) the probability of substrate binding. Experimentally this is observed when the plots of ν vs. [S ] are no longer hyperbolic (characteristic of
Michaelis-Menten Kinetics), but sigmoidal, as seen in Figure 1.10. The initial
velocity equation is given by the Hill Equation:
ν=

Vmax ·[S]n
[S]n +Kn
0.5
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Where n is the Hill coefficient that determines the degree of cooperativity. If
n is greater than (less than) one, it denotes positive (negative) cooperativity.
If n is equal to one, the Hill Equation reduces back to the Michaelis-Menten
Equation.

Ν HΜmolminL

10
8
6

+ Cooperativity
Michaelis-Menten

4

- Cooperativity

2
0
0

1

2

3 4 5 6 7
Substrate HΜML

8

9 10

Figure 1.10: Kinetic curves of positive and negative cooperativity and
Michaelis-Menten Kinetics.

1.7.4

Rapid vs. Steady-State Equilibrium

In all of the cases above, steady-state equilibrium is assumed. Steady-state
equilibrium presumes that

dES
=
dt

0 when [S ] >> [Eo]. If excess [S ] is added to

[E ] the [ES ] complex is immediately formed and the substrate is transformed
to product. The importance of steady-state kinetics is within milliseconds
of starting the reaction, the [ES ] complex concentration will not change significantly during the initial part of the reaction. Another characteristic of
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steady-state kinetics is K m , which is a complex function of all rate constants
in the reaction:

Km =

k−1 +kcat
k1

As stated earlier, K m is not a binding constant that measures the strength
of binding between the enzyme and substrate. However, if k cat is the limiting
step in the reaction, so k cat  k −1 , K m reduces to a dissociation constant.
This is the condition of rapid equilibrium where after the [ES ] complex forms,
it dissociates back to [E ] + [S ], before catalysis takes place. Therefore, most
of the bound [S ] will dissociate and not be converted to [P ]. The resulting
V max is the same, V max = k cat [ES ]. The assumption that

dES
=
dt

0 still holds

true for rapid equilibrium as well. As soon as [S ] dissociates or is catalyzed
another [S ] is immediately bound.

1.8

Introduction to Protein Structure

The three dimensional structure of proteins was first solved in 1960 by the
British biochemist John Kendrew using X-Ray Diffraction to photograph myoglobin with 0.2 nm resolution. His colleague Max Perutz later determined the
structure of hemoglobin. The two of them were awarded the 1962 Nobel Prize
in Chemistry for their achievement. Since then, thousands of protein structures have been resolved and made widely available on the Internet. Proteins
are very compact structures that are organized in a very specific way with an
apparent hierarchy. The levels of hierarchy are primary, secondary, tertiary,
and quaternary structure (Figure 1.11).
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Figure 1.11: Higherarchy of a predominantly α-helical protein

1.8.1

Primary Structure

A protein’s identity is based on its amino acid sequence (Figure 1.11).
The exact ordering of the amino acids is important because amino acids have
different physio-chemical properties. These properties interact with each other
in a specific manner to achieve the final, folded, function structure. Amino
acids generally fall into one of four groups: nonpolar, polar-neutral, electrically
charged, or aromatic. Nonpolar residues are hydrophobic and are usually found
in the core of the protein where they interact with one another to allow for a
tight compact structure. Polar amino acids are hydrophilic and are often used
for interaction with other molecules, catalysis, and are important for solubility.
Like polar amino acids, electrically charged amino acids are also found on
the surface because of their ability to interact with molecules and ligands.
However, since they are electrically charged, they can be either protonated
or de-protonated, meaning they can behave as either acidic or basic amino
acids depending on the pH of the cellular environment. Aromatic amino acids
can assume properties of both polar and nonpolar groups because of their
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large side-chains. Their ability to absorb UV radiation is also a characteristic
commonly taken advantage of for fluorescence and UV assays.

1.8.2

Secondary Structure

As the amino acids start to interact via non-covalent interactions, they
begin to fold into simple local structures, or also called secondary structure
(Figure 1.11). We can group secondary structures into three basic groups:
α-helix, β-sheet, and turns or loops. The α-helix is a very compact structure
where side chains of the amino acids face the periphery while intermolecular
hydrogen bonds or van der Waals contacts stabilize the core (Figure 1.12a).
The β-sheet secondary structure consists of a group of β-strands that arrange
themselves along each other in either parallel or anti-parallel directions connected by a short loop called a β-turn (Figure 1.12b). These are much more
extended confirmations and not as compact as α-helix. Loops and turns are
segments that lack a particular structure in order for flexibility.

(a) α-helix

(b) β-sheet

Figure 1.12: Secondary structures
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1.8.3

Tertiary Structure

As the local structures start to take shape, the entire sequence folds into
a complete overall unit called the tertiary structure (Figure 1.11). Though all
proteins consist of the same basic secondary structures, the overall fold of the
unit is quite diverse in order to achieve a specific function. Usually the folded
protein will fold into a globular or spherical shape if complex functions are
necessary or it will fold into a fibrous, elongated shape to carry out simpler
functions. In order to be functional in a crowded cellular environment, tertiary
structures need to be compact, soluble, and properly form their active or
binding sites. As the final folding structure is made, hydrophobic patches
again form the core of the structure. This stabilizes the structure by a myriad
of weak interactions. This is crucial because it keeps the structure stable while
still allowing dynamics crucial for functionality. On the surface of the tertiary
structure are usually hydrophilic secondary structures to regulate interactions.
Local secondary structures can fold into separate regions characterized by
its arrangement and function. These semi-independent units are known as
domains.

1.8.4

Quaternary Structure

In order to acquire full functionality, it is often required for multiple chains
to interact. The spatial arrangement of the chains is referred as the quaternary
structure (Figure 1.11). Each chain is then called a subunit. These quaternary
structures can be a construct of identical or different chains and are usually
two to six chains in size but can be as big as 60 polypeptide chains. The spatial
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arrangement of the subunits is often symmetrical; hence quaternary structures
tend to have an even number of subunits. Proteins evolved into adopting
quaternary structures because of the advantages they offer. It is common that
active sties are constructed by the contribution of side chains from different
subunits. This can help with the regulation of substrate specificity as well as
versatility. Biochemical pathways are multi-step processes that involve more
than one enzyme. For better efficiency of the pathway, enzymes evolved and
create binding sites from several subunits to accommodate different substrates
in the pathway. Multi-unit complexes may be more stable in the cellular
environment due to the contacts at the interface of the subunits restricting
motion and making the complex less accessible to proteolytic enzymes.

1.8.5

ADSL Landscape

The monomer amino acid sequence for ADSL is 484 amino acids long (Figure 1.13). The amino acids interact to form secondary structures that are
depicted by the cartoons above the letters. The pink sinusoidal wave, yellow arrows, and purple horseshoes correspond to α-helix, β-sheet, and loops
secondary structure respectively. The secondary structure is predominanty αhelix (62%) with a minor amount of β-sheet (4%). With the large percentage
of α-helix, the ADSL monomer is more elongated than globular (Figure 1.14).
Each monomer contains 3 domains: Domain 1 consists of residues 1 - 116 and
is compact; Domain 2 consists of residues 117-376 and is elongated; Domain 3
consists of residues 377 - 484 and is compact. The monomeric weight of ADSL
with a six-histidine amino terminal tag is approximately 57 kDa [47].
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Figure 1.13: Human ADSL primary structure with labeled secondary structure

Two PDB deposited crystal structures of H. Sapiens ADSL, 2J91 and
2VD6, have been determined at 1.8 and 2.0 Å respectively. 2J91 was crystalized with AMP located in all four active sites. 2VD6 was crystalized with
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Figure 1.14: Human ADSL tertiary structure

SAMP in two active sites and AMP plus fumarate occupying the other two
active sites. Both crystal structures show a tetramer structure comprised of
four identical subunits, with D2 symmetry (Figure 1.15). Three monomers
contribute amino acids to the active site [11], creating 4 active sites total in
the homotetramer. The active sites can accommodate both substrates [77],
with no necessary adaptations. This is because in SAICAR, the carbon to
which the succinyl moiety is attached is able to rotate 180◦ prior to ring closure [82]. The D2 symmetry of ADSL is important because it tells us that
ADSL is a “dimer of dimers”, or a protein with two distinct interfaces. This
strongly suggests the protein assembly pathway will follow a pathway com-
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prised of monomers and dimers to form the active tetramer structure [65].

Figure 1.15: Human ADSL crystal structure

ADSL is active only in the tetrameric form, which implies the tetramer
is in equilibrium with monomer subunits from which they are formed. However, the presence of dimers, trimers and higher order oligomers (aggregation
number higher than four) cannot be ruled out either. The different degree
of structures that exist among these different multimeric units can also vary.
Thus, there could be a highly heterogeneous pool of species with different size
and structure that may coexist with the functionally active tetrameric ADSL.
Under normal conditions tetramers will be the most stable and dominant state
and the populations of others will be negligible [3]. However the equilibrium
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Figure 1.16: ADSL substrates and products

among these different species may get significantly altered in the presence of
disease mutants and hence affect the function. The presence of aggregates due
to mutations has already been reported in some studies [3]. ADSL clearly has
a diverse and interesting landscape that will require carefully designed experiments and non-trivial solutions to modeling when investigating its inherent
properties.

1.9

Introduction to Protein Folding

From the 1850s to the 1950s, scientists followed the perception that proteins
were rigid entities that employed a “lock and key” model proposed by Emil
Fischer. This model attempted to explain the substrate specificity of enzymes.
The problem with this view is if the enzyme’s active site is complementary
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to the substrate and not the product. This would impede the reaction from
taking place because the free energy barrier between the enzyme-substrate and
enzyme-product complexes will be too large. The view of proteins changed
from static to dynamic when Daniel Koshland proposed the “induced fit”
model. It suggested proteins use small conformational changes in the active
site to create communication between enzyme structure and substrates. Thus
the establishment of a dynamic folded structure for functional proteins began.
These dynamics range from vibrational motions that last around the order
of femtoseconds to motions of side chains and secondary structures that last
around the order of microseconds.

1.9.1

Driving Forces for Protein Folding

The term “unfolded protein” can take on two different definitions: 1) The
state of the protein prior to folding after being transcribed by the ribosome,
or 2) the state resulting from a complete protein denaturation. From a thermodynamic point of view, it is not too important which definition is used as
long as the process is reversible. But the often thought idea of the unfolded
protein being a “random coil” is more of a hypothetical state than an actual
one because unfolded chain often retain residual structure. When done properly, protein denaturation experiments are able to quantify the free energy
between states. Suprisingly, such experiments reveal protein stability to be
marginal [25, 32]. Despite the thousands of non-covalent interactions existing
in the structures of folded proteins, the free energy between the native and
unfolded states is a mere 5-20 kcal/mol [24, 61, 66]. At first, this may seem
surprising, noting that a single covalent bond is 65-175 kcal/mol. However,
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when considering that proteins need to maintain their native fold and dynamic
nature in order to function, it seems reasonable.

Non-covalent bonds are important for the stability of the protein while
allowing enough motion for them to be functional. This leads to the belief
that they are the driving forces behind protein folding. The three main noncovalent interactions are non-polar, electrostatic, and van der Waals. Thus
the free energy of folding can be written as

∆Gf olding = ∆Gnp + ∆Gelec + ∆GvdW − T ∆S

(1.9.1)

where the last term is the stability due to configuration entropy. Which of these
free energies is the driving force for protein folding? In the unfolded state, most
of the peptide chain is exposed to the aqueous environment. Most of molecules
in the solvent will be water molecules. This would cause electrostatic and van
der Waals interactions between the chain and water. This is also stabilized
by the high configurational entropy. The folded state is stabilized by many of
these same interactions, but the majority of intramolecular interactions occur
in the protein core where the majority of the amino acids are non-polar. This
leads to the common hypothesis that the “hydrophobic effect” is the driving
force for protein folding while configurational entropy opposes it [18].
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1.9.2

Kinetics and Dynamics of Protein Folding

The folding rate of protein is a quick process, where some proteins fold up
on the microsecond time scale [28]. Theoretically the folding process involves a
search through many different configurations, intermediate states, and a large
degree of freedom. The two previous statements seem to be at odds with another and the problem was presented by Cyrus Levinthal in 1968, now known
as the Levinthal’s Paradox [51]. It can be summarized as follows:

Assuming a protein with a chain length of 100 amino acids long samples
all of the possible conformations or the protein and each residue has at least
3 states. The number of different conformations the protein can assume is
equal to 3100 = 5 x 1047 . Assuming the protein takes 1 ps to sample one
conformation, the total time to sample all the conformations would be 1.6 x
1028 years. This time period is longer than the age of the universe. How is
this reconciled with the fact that proteins fold up in the microsecond time
scale? The answer is proteins do not randomly sample all possible configurations. Rather, they fold in a cooperative manner where each step reduces the
number of folding possibilities for future steps. Protein folding cooperativity
can be depicted by the folding funnel (Figure 1.17) that has been developed
by Energy Landscape Theory [12, 13, 19, 20]. The shape of the folding funnel points out three key aspects of folding: 1) the folding process involves a
decrease in both entropy and free energy, 2) there are many transitions state
defined by local minima separated by energy barriers, and 3) there are multiple paths along which folding can occur from the unfolded to the native state.
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Figure 1.17: Current understanding of how a protein folds. The unfolded
protein starts at the top of the funnel with maximum entropy and free energy
and ends as a folded protein at the bottom of the funnel with minimum entropy
and free energy.

While the folding funnel provides a good general solution to Levinthal’s
Paradox, the kinetics of the folding process still needs to be addressed. This
is a particular issue with protein folding because of the difficulty to detect
an intermediate state or a structural change that has a very short life span.
From the current data, there have been three basic models proposed to describe the kinetics: framework model, hydrophobic collapse or molten globule
model, and the nucleation model(Figure 1.18). The framework model proposes the secondary structures form first, followed by the final fold into the
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tertiary or quaternary structure. The hydrophobic model suggest the driving
hydrophobic forces cause the protein to collapse. It is loosely packed due to
non-polar residues still being exposed to the solvent and it is possible some
secondary folds have occurred. Eventually the non-polar residues interact and
form the compact final fold. The nucleation model proposes both hydrophobic collapse and complete secondary folds occur simultaneously until the final
fold is acheived. There is always the possibility of a combination of the three
models as well referred to as the jigsaw model. The moral of the story is there
is no single, universal mechanism for the kinetics of protein folding. This also
hasn’t taken into account the in vivo factors of protein folding such as the
dense cytoplasm, translation process, and molecular chaperones and stabilizers.

It is clear that a protein needs to reach its native state to be functional.
However, even when the native state is reached, the dynamics of the folded
state are continuously happening. This means the protein may exist in an
equilibrium between many different native conformations. From thermodynamics, we would expect the protein to spend the most of its time occupying
the state with the least energy, which is what is seen in crystallographic structures. Other conformations are adopted by using the thermal energy of the
system for kinetic energy This results in structures that are very similar on a
macroscale where the observer would see the quaternary structure, but not on
a microscale where the observer would see atoms in different positions.
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Figure 1.18: Different proposed mechanisms for protein folding. Figure was
taken from [68]

1.9.3

Protein Misfolding in Human Genetic Disorders

Proteins are dynamic structures that can misfold after being synthesized
or will undergo reversible structural changes as long as the structural unfolding is followed by a fast re-folding process. Occasionally, the unfolding is a
permanent transition that can have detrimental effects on the cell. Misfolded
proteins lose their ability to perform their biological function (loss of function
disorders), however they often gain an ability to aggregate or interact inappropriately with other cellular components (gain in function disorders) leading to
cell function impairment and eventually cell death. Normal proteins will experience misfolding to some degree and if the process is not reversible, the protein
quality control system will tag the protein for degradation. One factor that can
increase the propensity of misfolding is genetic mutations of the amino acid
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sequence. Genetic mutations can destabilize the native structure of proteins,
induce aggregation, and may be congenital. There are numerous human genetic disorders that are now associated with protein misfolding such as Cystic
Fibrosis, Alzheimer’s Disease, Parkinson’s Disease, Huntingon’s disease, Amyotrophic Lateral Sclerosis, as well as many others. The establishment of the
misfolding theory as a pathogenic mechanism has had important implications
for pursuing research characterizing the stabilty-structure-function relationship of enzymes. Particularly for therapeutic treatments to either increase the
stability or enhance the functionality via pharmaceuticals.

1.9.4

Review of Thermodynamics

The get a true physical understanding of proteins, we need to characterize
them in terms of forces and energies, particularly their energetics and dynamics. A biophysical approach also requires careful attention to the direction
the forces are driving the process. Are they folding or unfolding the protein?
The basic principles of thermodynamics can be applied to describe the free
energy of the system and the probability of different states under different environmental conditions. It utilizes the dependency of energy on temperature,
pressure, volume, and chemical concentration to characterize these different
states. Since proteins experience a constant temperature and pressure, Gibbs
free energy (G) is used to determine directionality of the process. Specifically,
the change in free energy (∆G) describes the direction as the system will proceed toward a state of minimum free energy. (∆G) can be calculated by the
following equation
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∆G = ∆Go + RT lnKeq = ∆Go + RT ln

f ([products])
g([reactants])

(1.9.2)

where ∆G o is the standard free energy, R is the universal gas constant, T is
the temperature, and f and g are dependent on the stoichiometry and concentration of the products and reactants. Once the free energy is measured, it can
then be used to determine the fraction of the population that went through
the transition. The two major components to free energy are enthalpy and
entropy which will be described in the next two sections.

∆G

P ∝ e RT

(1.9.3)

Enthalphy
Enthalpy (H ) is related to the internal energy of the system (E ) and the
work from pressure (P ) and volume (V ) done on or by the system.

H = E + PV

(1.9.4)

Hence, any change in H will be due to internal energy changes of the system,
or by the work done on or by the system by changes in P or V. Since the
biological environment does not experience significant change in P or V, the
∆H is mostly due to ∆E
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∆H = ∆E

(1.9.5)

This ∆H is caused by three molecular phenomena: 1) formation or breaking of covalent bonds, 2) changes in electrostatic of van der Waals interactions,
or 3) changes in thermally induced atomic motions. These interactions involve
a heat transfer (q) between the system and the environment. In biological systems, q generally decreases the ∆H by the formation of exothermic chemical
bonds. This q can be experimentally measured by calorimetric methods such
as differential scanning calorimetry or isothermal calorimetry which measure
heat capacity (C p ). If the process is reversible, C p can be calculated by

∆Cp =

∆H
q
=
∆T
∆T

(1.9.6)

A positive ∆H would coincide with the breaking of bonds, hence the unfolding process. This results in a positive ∆C p . This infers the unfolded protein
has a larger ∆C p than the folded protein. This is not too surprising since the
unfolded protein has more accessible surface area (ASA) and intramolecular
interactions occurring. Therefore is would take more heat energy to increase
the temperature of the system. By modeling the dependence of the ∆ASA
in terms of chain length, Myers et al found an expression of ∆C p in terms of
∆ASA [60]
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∆Cp = −251 + 0.19(∆ASA)

(1.9.7)

Entropy
The entropy (S ) of the system is related to the number of possible configurations (ω).

S = kB lnω

(1.9.8)

A highly ordered system cannot adopt many configurations. This means the
entropy and the order of the system are inversely related. A higher order
system has a lower entropy than a disorders system. This is why S is associated
with the amount of disorder in a given system. The change in entropy (∆S )
is represents changes in the freedom of motion in either the solute or the
solvent for molecular processes. As a protein folds into secondary, tertiary,
and quaternary structures, the amount of order increases causing a decrease
in entropy. The entropy of the system increases because as the non-covalent
bonds form, it is accompanied by an increase of S in the solvent caused by
the disordering of the water molecules surrounding the non-polar regions. At
constant temperature, the ∆S can be related to the ∆H by

∆S =

∆H
q
=
T
T
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(1.9.9)

Using equation 1.9.6 to express ∆S in terms of ∆C p

∆S =

∆Cp
∆T
T

(1.9.10)

This relation suggests ∆S also measures the number of states the heat
energy can be dispersed over at a constant temperature. As we have already
discussed, the unfolded protein has a higher C p than the folded state. Equation 1.9.10 is consistent with that conclusion by showing a higher S will require
a greater amount of energy to raise the temperature. It also allows for experiments to quantify the ∆S with measure values of ∆C p and temperature.

1.9.5

Methods of Denaturation

Protein denaturation is the common method to study the free energy between states rather than protein folding. Up to this point, unfolding and
denaturation have been used interchangeably. However, denaturation is different than protein unfolding. By definition, it is the process by which it
loses functionality. Unfolding will occur in the process based on the structurefunction relationship and may lead to a completely unfolded protein, but the
denaturation pathway is not necessarily the same at the unfolding pathway.
Since thermodynamics is only concerned with the state of the peptide chain,
denaturation is accepted at a means to study the free energy of the transitions
induced by denaturant methods. The four standard methods of denaturation,
or different knobs we can turn to change the environment, are temperature,
pH, pressure, and chemical.
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Temperature
Raising the temperature of the system will cause an increase in the kinetic
energy of the system. The added kinetic energy boosts the configurational
entropy of the unfolded state due to increasing the vibrations and motion of
the peptide chain. Interestingly, at high temperatures, since the kinetic energy
of the water is too high to drive the hydrophobic effect, protein folding is an
enthalpy-driven process as opposed to an entropic-driven process. Denaturation can also occur at low temperatures where the dynamics of the protein are
slowed down and “frozen”. This lack of dynamics causes a loss of function,
but not necessarily structure. As the water begins to freeze and form a crystal
lattice, hydrogen-peptide water bonds are lost. This can lead to aggregation
and precipitation out of solution.

pH
Enzyme have an optimum pH range where they are able to catalyze reactions. If the pH is too far out of this range, the enzyme begins to lose function.
The pH can also affect the structure of the protein by changing the charge of
electrically charged amino acids. A low pH would cause pronation, while a
high pH would cause de-pronation. These ionic changes can have an affect on
stabilizing interactions such as salt-bridges by weakening the coulomb interaction or reducing the electrostatic screening. They could also affect catalysis
by altering the binding sites for substrates or the cleavage mechanism.

48

Pressure
Increasing the hydrostatic pressure will cause the density of the water to
rise. Eventually the water molecules will begin to penetrate the protein surface,
therefore increasing the probability to unfold. This is the least invasive method
of protein denaturation and is one of the better approximations for protein
unfolding.

Chemical
There are two types of chemicals that can be added to the solvent to induce
protein denaturation, organic and polar. Organic solvents interact with the
non-polar side chains eventually overcome the intramolecular interaction. This
causes an unfolding process to occur since the non-polar residues are now
stable in the denatured state. The mechanism by which polar denaturants,
such as guanidinium chloride and urea, cause denaturation is still unclear.
Being polar, they are believe to interact mainly with the surface residues.
This infers they induce denaturation by an indirect effect to the solvent which
requires a high concentration of the denaturing chemical. This is usually the
case for urea, while guanidinium chloride is a stronger chemical that takes a
lower concentration to induce denaturation.

1.9.6

Solutions to Unfolding Transitions

As stated in the thermodynamic review, the fraction of the population that
went through the transition can be determined by the free energy between
the states. For chemical denaturation experiments the free energy change
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for unfolding in the absence of denaturant (∆G o ) can be derived by linear
extrapolation of the free energy change of the unfolding in the presence of
various concentrations of denaturant

∆G = ∆Go + m[denaturant]

(1.9.11)

where m is the m-value of the protein. Simply, the m-value is the measure of
a protein’s response to the added chemical. A large response refers to a quick
unfolding process while a low response indicates a slow unfolding process.
There are two cases where the fraction folded (unfolded) can be solved for
directly: a simple two state transition and for a dimer unfolding.

Simple Two State Transitions

[Mi ]

[Ui ]

(1.9.12)

Where M, U, and i represents the monomer state, unfolded state, and
the stoichiometry respectively. Meaning a monomer or multimer could undergo a two-state transition from a folded monomer (multimer) to an unfolded
monomer (multimer). For the rest of this example, the i will be dropped.

∆G = −RT lnKeq
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(1.9.13)

Keq =

[U ]
[M ]

∆G = −RT ln

Solving for the ratio of

[U ]
[M ]

(1.9.14)

(1.9.15)

[U ]
[M ]

[U ]
= e−β∆G ; β = RT
[M ]

(1.9.16)

If the fraction of interest is the fraction of proteins that are unfolded (F u ),
solve for [M ] in terms of [U ]. If the fraction of interest is the fraction of proteins
that are folded (F f ), solve for [U ] in terms of [M ]. In this case, F u will be our
fraction of interest.

[M ] = [U ]eβ∆G

(1.9.17)

If the fraction of interest is the fraction of proteins that are unfolded (F u )

Fu =
51

[U ]
[P ]

(1.9.18)

Where [P ] is the total protein concentration

[P ] = [M ] + [U ]

(1.9.19)

Substituting equations 1.9.17 and 1.9.19 into equation 1.9.18

Fu =

[U ]
1
Keq
=
=
[U ]eβ∆G + [U ]
eβ∆G + 1
Keq + 1

(1.9.20)

Where Keq = e−β∆G
Dimer Unfolding
The only higher order unfolding process that can be solved for directly
without the use of iterative methods is the transition from folded dimer to
unfolded monomer

[M2 ]

[U1 ]

∆G = −RT lnKeq
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(1.9.21)

(1.9.22)

Keq =

[U1 ]2
[M2 ]

(1.9.23)

Keq =

[U1 ]2
[M2 ]

(1.9.24)

Solving for [M 2 ]

[M2 ] = [U1 ]2 eβ∆G

Fu =

[U1 ]
[P ]

(1.9.25)

(1.9.26)

Writing the total protein concentration in terms of monomer concentration

[P ] = 2[M2 ] + [U1 ] = 2 · [U1 ]2 eβ∆G + [U1 ]

(1.9.27)

Using the quadratic formula to solve for [U 1 ]

2[M2 ] + [U1 ] = 2 · [U1 ]2 eβ∆G + [U1 ] − [P ] = 0
53

(1.9.28)

where a = 2·eβ∆G ; b = 1 ; -[P ]

1

−1 ± (1 + 8eβ∆G · [P ]) 2
[U1 ] =
4eβ∆G

(1.9.29)

Choosing “+” because the final [U 1 ] concentration cannot be negative and
substituting K eq −1 for eβ∆G

1

1

2
−1
+ 8Keq · [P ]) 2 − Keq
(Keq
· [P ]) 2 − 1
(1 + 8Keq
=
[U1 ] =
−1
4Keq
4

(1.9.30)

Substituting equation 1.9.30 into equation 1.9.26

1

2
(Keq
+ 8Keq · [P ]) 2 − Keq
[U1 ]
Fu =
=
[P ]
4[P ]

(1.9.31)

Which can be solved by a minimization function in most mathematica softwares.
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Chapter 2
Inherent Properties of
Adenylosuccinate Lyase Could
Explain S-Ado/SAICAr Ratio
Due to Homozygous R426H and
R303C Mutations
2.1

Introduction

Enzymatic studies provide the specific activity and the maximum product
formation rate (V max ) as a result of enzyme catalysis of the substrate. They
also measure the equilibrium constant (K ) between the free enzyme state and
the enzyme substrate complex formation. The importance of the V max is that
it gives a quantitative measure of the extent to which the enzyme acts on
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its designated substrates, SAICAR and SAMP. Numerous studies attempt to
relate V max values with mutations associated with various types of ADSL deficiencies and the corresponding S-Ado/SAICAr ratio [3,4,44,62,63,67,76,98].
However, previously reported human ADSL kinetic parameters have been inconsistent. The wild-type (WT) SAICAR/SAMP activity ratio varies from
0.53 - 1.7 while SAMP and SAICAR K m values vary from 1.9 - 4.9 and 1.8
- 3.6 µM, respectively [4, 44, 70]. Recent studies using each substrate independently have identified only one disease associated mutation, R303C, resulting in a nonparallel reduction of enzyme activity favoring SAICAR over
SAMP [3,4,44,70,98]. An early study of fibroblasts taken from patients showing reduced ADSL activity showed that synthesis of completed adenine and
guanine nucleotides remains possible in both cell types [86, 87]. The affected
patients used in these studies were originally reported in 1988 by Jaeken and
Van den Berghe and the disease causing mutations reported later [38, 54, 67].
The fibroblasts used were from severely affected individuals including two patients homozygous for the R426H mutation and one mildly affected patient
homozygous for the R303C mutation. R426H is the most common mutation
occurring in 30% of all known patients; homozygous R426H mutations generally lead to severe disease type and result in a S-Ado/SAICAr value of 1.0
- 1.6 [41, 78]. The homozygous R303C mutation leads to the mildest form
of the deficiency and gives rise to a S-Ado/SAICAr ratio of 3.0 - 3.7 [78].
Interestingly, only fibroblasts from the individual with the R303C mutation
accumulated SAICAR or SAMP as measured by radiolabeled formate incorporation despite having a similar reduction in SAICAR activity as fibroblasts
from the R426H patient. This may help explain the elevated ratios of S56

Ado/SAICAr seen in the extracellular fluid of the R303C patients, and led to
the hypothesis that SAICAR accumulation may be toxic. A larger reduction
in SAMP activity would result in more accumulation of intracellular SAMP,
and subsequently more S-Ado. However, alternative hypotheses to explain this
difference in S-Ado/SAICAr ratios have been proposed, including the age of
the patients when tested, the dephosphorylation rate of each substrate (likely
required for extracellular transport), or the rate of extracellular transport itself [98].

As discussed above, most kinetic studies of ADSL mutant proteins have
been done with each substrate individually. This does not reflect the in vivo
situation, in which the presence of both substrates would be expected. Findings reported for the R303C fibroblasts by Van den Bergh et al. suggest that
for the in vivo situation, at least for the R303C mutation, the elevated SAdo/SAICAr is due to the intrinsic properties of the enzyme [86, 87]. Under
in vivo conditions both substrates bind with the ADSL enzyme. Competition
due to resource sharing can mediate an indirect communication between the
two substrates that do not interact otherwise. This hidden coupling can alter
the activities of the substrates from the non-competitive scenario, i.e. in the
absence of the other substrate. Emergence of complex patterns due to resource
sharing has been reported in other biochemical networks [56, 74].

In this study, we begin to explore the relationship between in vitro and in
vivo environments and the possibility of hidden coupling and resource sharing. We describe a novel electrochemical-detection (EC) method to obtain the
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V max for ADSL in solution with its two substrates at varying concentration
ratios. Using this method we are able to more accurately determine the affects
of hidden substrate coupling and resource sharing in dual substrate environments on the bi-functional ADSL enzyme and disease causing mutations. For
this purpose we chose two mutations that represent extremes of the phenotype,
R303C representing the mild form (Type II) and the R426H representing the
severe form (Type I). Additionally, studies were done on the A291V ADSL
mutation found in the CHO-K1 AdeI mutant. This mutant provides a useful
control since its activity has previously been reported to be extremely low or
undetectable with either substrate [7,84,90]. Finally an enzyme kinetic model
was developed to predict SAMP and SAICAR activity from a given ratio of
substrate concentration.

2.2

Enzyme Kinetics by UV

Enzyme kinetic parameters for WT and R303C have been previously reported [70]. V max values for the R426H mutant have been published for SAMP
and SAICAR activity [44, 98]. K m values have not been reported in the literature. In light of this, an initial investigation of enzyme activity using SAMP
and SAICAR individually was performed by standard UV kinetic assays for
the WT and for A291V, R303C, and R426H enzymes. All ADSL mutants with
the exception of A291V have measureable activity that could be evaluated by
monitoring the UV absorbance of SAMP or SAICAR. It has been shown previously that WT ADSL does not follow simple Michaelis-Menten kinetics [3].
Therefore, kinetic curves were analyzed with the Hill Equation (Figure 2.1).
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SAMP and SAICAR kinetic parameters can be found in Table 2.1 and Table 2.2 respectively. WT specific activity on SAMP and SAICAR is 13.9 and
23.3 µmol/min/mg respectively. The ratio of activity of SAICAR/SAMP is
1.7. This ratio is in agreement with the previously reported ratio of activities
using the UV assay [4, 67]. The R303C mutation reduces specific activity to
5% of SAMP and 38% of SAICAR relative to WT ADSL. This agrees with
previous reports the R303C mutation displays a nonparallel decrease in activity in vitro and in vivo [70, 87, 98]. The measured specific activities for R426H
with SAMP and SAICAR respectively are 6.7 and 6.4 µmol/min/mg. These
correspond to a reduction to 45% for SAMP activity and 27% for SAICAR activity relative to WT and a gives SAICAR/SAMP ratio of 0.96. This initially
suggests the R426H mutation also causes a nonparallel decrease in activity,
though not to the degree as R303C. Although the mutants reduce the activity
on both substrates, R303C increases the K 0.5 while R426H decreases the K 0.5 .
The decrease in K 0.5 may indicate an increase in substrate affinity in order
to maintain R426H enzyme efficiency at a level close to the WT ADSL. WT
and R426H ADSL appear to have equivalent cooperative binding on both substrates, while R303C demonstrates no cooperativity. This may indicate that
cooperative binding does not play a critical role in retaining enzyme activity and other factors such as substrate binding or alterations of the catalytic
mechanism are more important to retain activity [70].
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Table 2.1: SAMP UV Kinetic Parameters of Human ADSL at 25◦ C
Enzyme V max (µmol min−1 mg−1 )
WT
A291V
R303C
R426H

100 ± 4
ND
5±3
45 ± 3

K 0.5 (µM)

Hill Coeff.

kcat
K0.5

2.05 ± 0.08
ND
2.7 ± 0.2
1.4 ± 0.1

1.4 ± 0.1
ND
0.97 ± 0.07
1.5 ± 0.2

2.52 x 107
9.15 x 105
1.78 x 107

Kinetic parameters for SAMP activity, V max , k cat , K 0.5 , and the Hill
coefficient, were determined by standard UV assays by varying substrate
concentration and fitting the data to the Hill equation in Mathematica.
Protein was reconstituted for 2 h at 25 C prior to measurements. Activities are relative to WT SAMP activity. ND is Not Detectable. Values
are shown along with their standard error.

Table 2.2: SAICAR UV Kinetic Parameters of Human ADSL at 25◦ C
Enzyme V max (µmol min−1 mg−1 )
WT
A291V
R303C
R426H

100 ± 2
ND
38 ± 6
27 ± 3

K 0.5 (µM)

Hill Coeff.

kcat
K0.5

1.74 ± 0.08
ND
9 ± 0.9
0.7 ± 0.1

1.3 ± 0.1
ND
0.9 ± 0.1
1.3 ± 0.3

5.09 x 107
3.64 x 106
3.75 x 107

Kinetic parameters for SAICAR activity, V max , k cat , K 0.5 , and the Hill
coefficient, were determined by standard UV assays by varying substrate
concentration and fitting the data to the Hill equation in Mathematica.
Protein was reconstituted for 2 h at 25 C prior to measurements. Activities are relative to WT SAICAR activity. ND is Not Detectable. Values
are shown along with their standard error.
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Figure 2.1: Specific Activity vs [Substrate] plots.

2.3

Enzyme Kinetics by HPLC-EC

To explore the effect on the specific activity when both substrates are
present in solution we measured the levels of both substrates and products after separation by HPLC-EC and UV detection. The identities of the substrates
and products were verified by co-chromatography with known compounds. To
test the method, kinetic measurements on SAMP and SAICAR were run independently. WT specific activity on SAMP and SAICAR is 13.4 and 7.4
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µmol/min/mg respectively. This results in a SAICAR/SAMP activity ratio
of 0.55 and is similar to results previously reported using an HPLC based
assay [42, 44]. Interestingly, even though the V max for SAICAR is different
between the UV and HPLC-EC assays, R303C activities maintained the same
percentage drop in activity, 5% SAMP and 40% SAICAR. The HPLC-EC
data for R426H show reduction in activities for SAMP and SAICAR to 47%
and 51% respectively. As a further validation of the assay, we attempted to
measure the levels of ADSL activity in the A291V mutant, previously found
to be extremely low or not detectable with either substrate. This was found
to be the case using the HPLC-EC assay as well.

Having validated the HPLC-EC assay for each individual substrate, we
then assayed the ADSL activity for WT, R303C, and R426H mutant enzymes
in the presence of varying ratios of SAICAR and SAMP. Chromatograms
showed a preserved separation of products and substrates as well as the growth
of product and conservation of substrate from 0 - 5 minutes (Figure 2.2). Accumulation of products was linear for the five time points as shown in Figures
2.3. A summary of the results are shown in Table 2.3 and Table 2.4 and
represented graphically in Figure 2.4. For WT and R426H, as SAICAR concentration increases, SAICAR activity increases as SAMP activity decreases
as expected. For the R303C mutation, SAMP activity remains fairly constant as SAICAR concentration increases. To quantitatively analyze the data,
we calculated the ratio of activity rates (SAMP activity/SAICAR activity)
for ADSL as a function of substrate mixture (Table 2.5 and Table 2.6). For
SAMP/SAICAR mixtures of 3:1, 1:1, and 1:3, the ratio of activity rates for
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WT decrease from 3.4, to 1.3, to 0.39 respectively. R426H follows a similar
decrease in ratio of activity rates: 3.2, to 0.85, to 0.36. R303C ratios also decrease, but have values smaller than WT or R426H: 1.7, to 0.44, to 0.29. This
implies that mutants can behave similarly or differently to WT in solution with
both substrates and still result in succinylpurine accumulation. Interestingly,
the relative rates of activity (mutant activity/WT activity) of R426H remain
fairly constant while R303C relative rates change for any given substrate ratio
(Table 2.5 and Table 2.6). Both SAMP and SAICAR relative rates for the
R426H mutation remain about 50% of WT activity. The R303C mutation on
the other hand has an increase in SAMP relative rate, 5 - 21%, as well as in
SAICAR relative rate, 18 - 43%.
Table 2.3: Rate of Formation Values for Mixing Ratios for WT and R303C
WT
SAMP:SAICAR
1:0
3:1
1:1
1:3
0:3

SAMP

R303C

SAICAR

13 ± 3
9±3
2.7
7±3
5.1
2.4 ± 0.6 6.2
7.4

±
±
±
±

SAMP

0.702
0.3 0.79
0.5 0.44
0.8
0.5
0.9

±
±
±
±
-

SAICAR

0.003
0.02 0.47 ± 0.08
0.06
1.0 ± 0.2
0.2
1.7 ± 0.5
3.2 ± 0.3

Rate of product formation (dP/dt) for different mixing ratios from
HPLC-EC enzyme assays. 1:0 refers to 100% SAMP, 0:1 refers to
100% SAICAR.
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Figure 2.2: Representative chromatograms showing separation of both substrates (SAICAR, SAMP) and products (AICAR, AMP) of the wild-type
ADSL kinetic assay at T=0 (A). The formation of product is visually evident as well as the conservation of substrate at reaction time T=5 (B). The
EC channels shown are in 100 mV intervals from 0-900 mV. Data were taken
from WT 1:1 mixing ratio of SAMP and SAICAR.

2.4

Prediction of the Specific Activity when
both Substrates are Present

We carried out an enzyme mixing kinetics analysis to predict the rate of
product formation when two substrates catalyzed by the same enzyme are
present in solution at different concentrations. The analysis is based on the
coupling of two independent enzymatic reactions via resource sharing. By
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Figure 2.3: Representative linear trends of product (AICAR, AMP) growth vs
time for different mixing ratios of SAMP and SAICAR using the HPLC-EC
assay. Data were taken from WT 1:1 mixing ratio of SAMP and SAICAR.
The activity was given by the slope of the line in units of Molarity*min−1 and
changed into units of µmol*min−1 *mg−1 .

independent reactions, we mean two separate reactions for each substrate in
the absence of the other. However, resource sharing induces a coupling due
to the fact that if one enzyme molecule is occupied by substrate one, it is
not available for substrate two. Although the enzyme has multiple binding
sites, we assume on a given enzyme each site is occupied by substrates of the
same type thus avoiding any other possible sources of coupling that may alter
the equilibrium constant (K m ). Thus competitive binding has been enforced
in the simplest form by conserving the total number of resources between
the two substrates. This is the only source of interaction between the two
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Table 2.4: Rate of Formation Values for Mixing Ratios for WT and R426H
WT
SAMP:SAICAR
1:0
3:1
1:1
1:3
0:3

SAMP

R426H

SAICAR

13 ± 3
9±3
2.7
7±3
5.1
2.4 ± 0.6 6.2
7.4

±
±
±
±

SAMP

SAICAR

6.3 ± 0.4
0.3 4.1 ± 0.1 1.3
0.5 2.2 ± 0.1 2.6
0.8 1.1 ± 0.2 3.1
0.9
3.8

±
±
±
±

0.1
0.3
0.1
0.2

Rate of product formation (dP/dt) for different mixing ratios
from HPLC-EC enzyme assays. 1:0 refers to 100% SAMP, 0:1
refers to 100% SAICAR.

reactions in our resource sharing model. Based on work by Ray, Deaton et
al, cooperativity may play a small role in substrate binding and catalysis.
Therefore, for simplicity, we disregard cooperativity in the present model [70].
From these assumptions, the rate of product formation for each substrate in
mixing conditions can be predicted. The resulting equations 2.4.1 and 2.4.2
are predictions for the rate of product formation when both substrates are
present in solution.

d[P1 ]
=
dt

Vmax,1
Km,1
·x+
Km,2

1

d[P2 ]
=
dt

Vmax,2
Km,2 1
· +
Km,1 x

1
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(2.4.1)

(2.4.2)

Table 2.5: Activity Ratios and Relative Rates for Mixing Ratios for WT and
R303C
WT

R303C

R303C/WT (%)

SAMP:SAICAR

SAMP/SAICAR

SAMP/SAICAR

SAMP

SAICAR

1:0
3:1
1:1
1:3
0:3

3.4
1.3
0.38
-

1.7
0.44
0.29
-

5.2
8.7
6.6
21
-

18
20
28
43

WT and mutant ADSL activity ratios of the rate of product formation
and relative rates of activity from values in Table 2.3. WT has decreasing
activity ratios while R303C always has a lower activity ratio. The R303C
mutation results in a changing relative ratio.

where dP/dt is the rate of product formation of the substrate at a given ratio
of substrates, x = S2/S1. The Vmax,i and Km,i values refer to the pure reaction
when there is only one substrate (i =1 or 2) present.

To test the prediction of the rate of product formation for a given substrate
ratio for WT and mutant ADSL, V max values from the HPLC-EC assay and
K m values from the UV assay were used in equations 2.4.1 and 2.4.2. Specific activities from the HPLC-EC assay were used since it was the method
employed to measure rate formation under mixed substrate conditions. The
overlay of the prediction to the experimental data can be seen in Figure 2.4.
The black line is the calculated rate of product formation for AMP while the
red line represents the rate of AICAR formation. The black and red data
points and error bars are the experimental data for AMP and AICAR respectively. The blue line is the V max value for SAMP activity. Even though 2.4.1
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Table 2.6: Activity Ratios and Relative Rates for Mixing Ratios for WT and
R426H
WT

R426H

R426H/WT (%)

SAMP:SAICAR

SAMP/SAICAR

SAMP/SAICAR

SAMP

SAICAR

1:0
3:1
1:1
1:3
0:3

3.4
1.3
0.38
-

3.2
0.85
0.35
-

47
46
33
48
-

48
50
50
51

WT and mutant ADSL activity ratios of the rate of product formation
and relative rates of activity from values in Table 2.4. WT and R426H
have equivalent decreasing activity ratios. R426H results in a constant
relative ratio for all substrate mixtures.

and 2.4.2 were generated assuming no change in equilibrium constants due to
the presence of the other substrate, the predictions are in good agreement with
the experimental data. These results suggest the rate of product formation is
mainly dependent on the ratio of K m values for pure SAMP and SAICAR and
the stoichiometry of the two substrates (equation 2.4.1 and 2.4.2).

2.5

HPLC vs. UV Enzyme Assay

The discrepancy between the HPLC and UV assay is interesting. Both
methods agreed with the respective previously reported specific activity ratio
of SAICAR:SAMP. The two methods had equivalent SAMP specific activity,
but contrasting SAICAR activity. The HPLC method utilizes a quantitative
analysis of the increase in product and relatively constant substrate. The
amount of product and substrate in solution is based on a set of known stan-
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dards. The UV method is a standard assay that is dependent on the difference
extinction coefficient, , which is determined by the difference in absorbance
between the substrate and product at a given wavelength. The  for SAMPAMP is 10,000 M−1 cm−1 whereas it is 700 M−1 cm−1 for SAICAR to AICAR.
This low  leads to a less sensitive assay that could cause error in the measurement. Given the HPLC method equipped with EC detectors provides
increased sensitivity and quantitative analysis of the growth of the products
and the lack of sensitivity in the SAICAR UV assay, this provides confidence
the HPLC method is the more robust and accurate assay for measuring specific
activity. However, if the  is significantly high, then both assays are equally
reliable. This verifies the use of specific activities from HPLC and the K m
from the UV assays.

2.6

Quantitative Analysis of Mixing Kinetics

Upon mixing substrates in solution at different ratios, the specific activity
depends on the amount of substrate present in a non-linear fashion. Equations
2.4.1 and 2.4.2 reduced pool of enzyme molecules available for the second reaction. This is the only allowed source of coupling between the two reactions
accounted by equation A.2.8 in the appendix and the basis of our simple resource sharing model. The reasonable agreement between prediction and data
supports the validity of our assumption as well as our assumption that cooperativity can be disregarded. Although modified reaction constants and hill
coefficients due to mixed binding of two different substrates on a given enzyme
cannot be ruled out, they may be smaller effects compared to the primary ef-
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fect of sharing limited resource modeled by equation A.2.8. It is also worth
noticing, as a result of competitive binding, the R303C relative activity (defined as a ratio of mutant V max to WT V max ) is no longer a constant but
a function of SAMP/SAICAR ratio whereas R426H is constant for any given
ratio of SAMP/SAICAR.

It has been observed that there is inconsistency in enzyme activities reported for ADSL, even from the same lab using the same assay. The only
discrepancy reported here is the specific activity on SAICAR from two different assays. Since in the case of the HPLC based assay we quantify the
growth of the product AICAR, which is identified by both retention time and
EC-profile, we believe this is a more direct method to measure enzyme activity. The HPLC-EC data also indicates R426H does not cause a nonparallel
decrease in activity in agreement with the results from Race et al, Kmoch et
al, and Zikanova et al [44, 67, 98].

2.7

Potential Relevance to S-Ado/SAICAr Ratios Observed in ADSL Deficiency

The current clinical diagnosis of ADSL deficiency is based on the detection
of the succinylpurines in body fluids. It has been questioned whether the ratio
of these dephosphorylated derivatives of the substrates is predictive of phenotypes or not, but rather depends on the life stage of the cell or patient that
determines the S-Ado/SAICAr ratio [98]. Since the in vivo condition involves
presence of both the substrates it is imperative to consider the relative drops
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in activity of the enzymes under mixed conditions as opposed to independent
conditions. This has been experimentally assessed in whole cells for the R303C
mutation, but not for WT or R426H. Our present study provides quantitative
analysis of this scenario in vitro, complementing earlier in vitro or cell extract
studies reporting the percentage drop in activities when only one substrate
is present. Thus, with the whole kinetic picture available, it is possible to
determine if the S-Ado/SAICAr ratio could be due to intrinsic properties of
mutant ADSL. If the amount S-Ado to SAICAr in body fluid were due to mutations of ADSL, there would be an inverse relationship between the ratio of
activities (SAMP activity/SAICAR activity) and the accumulated substrates
(SAMP/SAICAR) within the cell. Using the mixing kinetics model, it is possible to predict the intracellular concentrations of SAMP and SAICAR. R426H
causes a S-Ado/SAICAr ratio of ∼1. From the prediction curves, we would
expect the SAMP/SAICAR ratio to be 13:10 where the SAMP and SAICAR
activities are equal. Whereas R303C causes a S-Ado/SAICAr ratio of ∼4.
This corresponds to a SAMP/SAICAR ratio of 2:5 where the SAMP activity
is four times less than SAICAR. These are quite different predicted intracellular ratios. Quantitative accumulation of these substrates has not been studied
in mammalian cells [34, 71]. Normal levels of purine nucleotides and variable
levels of residual enzyme activity from various tissues have been reported in
tissues of ADSL deficiency patients [37,88]. However, human WT and mutant
ADSL were notoriously unstable at the time of the study.

One of the leading hypotheses for the pathogenic mechanism of ADSL deficiency is the toxic effect of accumulating succinylpurines, specifically SAICAR.
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Therefore, it is important to understand how SAICAR might accumulate and
to understand the consequences of this accumulation. Similarly, it has been hypothesized that the accumulation of SAMP might ameliorate the toxic effects
of SAICAR accumulation. The observation that both SAICAR and SAMP
accumulate in fibroblasts derived from an ADSL patient homozygous for the
R303C mutation is consistent with this hypothesis.

Recently, SAICAR has been shown to activate pyruvate kinase M2 (PKM2)
under conditions of limiting glucose, thus enhancing energy (ATP) production
[43]. SAMP also activates PKM2 but at a much higher concentration. PKM2
is expressed in human brain and glucose uptake in the brain of ADSL deficient
patients may be reduced [71]. Interestingly, ADSL deficient cells were shown
to produce more ATP and higher pyruvate kinase activity than cells with
normal levels of ADSL [43]. PKM2 has been considered to be present primarily
in cancer cells, embryonic tissues, and in cells with a high proliferation rate
[59]. However, there is evidence that PKM2 is the prominent isoform in most
tissues [9]. If PKM2 is present in most tissues, then the relative amounts of
accumulation of excess SAICAR and SAMP may cause aberrant regulation of
PKM2 leading to toxic effects. Different relative amounts may regulate PMK2
differently, which could play a role in the heterogeneity of ADSL deficiency.
Alterations in the activity of PKM2 in embryonic tissues may also contribute to
defects in brain maturation and overall development in early stages of life when
purines are mainly supplied by purine biosynthesis [1, 91]. If aberrant glucose
metabolism occurs because of SAICAR accumulation and leads to toxicity, it
may be possible to ameliorate this effect by modulating glucose metabolism
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or by lowering accumulation of SAICAR. Clearly the ability to control the
amount of SAICAR activity would be useful to maintain a low intracellular
SAICAR concentration. If enzyme activity is measured in healthy individuals,
then equation 2.4.1 and 2.4.2 could be used to introduce appropriate inhibitors
to alter the concentration of the substrates in the cell to gain desired activities
for SAMP and SAICAR.

2.8

Conclusions

In this study, we provide a model that predicts the dependency of product
rate formation (dP/dt) as a function of substrate mixing that was verified by
experimental HPLC-EC measurement for WT ADSL and two clinically associated mutations, R303C and R426H. This strongly suggests competition due to
resource sharing mediates indirect communication between the two substrates.
This hidden coupling causes a non-linear dependency of the activities on the
substrate ratios. Electrochemical detection is a robust method for this purpose
because of its ability to detect low concentrations of chemical compounds and
two degrees of separation: retention time and electrochemical profile. From
in vitro results, it is clear that mutations behave differently when mixtures of
substrates are present. R426H retains a constant relative activity ratio while
R303C does not. We propose that making inferences about intrinsic properties
of ADSL should be based on how it functions in the presence of both substrates
as opposed to two isolated activities may more accurately reflect the in vivo
situation. Currently, the only mutation that has been experimentally verified
to accumulate succinylpurines in whole cells is R303C while accumulation in
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R426H was undetectable. HPLC-EC could provide a more sensitive assay to
quantify intracellular concentrations of succinylpurines. The prediction model
could then be used to calculate ADSL relative activity to determine if the
S-Ado/SAICAr ratio is caused by inherent properties of mutant ADSL.
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Figure 2.4: Graphical representation of mixing kinetic data from HPLC-EC
analysis and prediction curves: A) WT, B) R303C, C) R426H. Plots are specific activity of SAICAR (circle, red) and SAMP (square, black) vs. substrate
ratio (SAMP/SAICAR). The V max value for SAMP activity is depicted by a
blue line. Plots show a non-linear dependence of product rate formation vs
substrate ratio.
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Chapter 3
Structural and Biochemical
Characterization of Human
Adenylosuccinate Lyase (ADSL)
and the R303C ADSL
Deficiency Associated Mutation
3.1

Introduction

Crystal structures of the bacterial ADSL and other studies have provided
insight into the active site and the catalytic mechanism; however these studies
predominately use bacterial strains of ADSL, such as Thermotoga maritima
or Escherichia coli [82, 83]. T. maritima and Homo sapiens have a sequence
identity of 25% and similarity of 57%. E. coli and H. sapiens have a se76

quence identity of 23% and a similarity of 57%. ADSL was found in these
bacterial species to function in the pathway as a homotetramer (Figure 3.1).
Interestingly, three monomers contribute to each of the four active sites in
the tetramer [11, 77]. The use of Bacillus subtilis ADSL in particular as a
model to study properties of mutant enzymes in some cases involved modification of additional amino acid residues in the B. subtilis ADSL to more
closely resemble human ADSL [62, 76]. However, attempts to make use of
a B. subtilis model system to replicate the R303C phenomenon have proven
difficult because B. subtilis and H. sapiens only have a sequence identity of
30% and a similarity of 63%. Specifically the sequence diversity of B. subtilis and H. sapiens results in multiple alterations within the active site to
include but not limited to an asparagine residue in place of the corresponding
R303 in human ADSL as well as an arginine residue in place of human corresponding T354. Not surprisingly, the removal of B. subtilis’s asparagine at
the corresponding human ADSL R303 position for cysteine did not generate
a disproportional reduction in catalytic ability [62, 76]. This observation as
well as others suggest that the study of the bacterial enzyme, while useful for
understanding some of the basic features of ADSL, may not be as useful for
understanding the effects of various disease causing mutations on the human
enzyme. Only limited structural information exists of human ADSL active site
in the unpublished SAMP bound and S-AMP/AMP-fumarate bound PDB deposited entries (2J91, 2VD6). Current studies on disease-associated mutations
of human ADSL have focused on correlation of substrate activity with clinical phenotypes, thermal stability of ADSL, activity of hybrid WT ADSL and
mutants, and global changes in structure [3,4,44,67,98]. They have not inves77

tigated local structural changes or binding properties to the products within
the ADSL active site. In this study, we present structural and biochemical
characterization data of WT and mutant R303C ADSL by enzyme kinetics,
product binding by isothermal titration calorimetry (ITC), and X-ray crystallography to reveal the effects of the R303C mutation that results in nonparallel
reduction in enzyme activity. This work was completed in collaboration with
the Pegan Lab at the University of Denver. Michelle Deaton completed X-Ray
Crystallography. Glenn Capodagli collected Isothermal Titration Calorimetry
data. Lucas Sawle performed energy minimization for SAICAR active site
modeling.

3.2

Peculiarity of R303C Enzyme Kinetics

To ensure that the previously observed reduction in activity of the ADSL
possessing the R303C mutation was not due to aberrant tetramer formation or
outright global instability of the mutated protein in solution, static light scattering was employed to determine the polymeric distribution of the R303C and
WT ADSL. As expected, WT ADSL is predominantly found to be a tetramer,
92.7 ± 2.6%, with aggregates contributing the final percentage. Similarly,
R303C ADSL is predominantly a tetramer, 94.3 ± 0.1%, with aggregates contributing the final percentage. Observed weights of the WT and R303C ADSL
tetramers were 225.0 ± 2.9 kDa and 214.5 ± 12.2 kDa, which is in close agreement with the His-tagged WT and R303C ADSL predicted tetrameric weights,
suggesting that the R303C mutation results in no degradation of the ADSL
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Figure 3.1: Sequence alignment of ADSL from various species. ADSLs are from
H. sapiens (GenBank AAC83935.1), M. musculus (GenBank AAB60684.1), B.
subtilis (NCBI Reference Sequence: YP 003865018.1), and C. griseus (NCBI
Reference Sequence: NP 001230974.1). Secondary structure of hADSL according to Defined Secondary Structure of Proteins (DSSP) is represented by
green cylinders (helical regions), orange arrows (β-sheet regions), black lines
(loops), and black dashes (unstructured regions). Mutation site 303 is marked
with an asterisk. The location of helices α3 and α4 is highlighted with a red
box. The C3 loop is enclosed in black brackets. Catalytic residues H159 and
S289 are marked with blue asterisks. Domains 1, 2, and 3 are indicated with
bars in shades of brown.

tetramer.

Previously, a report noted that the ADSL carrying the R303C mutation
displayed non-parallel decrease in activity at a single concentration [98]. Addi-
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tionally, the kinetic parameters for human ADSL utilization of SAICAR have
never been fully determined. Interestingly, only one earlier report, Stone et.
al. 1993, details a K m and k cat of ADSL for SAICAR [79]. Unfortunately,
the boundaries of ADSL were not well established at the time of that study,
resulting in their use of a 25 amino acid N-truncated version of ADSL and not
accounting for cooperativity. A subsequent study by Kmoch et al. also did
not account for ADSL cooperativity nor did they report on the R303C mutant [44]. To further investigate the R303C phenomenon and determine the
K m and k cat of ADSL for SAICAR, kinetic assays were performed on both WT
and R303C ADSL using SAICAR and SAMP as substrates [98]. Both WT and
R303C ADSL had measurable activity that could be evaluated by monitoring
the UV absorbance of either SAMP or SAICAR. As WT ADSL was previously
reported not to follow simple Michaelis-Menten kinetics for SAMP and perhaps be cooperative, the Hill equation was initially employed for calculating
WT ADSLs kinetic parameters (Table 3.1; Figure 2.1) [3]. The resulting Hill
coefficients of WT ADSL for SAMP and SAICAR are both significantly above
one, indicating cooperativity for the substrates. The resulting k cat and K 0.5 of
WT ADSL for SAMP was in agreement with a prior study that utilized the full
ADSL protein [3]. For WT ADSLs utilization of SAICAR, its K 0.5 was 1.8 ±
0.1 µM, which is only slightly higher than SAMPs. However, WT ADSLs k cat
for SAICAR was 1.6 fold higher than that for SAMP suggesting that ADSL is
more kinetically efficient for the catalysis of SAICAR over SAMP. This is confirmed by WT ADSLs k cat /K 0.5 for SAICAR being 2 fold higher than SAMPs.
Additionally, the k cat for both substrates was found not to be diffusion limited.
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Table 3.1: Enzymatic Activities of ADSL with SAMP and SAICAR at 25◦ C
SAMP
WT
R303C
k cat,H (1/sec)
52 ± 2
2.33 ± 0.07
k cat,H (%)
100 ± 3
4.5 ± 0.1
K 0.5 (µM)
2.1 ± 0.2 2.3 ± 0.1
Hill Coeff.
1.5 ± 0.2 1.03 ± 0.08
−1
−1
k cat,H /K 0.5 (sec µM )
25
0.99
k cat,M (1/sec)
N/A
2.36 ± 0.04
k cat,M (%)
N/A
4.5 ± 0.1
K m (µM)
N/A
2.3 ± 0.1
k cat,M /K m (sec−1 µM−1 )
N/A
0.99

SAICAR
WT
R303C
90 ± 2
100 ± 2
1.8 ± 0.1
1.22 ± 0.09
50
N/A
N/A
N/A
N/A

27.8 ± 0.8
31 ± 1
8.4 ± 0.8
0.94 ± 0.06
3.4
27.2 ± 0.4
30 ± 1
8.4 ± 0.8
3.5

The k cat , K 0.5 , K m , and Hill coefficient were determined by varying substrate concentration and fitting data to the Hill Equation (H) or the
Michaelis-Menten Equation (M) in Sigma Plot. Protein was reconstituted for 2 hours at 25◦ C prior to measurements. R303C activity is relative to % WT. The values are shown along with their standard errors.
N/A stands for not applicable.
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Introduction of the R303C mutation into ADSL has multiple effects. Initially expecting similar cooperativity observed in WT ADSL, the Hill equation
was utilized (Table 3.1). Unlike WT ADSL, the R303C ADSL demonstrates
no cooperativity, with a Hill coefficient for both substrates of one. As a result,
the simple Michaelis-Menten equation was employed for R303C. The R303C
ADSL mutation reduces k cat to 4.5% and 30% of that relative to WT ADSL
for SAMP and SAICAR, respectively. Interestingly, this 7-fold difference in
residual in vitro activity is in line with cell free extract studies of a Type II
patients fibroblasts carrying the R303C mutation, which had 3% of normal
SAMP activity and 30% of normal SAICAR activity [44, 87]. As a result, the
bias of ADSL for SAICAR:SAMP is 1.7, which is in agreement with a previously published ratio of 1.6, but shifts to that of 11.5 in R303C ADSL [4].
Interestingly, K m values of R303C ADSL increased for SAICAR compared to
that of WT ADSL. The change observed in K m of R303C ADSL for SAMP
is almost negligible, with the K m for SAICAR increasing more than 4-fold.
This may initially suggest the mutation affects the ability of R303C ADSL
to bind SAICAR more than SAMP resulting in the disparity in their cleavage. However, the rate of catalysis of R303C ADSL for SAICAR is 5 times
larger than SAMP at R303C ADSLs K m of SAMP. Therefore, the effect of the
R303C mutation on ADSL may not solely be reflective in its divergent ability
to bind SAICAR and SAMP. It suggests that R303C may affect the catalytic
mechanism of SAMP and SAICAR in addition to binding of the substrates.

82

3.3

SAICAR Forms an Extra Hydrogen Bond
Compared to SAMP

To explore the possible thermodynamic factors involved in the non-parallel
reduction in activity resulting from the R303C mutation and in general ADSLsubstrate interactions, ITC was performed on WT and R303C ADSL with
their products AMP and AICAR. By measuring the amount of heat liberated
per injection as a function of the molar ratio of the substrate and protein,
thermodynamic parameters for R303C and WT ADSL’s interaction with their
products were calculated (Table 3.2; Figure 3.2). Intriguingly, product binding
does not show any evidence of cooperativity, as the data fit to an independent
model rather than a multiple binding site model. This does not necessarily
rule out the possibility that the substrate binding is cooperative, but suggests
that cooperativity may require inclusion of interactions between the fumarate
component of the substrates and ADSL, which is lacking in the products.

Beyond the absence of cooperativity observed, the K d values for WT ADSL
were 54 and 34 µM for AMP and AICAR, respectively (Table 3.2; Figure
3.2). The thermodynamic properties that are responsible for AICAR and
AMP binding to WT ADSL globally are similar with the enthalpic component, ∆H, being the predominant driving force and the entropic component,
∆S, being unfavorable. Although similar, the thermodynamic properties are
not identical. AICAR binding liberates an additional 18 kJ/mol, suggesting
an additional hydrogen bond may be formed between AICAR and WT ADSL
that is absent in a AMP and WT ADSL complex. The lack of this additional
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enthalpic contribution is partially offset in the AMP and WT ADSL complex
by the reduced unfavorable entropic component compared to the AICAR and
WT ADSL complex. Overall, this leads to a difference in ∆G of AMP and
AICAR to WT ADSL to be only 1.2 kJ/mol in AICARs favor.

Intriguingly, the R303C mutation impacts the ability of ADSL to form
a complex with AMP and AICAR in two distinct manners. The enthalpic
component for both products decreases by a similar degree of ∼30 kJ/mol
suggesting the loss of one to two hydrogen bonds, whose identity could be
common between the two products and ADSL. Additionally, the R303C mutation shifts the ADSL complex formation with AMP and AICAR from an
unfavorable to favorable entropic event. Taken together, these thermodynamic
factors result in a similar decrease of ∆G and increases of 76 and 88 µM in
the K d of AMP and AICAR respectively. As a result, the R303C mutation
appears to negatively affect ADSLs interaction with AMP and AICAR almost
indistinguishably.

3.4

Origin on ADSL Cooperativity

The elucidation of the ADSL-SAMP structure has previously been suggested to support cooperativity in human ADSL, as AMP and fumarate are
found in two active sites and with the other two occupied by SAMP. However, previously limited biochemical data existed to support the origins or
form of the cooperativity found in ADSL. Interestingly, the kinetic and thermodynamic properties of the WT ADSL and the R303C mutant suggest that
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Table 3.2: ITC Thermodynamic Parameters of ADSL at 20◦ C
AMP
WT

R303C

K d (µM)
54 ± 3
130 ± 8
−1
∆H (kJ mol )
-35 ± 2
-5.9 ± 0.2
T ∆S (kJ mol−1 )
-12 ± 1
15.92 ± 0.06
∆G (kJ mol−1 ) -23.9 ± 0.1 -21.8 ± 0.2
n
0.99 ± 0.01 1.01 ± 0.04

AICAR
WT
R303C
34 ± 2
121.9 ± 0.9
-53 ± 1
-16.7 ± 0.5
-28 ± 1
5.3 ± 0.5
-25.1 ± 0.1 -21.95 ± 0.02
1.00 ± 0.02 1.00 ± 0.02

Data sets were collected in duplicate and analyzed with NanoAnalyze and
fit to an independent model concurrently with a blank constant model
to adjust for the heat dilution. All measurement were from 25 injections
of 2.5 mM AMP into 170 µL of protein in 25 mM HEPES (pH 7.0), 150
mM KCl, and 2 mM DTT at 20◦ C

the involvement of all three monomers that comprise an ADSL active site is
necessary to achieve ADSLs positive cooperativity. Specifically, no cooperativity was observed when binding AICAR, or AMP, to WT ADSL. Binding
of these products form the majority of their interactions with only two of the
monomers. For example, in active site 1, AMP interacts with six residues from
monomer A, and one from monomer B. Additionally, the phosphate group of
AMP is anchored with two additional residues from a relatively immobile portion of monomer D. (Figure 3.3a). This leaves the fumarate product to span
interactions between monomer As mobile α-helices 2-4, monomer B, and the
near α3-α10 catalytic loop region of monomer D, suggesting that it is necessary for cooperativity to be observed. In line with this hypothesis, mutation
of R303 to cysteine, which removes two hydrogen bonds, thus removing the
majority of the interactions between monomer D and SAMP, results in no
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Figure 3.2: Calorimetric titration of ADSL with AMP and AICAR. Integrated
heat peak areas against the molar ratio of AMP (a and b) and AICAR (c and d)
added to ADSL-WT and ADSL-R303C. The inset shows raw heat data gained
from 25 injections of 2.5mM AMP into 170µL protein in 25 mM HEPES, pH
7.0, 150 mM KCl, 2 mM DTT at 20◦ C. Data sets were collected in duplicate
and analyzed with NanoAnalyze software and fit to an independent model
concurrently with a blank constant model to adjust for heat of dilution. The
line shows the best fit to an independent model. Figures generated using the
NanoAnalyze Software provided by TA Instruments.

cooperativity (Figure 3.3b).

Beyond the necessity for the substrate, or products, to involve all three
monomers when binding to achieve an allosteric response, comparison of the
WT-ADSL-apo and ADSL-SAMP active sites provided a glimpse into the
model of allosteric regulation that ADSL undergoes. Specifically, the WTADSL-apo active sites are considerably more open to the bulk solvent then
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those of the ADSL-SAMP and ADSL-AMP structures (Figure 3.4a). The 0.27
nm shift of α-helices 2, 3 and 4 observed between the WT-ADSL-apo active
sites and those bound with AMP, or AMP and fumarate, illustrates a clamping down of the active site over SAMP, or AMP. With AICAR and SAICAR
having homologous phosphate, fumarate, and ribose moieties to that of AMP,
the same shift is likely to occur upon the binding of these ligands as well. This
closure of the active site around SAMP suggests that a concerted model of
allosteric regulation would not be possible (Figure 3.4c). In other words, if
this shift occurred in a neighboring active site as a result of binding SAMP and
SAICAR for the reaction running in the forward direction, SAMP attempting
to bind to the neighboring active site would be sterically impeded. This would
not be reflective of the positive cooperativity observed. Applying sequential
allosteric regulation to the reverse reaction is less certain. The binding of AMP
and AICAR would also be sterically impeded from binding to an active site
that already underwent a shift of α-helices 2, 3 and 4. However, as illustrated
by the thermodynamic information, the binding of AMP and AICAR is does
not illustrate cooperativity. With fumarate binding at the top of the active
site, which is exposed to the bulk solvent, a concerted model cannot be ruled
out in the reverse direction (Figure 3.4b).

Beyond the sequential model of allosteric modulation of ADSL, in what
order, or the extent to which the active sites fill with substrates remains an
open question. The ADSL-SAMP structure has its two active sites on the
same end of ADSL occupied by SAMP and other distal active sites bound
with fumarate and AMP. The absence of SAMP in all of the active sites could
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be due to restraints of the enzyme imposed by the crystal lattice, but alternatively might propose that substrates bind to adjacent active sites first, or only
can bind to them. The latter would infer that the active sites at one end of the
ADSL tetramer communicate to its distal neighbors. Although the mild loss of
cooperativity observed by Ariyananda et al. [3] by an ADSL mutation L311V
at the center of the tetramer would support this possibility, additional structurally guided mutagenesis along monomers interface and molecular dynamics
simulations will be required to completely tease out the global allosteric nature
of ADSL.

3.5

Proposed Catalytic Mechanism

The loss of cooperativity because of the R303C mutation removal of hydrogen bonds with one of the three monomers comprising the active site as
reflected in the structures of ADSL-SAMP, or ADSL-AMP, would not itself
explain the divergent catalytic properties of ADSL observed towards SAICAR
and SAMP. However, the combination of the kinetic and thermodynamic data
coupled with the structural evidence suggests that the R303C mutation illuminates SAICAR as a better substrate for ADSL. At first glance, the unparallel
reduction in k cat between SAMP and SAICAR upon the R303C mutation
could suggest that the divergence in catalytic ability of ADSL between SAMP
and SAICAR is due to a lack of substrate binding that favors SAICAR, or
AICAR binding over that of SAMP. However, the K m for SAICAR is slightly
elevated relative to that of SAMP indicating that binding of SAICAR might
be slightly weaker (Table 3.1). Moreover, the ADSL ligand bound structures
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have R303 forming hydrogen bonds to the phosphate group that is conserved
between SAICAR and AICAR (Figure 3.3). Also, the thermodynamic data
reflects that the mutation causes a loss of enthalpy at almost equal magnitude
for both AICAR and AMP, reflective of a loss of the same ADSL-phosphate
group interactions. Despite the loss of the bond to the phosphate group, the
overall ∆G bind for both products remains similar to WT ADSL. This is accomplished by shifting the product binding from an unfavorable to favorable
entropic event. The resulting K d ’s for both substrates are nearly equally decreased by approximately 2.5-3 fold. This near equal drop in K d but not k cat
suggests that the R303C mutation is indirectly affecting the catalytic ability of
ADSL divergently for its two substrates. In other words, this thermodynamic,
kinetic, and structural evidence suggests that the substrate can bind to the
active site at a significant affinity despite the R303C mutation. As a result,
unlike WT ADSL, the R303C mutant is likely operating at rapid equilibrium
state, where if the substrate binds to ADSL, most substrate will dissociate,
and only a small amount will be converted to product.

This would suggest that ADSL is more efficient at cleaving the fumarateAICAR/AMP bond of SAICAR than SAMP. The inequality of catalysis might
suggest that SAICAR and SAMP do not follow the same mechanistic pathway. The reaction mechanism for conversion of SAMP and SAICAR by ADSL
has been previously described as a general acid-base mechanism resulting in βelimination of fumarate (Figure 3.5) [83]. Although, the conversion of SAICAR
to AICAR and fumarate could follow the same steps as the SAMP to AMP
mechanism, due to the presence of an additional carbonyl in SAICAR, there is
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another possibility. In this SAICAR selective pathway, the first two steps are
the same: the Cβ -proton is removed, and the negative charge is stabilized by
the δ-carboxyl group. However, in the third step, as the electron density from
the double-negatively charge carboxyl group is shifted down and the Cα -N6
bond is broken, a double bond is formed between N6 and the carbonyl carbon,
and electron density is pushed up onto the carbonyl oxygen. Then, in the last
step, this negative charge moves back down to form a C-O double bond as N6
becomes protonated by H159. This negatively charged oxygen may be stabilized by nearby positively charged residue, R235. This additional stabilization
of the intermediate may be a factor in the faster reaction rate of SAICAR
compared to SAMP.

An alternative possibility, or potential additional factor, for the inequality
of bond cleavage between SAMP and SAICAR is the ability of SAICAR to
be positioned with the active site in a more catalytically effective orientation
than SAMP. The loss of the hydrogen bonds that R303 contributed to substrate binding potentially affected the ability to orient SAMP and SAICAR
ideally for cleavage. Unlike SAMP, which possess a pyrimidine ring, SAICAR
has a single rotatable bond that has been previously suggested to infer greater
flexibility to adopt different conformations (36). This also might explain the
lack of unparallel reduction in catalytic ability of B. subtilis ADSL. In that
case, B. subtilis ADSL has an arginine in place of human ADSL T354 that
may provide a similar influence. Unfortunately in the Palenchar et al. study
that looked at B. subtilis ADSL corresponding human ADSL R303C mutation
(B. subtilis ADSL N276C), only performed a double mutation to mimic the
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human active site configuration and did not include a single mutation for the
corresponding arginine at human ADSLs T354 [62]. This prevented observing whether elimination of anchoring ADSLs substrates by a third arginine
resulted in unparallel catalytic ability.

Additionally, the thermodynamic data suggests that AICAR forms an additional hydrogen bond not present in the ADSL-AMP complex. The enthalpic divergence between the two substrates remains after the introduction
of the R303C mutation. The ability of SAICAR to possess an additional point
of contact within the ADSL active site could ensure that SAICAR properly
oriented within the active site more often then SAMP, contributing to the
unparallel k cat between SAMP and SAICAR observed. Based on the ADSLAICAR-fumarate model, the additional hydrogen bond could be reflective of
an interaction between AICAR and the highly conserved S334 (Figure 3.6a).
Curiously, even in human ADSLs distant homologue of B. subtilis, this serine
is conserved. This serine has not previously been implicated in substrate binding or catalysis, as it does not interact directly with SAMP or AMP within the
ADSL-SAMP and ADSL-AMP structures. Naturally, additional site-directed
mutagenesis efforts within the active site including S334, or an X-ray structure of ADSL with SAICAR, or AICAR, will be necessary to fully identify the
ADSL residue acceptor that forms the additional hydrogen bond with AICAR
and bring final clarity to the unparallel catalytic activity observed.
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Figure 3.3: Comparison of ADSL active sites for WT, WT with substrate,
and R303C mutant. (a) Wall-eyed stereo view of a ADSL-SAMP active site
with AMP and fumarate occupying the active site. AMP is rendered pink and
fumarate is rendered tan. Heteroatoms are colored according to their element.
Water molecules (grey) are depicted as spheres and are scaled to 50% for
clarity. The monomer each residue belongs to is given in parentheses after the
residue number. (b) Wall-eyed stereo view of a ADSL-SAMP active site with
SAMP occupying the active site. SAMP is rendered purple, and heteroatoms
are colored according to their element. Water molecules (grey) are depicted as
spheres and are scaled to 50% for clarity. The monomer each residue belongs
to is given in parentheses after the residue number. (c) Wall-eyed stereo view
of R303C ADSL active site. Monomers A, B and D are rendered red, green,
and yellow, respectively. Heteroatoms are colored according to their element.
Water molecules (cyan) are depicted as spheres and are scaled to 50%, and
the side chain of R85 is hidden for clarity. The monomer each residue belongs
to is given in parentheses after the residue number.
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Figure 3.4: Constriction of the ADSL active site upon substrate binding. (a)
Surface rendering of WT-ADSL-apo active site 1. WT active site depicted
in salmon, light yellow and pale green corresponding to monomer A, B, and
D respectively. R85 side chain is shown with transparency to reflect the lack
of electron density for the side chain in all monomers. AMP and fumarate
from active site 1 of ADSL-SAMP was placed in the apo active site for scaling
purposes. (b) Surface rendering of SAMP and fumarate bound active site 1 of
ADSL-SAMP. Coloring of light grey, medium grey, and dark grey correspond
to monomers A, B, and D respectively. (c) Surface rendering of SAMP and
fumarate bound active site of ADSL-SAMP. Coloring of light grey, medium
grey, and dark grey correspond to monomers A, D, and C respectively. All
waters were removed from surface renderings in (a-c).
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Figure 3.5: Catalysis mechanism of ADSL on SAICAR and SAMP
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Figure 3.6: ADSL-AICAR-fumarate model. (a) Wall-eyed stereo view of model
of WT active site with AICAR and fumarate occupying the active site. AICAR
and fumarate are rendered yellow. Heteroatoms are colored according to their
element. The monomer to which each residue belongs is given in parentheses
after the residue number. (b) View of model of WT active site with AMP and
fumarate overlaying model of WT active site with AICAR and fumarate. WT
with AMP is rendered grey with AMP in pink and fumarate in tan, while WT
with AICAR residues are teal with AICAR and fumarate in yellow.
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Chapter 4
Protein Folding and Stability of
ADSL and Potential Connection
to Pathogenic Mechanisms
Protein denaturation, by definition, is characterized by the loss of enzyme
activity due to an induced stress on the system. A common biochemical
method to characterize protein stability is by thermal inactivation of the enzyme. Generally, this is how stability of ADSL has been studied [3]. Recently the use of blue native gels have been used to view whether the ADSL
maintains its tetramer structure after incubation at higher temperatures [98].
While these studies are informative, they only provide an answer to the question, “Does the mutation cause instability or a loss of function at a raised
temperature?” A mutated enzyme can appear to be in the same state at
raised temperature, when in reality, it is in a different final folded state with
residual activity. Therefore, a more interesting question to ask is, “How much
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does the stability decrease (or increase) due to a clinically associated mutation
at standard conditions?” The answer to this question requires a quantitative
analysis of the free energy between states of the denaturation process. The
change in free energy between states would provide insight as to where the
protein ends in the folding funnel, whether it has reached its minimum energy
state, or if it has folded into a less (or more) favorable state. The studies
presented in the this chapter begin the process of revealing which states are
present during ADSL denaturation (Figure 4.1), quantifying the free energy
between those states, and determining how the extreme mutations of ADSL
change the stability. This fundamental research can assist in directing therapeutics by suggesting whether the pathogenic mechanism could be due to a
“loss of function” or “gain in toxic function” as a result of protein misfolding.

Figure 4.1: Schematic of the ADSL landscape. The are a myriad of different
states available for a tetrameric protein.
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Table 4.1: ADSL Population Distribution

4.1

Enzyme

Tetramer Weight (kDa)

Tetramer (%)

Aggregate (%)

WT
R303C
R426H

220.8 ± 0.2%
219.2 ± 0.2%
225.4 ± 0.2%

96.2 ± 0.6
97.8 ± 0.1
94.4 ± 1.6

3.6 ± 0.6
1.8 ± 0.1
5.6 ± 1.6

WT, R303C, and R426H Are Identical at
Standard Conditions

Prior to denaturation experiments, it was verified that WT, R426H, and
R303C begin in the same state with the same amount of secondary structure. Upon measuring the population distribution using Static Light Scattering, WT, R303C, and R426H were all found have similar distributions
with tetramer as the dominant state and a small percentage of aggregates
(Table 4.1). Circular Dichroism was then employed to measure the signal
from secondary structure and found near identical curves for WT and mutant ADSL (Figure 4.2). Therefore, assuming the aggregation is negligible, a
folded tetramer can be considered the final state for thermodynamic modeling.

The absence of aberrant tetramer formation initially rules out the “gain of
toxic function” for these two ADSL mutations. Experiments such as sedimentation equilibrium may be useful to investigate this further. This merely rules
out R303C and R426H causing a “gain in toxic function”. It does not rule
out “gain in toxic function” as a pathogenic mechanism for other clinically
associated mutations.
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Figure 4.2: CD Spectra of WT, R303C, and R426H ADSL.

4.2

Protein Unfolding by Thermal Denaturation is Irreversible

Thermal denaturation of proteins is a powerful tool to use. From differential scanning calorimetry measurements, values of ∆G, ∆H, and ∆C p can be
quickly quantified by equation 4.2.1 and equation 4.2.2.

∆G(T ) = ∆H(1 −

T
T
) + ∆Cp (T − Tm − T ln[ ])
Tm
Tm

∆S(Tm ) =
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∆H(Tm )
Tm

(4.2.1)

(4.2.2)

DSC measurements were initially taken on a VP-DSC at the biophysics
core at the University of Colorado Anschutz Medical Campus. Following the
transition peak around 60 ◦ C, instead of an expected rise in the baseline, there
is a “crash” in signal at 65 ◦ C that likely represents protein aggregation (Figure 4.3a). Unfortunately, as is the case with the majority of proteins, thermal
denaturation for ADSL is irreversible. Defining a baseline does allow for characterization of the enthalpy needed to unfold the system up to a point of
aggregation. This can be useful information in limiting parameters for other
modeling methods.

The VP-DSC sample cell is referred to as a cylindrical cell. The protein molecules in solution are free to move throughout the entire cell as it is
heated. TA Instruments’ Nano DSC offers a new design called the capillary
cell that limits the movement of proteins to increase the chance of reversibility. The unfolding transition of ADSL was resolved in the Nano DSC as there
is a clear baseline following the transtion (Figure 4.4). It appears from the
non-Gaussian shape that an intermediate form may exist or that the protein
consists of two separate processes. With the information known about ADSL,
it is likely that the slow initial pre-transition is the dissociation of the tetramer
into its monomeric subunits and the unfolding of the protein is faster, as seen
visually in the sharp post-transition. However, ADSL was also found the be
irreversible in the Nano DSC as well. Information from this method confirmed
the presence of an intermediate state. While it can be presumed to be tetramer
dissociation, further investigation is needed to confirm this assumption. While
the process is not reversible, since the unfolded transition was resolved, this
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Figure 4.3: Representative plots for measuring excess heat capacity as a function of temperature with VP-DSC from MicroCal. As depicted in a) instead
of an expected rise in the baseline after the melting temperature, there is a
“crash” in signal that likely represents protein aggregation. Defining a baseline allows characterization of the enthalpy needed to unfold the system up to
a point of aggregation.
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provides better estimates for the enthalpy, heat capacity, and melting temperature of the ADSL than the VP-DSC. These values can be substituted into
equation 4.2.1 for an approximate free energy of folding curve (Figure 4.5).

Figure 4.4: DSC curve for WT ADSL from TA Instruments Nano DSC.

Thermal denaturation by CD measurements for R303C and R426H were
performed as well (Figure 4.6). Interestingly, R303C, the mild phenotype
mutation, appears identical to WT while R426H has a much lower melting
temperature. Although this is interesting, it still does not indicate whether
R426H is less stable in standard conditions at physiological temperatures.
The free energy of folding curve from DSC can be used to predict the fraction
folded curve from CD. A three state model was used to calculate the prediction
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Figure 4.5: Free Energy of Folding vs. Temperature based on thermodynamic
parameters values from the Nano DSC. This is only an estimate for the free
energy curve since the unfolding process was resolved, but not reversible.

since it was suggested ADSL has one intermediate in the unfolding process.
The prediction was compared to a fraction folded curve obtained by thermal
denaturation from CD. The agreement between experiment and prediction
is good as can be seen in Figure 4.7. Unfortunately, since the process is
irreversible, we cannot make any conclusions regarding protein stability from
thermal denaturation. If conditions are found where reversibility is achieved,
it would pave the way for quick stability comparisons between WT and disease
associated mutations.
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Figure 4.6: Thermal melting curves for WT, R303C, and R426H ADSL.

4.3

ADSL Unfolding is Reversible by Chemical Denaturation

Since it is clear that thermal denaturation, in the conditions tested, is not
reversible, chemical denaturation was attempted next. Fraction folded curves
for WT (a), R426H, (b), and R303C (c) exhibit a reversible process shown
in Figure 4.8. Unfortunately, a complete refolding signal was not achievable.
Refolding was tested by dialyzing protein at 6 M denaturant in 0 M denaturant
buffer. The protein always precipitated out of solution, most likely due to the
shock of being exposed to 0 M denaturant solution. It is noted that R426H
shows some hysteresis from 1-2 M denaturant. There is no current explanation
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Figure 4.7: CD melting curve with 3-state fraction folded prediction. The blue
line is experimental data calculated from CD. The red line is the prediction
from DSC thermodynamic parameters.

for the hysteresis. Similarly to thermal denaturation, R426H appears to be
less stable while R303C is very similar to WT.

4.4

ADSL Dissociates Into Monomers

The landscape of ADSL is very diverse. Starting from a folded tetramer,
there are many different pathways that can be taken, meaning there are a
number of states that could be occupied. Differential scanning calorimetry
suggested at least one detectable intermediate is present. To detect what
states are present, samples from the fraction folded curve were ran on blue
native gels. The results for WT showed a main band at 0 M denaturant the
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(a)

(b)

(c)

Figure 4.8: Chemical Denaturation plots of Fraction Folded vs. Denaturant
Concentration (M) for WT (a), R426H (b), and R303C (c). Denaturation
plots are in blue while renaturation plots are in red.
corresponds to the tetramer (Figure 4.9a). The first transition around begins
at 1.2 M denaturant, in agreement with CD data. A faint, new band begins
to appear half way down the gel as the main band fades and potentially starts
to move upward on the gel. It is also noted that the new band decreases in
intensity as denaturant concentration increases. A new band appearing, and
the tetramer band fading, is interpreted as the tetramer unit dissociating into
smaller subunits. A possible explanation for the low band intensity for the new
band is that the large concentration of guanidinium chloride is not allowing
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the stain to bind to the protein. This pattern is also true for R426H (Figure
4.9b). It is also confirmed in the blue native gels that the R426H mutation
causes the tetramer to fall apart sooner.

(a)

(b)

Figure 4.9: Chemical denaturant experiments on blue native gels. Concentration of denaturant increases toward the right.
The molecular weight of the new band falls between two standards around
the molecular weight of the ADSL monomer and dimer. The resolution was
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not good enough to confirm it was one, or the other. Therefore, a secondary
and more quantitative analysis using sedimentation velocity was used on WT
ADSL to determine the state of the second band. It showed at 0 M, tetramers
were mainly present and as denaturant concentration increased, molecules with
molecular weight of 57 kDa began to appear. This experimentally shows the
tetramer is indeed dissociating into monomers as denaturant concentration
increases (Figure 4.10). Aggregation is also present throughout the unfolding
process. It is fairly consistent around 4% of the total concentration fraction.
Sedimentation velocity also calculates the average hydrodynamic radius (R h )
of the different molecular states. Average R h values for tetramer and monomer
molecules are shown in Figure 4.11 overlaying the fraction folded curve for
WT. The fraction folded curve (black, circles) corresponds to the left scale
and average R h values for the tetramer (blue, triangles) and monomer (red,
squares) correspond to the right scale (Figure 4.11).
Theoretical boundaries for folded and unfolded ADSL can be calculated
based on random walk (R g ) [92]. Based on chain length, the R h for folded
protein is

Rh = (4.75 ± 1.11)N 0.29±0.02

(4.4.1)

The R h for a completed unfolded protein is

Rh = (2.21 ± 1.07)N 0.57±0.02
108

(4.4.2)

Figure 4.10: Fractions of protein states with different concentrations of denaturant.

This particular study included more α-helical proteins, so it is thought it
will give a better estimate for ADSL monomer and tetramer R h . The boundaries can be seen in Figure 4.12. The folded state R h prediction is depicted
by a solid line and a double line for the unfolded state. The R h experimental
data for the monomer fits well between the calculated boundaries and appears
to start at the folded boundary and increase linearly to the unfolding boundary. Accordingly, it can be inferred the monomer is undergoing an unfolding
process. The boundaries for the tetramer were not as clear. The calculated
folded R h was 4.2 nm too small. Since at 0 M denaturant, the enzyme is
known to be in its native state, the average of the first two points was used as
the boundary value. The completely unfolded boundary is very high, leading
to the conclusion that most of the tetramer must be dissociating, but because
of the noticeable increase in radius, there may be some unfolding occurring
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Figure 4.11: Overlay of fraction folded curve (black, circles) corresponding
to the left scale and average R h values for the tetramer (blue, triangles) and
monomer (red, squares) corresponding to the right scale.

prior to breaking apart. It is unclear whether the tetramer is being completed
unfolded, partially folded, or “swelling”.

4.5

Thermodynamic Modeling of ADSL Stability

4.5.1

Validation of Code

Lactose repressor protein is a well characterized homotetrameric protein
of molecular weight 150 kDa. Its monomer has three structurally separated
domains and it is a dimer of dimers. Three papers have been published on the
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Figure 4.12: Theoretical boundaries for folded and unfolded tetramer (blue,
diamonds) and monomer (red, squares). Solid lines are the folded boundary
while the double lines are the unfolded boundary.

chemical stability of lactose repressor [6, 15, 69]. This makes lactose repressor
a good system to test a prediction model for ADSL chemical denaturation.
Lactose repressor is an interesting tetramer that under high concentration of
urea, does not undergo dissociation [6]. Instead it transitions from a folded
tetramer to an unfolded tetramer. Since there is no dissociation, the transition
was treated as a two state problem [6,69]. To gain a complete characterization
of the pathway, Chen et. al employed two alterations of lactose repressor to
make the system form dimers instead of tetramers, a deletion mutant missing
11 amino acids (-11 aa) at the C-terminus that has diminished apparent operator binding and a mutant designated as R3 where the substitution of the
C-terminal leucine heptad repeat region of the normally tetrameric lactose repressor by the leucine heptad repeat dimerization domain of GCN4 [15]. Since
111

Table 4.2: Comparison of Free Energy for Dimer Unfolding
Mutation

∆G D−U - Chen (kcal/mol)

∆G D−U - Ray (kcal/mol)

-11 aa
R3

19.3 ± 1.4
23.9 ± 1.0

19.2 ± 0.9
24.4 ± 0.5

Table 4.3: m-value for lactose repressor
Mutation m-value - Ray (kcal/mol/M)
-11 aa
R3

-4.2 ± 0.2
-6.1 ± 0.3

dimer unfolding has an exact solution, a numerical, iterative solution could be
tested with this data set.

The reported values for dimer unfolding were 19.3 ± 1.4 kcal/mol and 23.9
± 1.0 kcal/mol, for -11 aa and R3 respectively (Table 4.2). Using PlotDigitizer
to estimate the values of the fraction unfolded curves from ref [15], thermodynamic parameters were found by fitting with the exact solution (equation
1.9.31) in Mathematica 8.0. The solved parameters were very close to the published values (Table 4.2). The m-values were also determined. It is assumed
they are correct because of the matching free energies because they were not
included in the publication.

These values were then used for the numerical solution for a dimer unfolding. The graph was visually identical to the exact solution for both mutants
as seen in Figure 4.13. A better way to test the numerical solution would have
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been to run an iterative process to find the best fit values. Unfortunately, time
did not permit such a test. However, this gives enough confidence that the
method used for arriving at a numerical solution for dimer unfolding will also
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Figure 4.13: Graphs from exact solution of dimer unfolding (a and c) and
numerical solution (b and d) for the -11 aa (a and b) and R3 (c and d) mutations. The two solutions provide almost identical graphs given the same
thermodynamic parameters.

4.5.2

Two State Model Fails

All data suggests that there is an intermediate state present in ADSL
denaturation. This is also confirmed by the following two state models for a
folded tetramer to an unfolded monomer.
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Boltzmann Distribution
The Boltzmann Distribution is a quick check for two state models. The
only limitation is it does not account for concentration dependence due to
tetramer dissociation.

Pf =

1
1 + exp[β∆G]

(4.5.1)

The ∆G for the transition can be written as a linear dependence on denaturant
concentration; ∆G = ∆G o + m[d]

Pf =

1
1 + exp[β(∆Go − m[d]]

(4.5.2)

The two-state model fails to capture the features of the fraction folded graph
(Figure 4.14).

Numerical Solution
Unlike the dimer unfolding, tetramer unfolding does not have an exact
solution that is dependent on concentration. Therefore the following numerical
model was built.

Ntotal = Nf,t + Nu,m
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(4.5.3)
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Figure 4.14: Two state prediction for the Boltzmann Distribution.

Where N total is the initial monomer concentration, f and u denote folded and
unfolded state, and t and m represent the tetramer and monomer state. Since
the solution is in a state of equilibrium, we can relate N f,t and N u,m by

4
4
Nf,t = Nu,m
exp[−β∆G] = Nu,m
exp[−β(∆Gf,t − 4∆Gu,m )]

(4.5.4)

The ∆G for the transition can be written as a linear dependence on denaturant
concentration; ∆G = ∆G o + m[d ]

4∆Gu,m − ∆Gf,t = ∆Go − m[d]

where ∆G o and m > 0
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(4.5.5)

4
Nf,t = Nu,m
exp[β(∆Go − m[d])]

(4.5.6)

This allows equation 4.5.3 to be written in terms of N u,m .

4
Ntotal = Nu,m
exp[β(∆Go − m[d])] + Nu,m

(4.5.7)

From here, an iterative process can be coded to find the ∆G o and m-values
that result in the best prediction of the fraction folded curve.

Pf =

4
Nu,m
exp[β(∆Go − m[d])]
Ntotal

(4.5.8)

The two state model again fails to capture the features of the fraction folded
graph (Figure 4.15). This confirms at least one intermediate state is present
during denaturation.

4.5.3

Three State Model Improves Prediction

A similar method for a numerical solution can be applied for a three state
model. The three state model was based on data supporting a folded monomer
intermediate state (Mf,t → Mf,m → Mu,m ). The numerical solution can attained as follows:
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Figure 4.15: Two state predictions for the numerical solution.

Ntotal = Nf,t + Nf,m + Nu,m

(4.5.9)

4
Nf,t = Nf,m
exp[−β(∆Gf,t − 4∆Gf,m )]

(4.5.10a)

Nu,m = Nf,m exp[−β(∆Gu,m − ∆Gf,m )]

(4.5.10b)

Substituting the linear expression of ∆G in terms of ∆G o and m.

4
Nf,t = Nf,m
exp[β(∆Go,1 − m1 [d])]

(4.5.11a)

Nu,m = Nf,m exp[−β(∆Go,2 − m2 [d])]

(4.5.11b)
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Writing equation 4.5.9 in terms of N f,m

4
exp[β(∆Go,1 − m1 [d])] + Nf,m + Nf,m exp[−β(∆Go,2 − m2 [d])]
Ntotal = Nf,m

(4.5.12)
The fraction folded can then be predicted by

4
Nf,m
exp[β(∆Go,1 − m1 [d])] + Nf,m
Pf =
Ntotal

(4.5.13)

where ∆G o,1 and ∆G o,2 are the free energies of the tetramer dissociation and
monomer unfolding respectively. The iteration was run with unbound and
bound parameters. Executing the code with unbound parameters should lead
to a global minimum. The resulting values are summarized in Table 4.4.
There is a large contrast in the free energies. The ∆G for dissociation is 119.3
kT/mol while the monomer unfolding is 3.1 kT/mol. Since four monomers
are unfolded, the total free energy is 12.4 kT/mol. This value is still a small
contribution to the total free energy of unfolding (∼10%). Based on chain
length, the expected m-values for unfolding of a tetramer and monomer would
be 68-81 and 18-21 respectively [27, 60]. The m-value for dissociation is close
to the expected m-value for a tetramer that undergoes unfolding. The m-value
for the monomer is much lower than expected. Compared to lactose repressor,
which is similar in structure and chain length, there is a significant difference
in the total free energy of unfolding and m-values. The graph resulting from
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Table 4.4: WT 3 State Parameters for Bound and Unbound Parameters
Parameter

Bound

Unbound

Theoretical

∆G M4 −4M (kT/mol)
∆G M −U (kT/mol)
mM4 −4M (kT/mol/M)
mM −U (kT/mol/M)

119.3
3.1
74.0
1.5

65.0
3.1
23.0
1.5

68-81*
18-21

*Theoretical range for tetramer unfolding

the fit parameters is in good agreement with the data (Figure 4.16a).

The bound parameters only set a limit on the total free energy of the unfolding process based on DSC results. The thermodynamic parameters for the
monomer unfolding were identical to the unbound results. The values for the
tetramer unfolding were lower, but the resulting graph is clearly not as good
of a fit (Figure 4.16b). While the unbound fit may be the better of the two
graphs, the bound fit is closer to physically relevant values for ∆G o . It is also
difficult to compare the theoretical m-value for the first transition because the
modeled transition was dissociation and not unfolding.

Parameters from the bound numerical solution were used to predict the
average R h . The upper and lower limit for folded and unfolded monomer were
set to 2.9 nm based on reference [92] and 6.1 nm respectively. The unfolded
boundary came from the experimental data at 4.8 M denaturant concentration.
Since the data point on the fraction folded curve is on the unfolded baseline,
we believe this to be a good estimate for the final transition. The predictions
(lines) for the average R h displayed an overestimation of the monomer unfold119
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Figure 4.16: Three state predictions for unbound (a) and bound (b) parameters.
ing and failed to capture the increase in tetramer radius (Figure 4.17). The
fraction folded curve is calculated based off the loss of secondary structure. In
the current three state model, the only cause for a loss of structure is due to
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the monomer unfolding. Thus, the overestimation is not a surprise. What this
indicates is that a fourth state is necessary to accurately describe the system.
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Figure 4.17: Overlay of fraction folded curve (black, circles) and average R h
values for the tetramer (blue, triangles) and monomer (red, squares). The
fit for the 3 state model is the black line. The prediction of the R h for the
tetramer and monomer species are blue and red respectively. Evident from
the monomer prediction, the unfolding of the monomer is over-predicted.

4.5.4

Four State Model is the Next Step

Though the three state model has a reasonable fit to the CD data, it
is unable to predict the AUC measurements. The major flaw was it over
predicted the fraction of molecules in the monomer state and under predicted
the tetramer state. It also fails to capture the increase in radius of the tetramer.
This motivates the need for a fourth state in the model. Based on observations
121

in our data and on the homotetramer lactose repressor protein, the fourth state
will initially be consider an unfolded tetramer [6].
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Chapter 5
Future Work
5.1
5.1.1

Research Directions for Enzyme Activity
Further Development of HPLC-EC Enzyme Assay

A current limitation to the HPLC-EC Enzyme assay is we have only developed an experimental method for measuring the V max kinetic parameter.
It would be beneficial to develop an experimental method that captures the
whole kinetic curve that can be modeled with either the Michaelis-Menten or
Hill Equation. The challenge is measuring the initial velocities at low concentration of substrate. According to the UV assay, the linearity of the initial
velocity lasts only a few seconds at low concentrations before the substrate is
no longer saturated or the substrate is completely undetectable by UV. Using
the current method to stop the reaction would not give enough resolution to
determine the initial velocity. An automated stop-flow system would have to
be engineered to achieve good resolution. Although, It is possible with the
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sensitivity of the HPLC-EC that the linearity actually lasts longer than what
the UV enzyme assay is able to detect.

5.1.2

Finish Characterization of D87E and E80D Mutations

The E80D and D87E mutations are an enigma in regards to why they cause
ADSL deficiency. They both have relatively high activities and appear to be
qualitatively as stable as WT (Figures 5.1, 5.2 and 5.3; Table 5.1 and 5.2). The
stability of each protein was checked by thermal melting curves using circular
dichroism (CD). WT ADSL melts at 65.5 , E80D at 63.9, and D87E at 67.7
o

C(Figure 5.2). Though these differences are small, the higher melting tem-

perature of D87E is consistent with our finding that this mutation stabilizes
the equivalent B. subtilis mutant ADSL. We also checked this by performing
chemical denaturation for WT and mutant ADSL and found similar transition
patterns (Figure 5.3). We assessed the molecular weight of each mutant and
WT ADSL by light scattering. In each case, the predominant species has a
molecular weight around 228 kDa, as would be expected for the tetrameric
form of ADSL. About 3.6% of WT ADSL was present as aggregates larger
than tetramer, with slightly larger amounts for E80D (4.6%). Importantly,
13.1% of the D87E protein was present in large aggregates (Table 5.3). This
could point to the mutations E80D and/or D87E causing a “gain in toxic function” as the pathogenic mechanism for ADSL deficiency. Since they are both
present in the same patient, it may be pertinent to perform experiment on
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Table 5.1: SAMP UV Kinetic Parameters of Human ADSL at 25◦ C
Enzyme V max (µmol min−1 mg−1 )
WT
E80D
D87E

13.9 ± 0.2
9.2 ± 0.2
8.0 ± 0.2

K0.5 (µM)

Hill Coeff.

kcat
K0.5

2.05 ± 0.08
2.49 ± 0.06
1.09 ± 0.07

1.4 ± 0.1
1.6 ± 0.1
1.3 ± 0.1

2.52 x 107
2.35 x 107
2.80 x 107

The SAMP kinetic parameters were determined by varying the concentration of SAMP and fitting thedata to the Hill equation using Mathematica. The values are shown along with their standard error.

hybrid tetramers as well [4].

In vivo studies by other members of the Patterson Lab show WT and
E80D transfectants grew well in the absence of adenine. Surprisingly, the
D87E transfectants were unable to grow in the absence of adenine in the
growth medium. RT-PCR analysis of the transfectants revealed that all made
abundant hADSL mRNA (data not shown). However, while WT and E80D
transfectants made significant amounts of hADSL protein, this protein was not
detectable in D87E transfectants. Consistent with these observations Spiegel
has shown that P1 genomic clones containing either WT or E80D genomic
hADSL can allow growth of AdeI cells, whereas P1 clones containing D87E
hADSL cannot. More work needs to be done to fully characterize these two
mutations in order to fully understand how they change the properties of WT
ADSL.
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Figure 5.1: Specific Activity vs [Substrate] plots.

5.1.3

Further Investigate the Flexible Loop Region

The current understanding of the functions of the amino acid residues from
284 to 292 in ADSL is incomplete. They are hypothesized to function as a
flexible loop that enclosed the active site upon substrate binding. The A291V
mutation results in an inactive ADSL enzyme. To test the flexibility hypothesis, a collaboration with Banu Ozkan via Kingshuk Ghosh was initiated to use
a harmonic oscillator model predict the loss of flexibility due to the A291V
mutation (Figure 5.4).
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Table 5.2: SAICAR UV Kinetic Parameters of Human ADSL at 25◦ C
Enzyme V max (µmol min−1 mg−1 )
23.3 ± 0.5
18.0 ± 0.4
13.7 ± 0.4

WT
E80D
D87E

K0.5 (µM)

Hill Coeff.

kcat
K0.5

1.74 ± 0.08
1.06 ± 0.07
0.75 ± 0.08

1.3 ± 0.1
1.3 ± 0.1
1.3 ± 0.2

5.09 x 107
6.45 x 107
6.88 x 107

The SAICAR kinetic parameters were determined by varying the concentration of SAICAR and fitting the data to the Hill equation using
Mathematica. The values are shown along with their standard error.

Table 5.3: ADSL Population Distribution
Enzyme

Tetramer Weight (kDa)

Tetramer (%)

Aggregate (%)

WT
E80D
D87E

220.8 ± 0.2%
221.8 ± 0.3%
231.5 ± 0.2%

96.2 ± 0.6
95.4 ± 0.8
86.7 ± 0.2

3.6 ± 0.6
4.6 ± 0.8
13.1 ± 0.1

The results indicate a predicted decrease in the regions flexibility supporting the current hypothesis. More work needs to be done on the complete loop
region to provide a better understanding of these amino acids.

5.1.4

Incomplete Models Relating to Enzyme Activity

Two Site, Two Substrate Model
The mixing ratios and cooperativity led to an attempt to derive a model
based on of the mass action principle to predict relative rates of formation of
the products at any mixing ratio of substrate. It is based on the idea that the
“top” two active sites and “bottom” two active sites are too far away from
each other to induce a conformational change. Under this assumption, the
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Figure 5.2: E80D and D87E Thermal Melts

only cooperativity that could occur would be between two active sites and
only models the activity of the top (or bottom) two active sites as depicted in
Figure 5.5. This model attempts to predict the relative rates of formation of
the products at any mixing ratio of substrate. Preliminary results can be seen
in Figure 5.6 for WT (a), R303C (b), and R426H (b). Nothing new came from
this early prediction, but it could be that it may need to be developed more.

Purine Biosynthesis Pathway
A limitation to the in vitro experiments is they do not take into account the
upstream and downstream activities of the other enzymes involved in de novo
purine biosynthesis. It is a very basic model that does not take into account
anything but the relative catalytic constants of the enzymes that were all
assumed to be equal to 1 except ADSL. It does not account for purinosome
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Figure 5.3: Chemical denaturation of E80D and D87E

formation, potential substrate trafficking, feedback loops, etc. Preliminary
results can be seen in Figure 5.7 using k cat values for WT (a), R303C (b), and
R426H (c). The most dramatic difference is with R303C where the AICAR
(red line) peak is significantly lower and is broader. This causes a rise in both
substrates, but a more prominent rise in SAMP (green line). More work is
required to come to any inferences or conclusions.

5.2

Investigate Crowding Effect

A shortcoming of current biochemical studies is they are performed under ideal conditions with pure enzymes stored in dilute buffers that may not
accurately reflect the actual intra-cellular environment. It has been shown
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Figure 5.4: Harmonic oscillator model for the flexible loop of ADSL that is
thought to cover the active site to speed up catalysis. The mutation A291V
severely affects the flexibility of the loop.

Figure 5.5: Pictorial representation of the enzyme reactions for a two site, two
substrate model that accounts for cooperativity
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Figure 5.6: Prediction of ADSL kinetics by a model of a system with 2 active
sites and 2 substrates present. Graphs represent a 50/50 mixture of substrate
concentration. Black - SAICAR, Red - AICAR, Green - SAMP, Blue - AMP.
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Figure 5.7: Prediction of accumulation of ADSL metabolites in the de novo
purine pathway. Black - SAICAR, Red - AICAR, Green - SAMP, Blue - AMP.
that the dynamics and stability of biomolecules in vitro is modified by crowding [16, 26, 35, 39]. The majority of cellular functions take place in a crowded
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environment due to the presence of macromolecules that occupy up to 5% to
40% of the total cell volume [23]. Due to synergistic effects of volume exclusion by macromolecules, even less space becomes available to other functional
macromolecules such as enzymes [23, 96]. Thus crowding can significantly
alter biochemical properties of these enzymes. For example, crowding usually promotes processes that stimulate increase in the accessible volume such
as aggregation [23]. A reduced accessible volume available for the proteins
may effectively enhance the probability of association of different monomers
into higher order protein aggregates. However, this is not the only effect of
crowding; there are other competing effects as well. For example, protein association often occurs by simple diffusion and the presence of crowding may
significantly reduce the diffusion constant thus kinetically hindering the aggregation process. This may adversely affect the rate of formation of tetrameric
ADSL. Presence of confinement and crowding can also induce steric hindrance
reducing stability of disordered or flexible conformations that may affect the
enzyme activity as well. It is thus imperative to carry out structure function
analysis of ADSL enzyme in the presence of crowding to better mimic in vivo
conditions. The peculiar sensitivity of ADSL and several atypical activities
measured under in vitro conditions that does not correlate well with expected
function of the enzyme could be attributed to the absence of crowding in such
experiments which perhaps play a significant role in vivo and hence in disease
pathogenesis.
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5.3
5.3.1

Research Directions for Protein Stability
Immediate Projects for Chemical Stabilty

Once analysis is complete for the first ∆G at 25 ◦ C (Figure 5.8a), it can be
applied systematically to chemical denaturant experiments at different temperatures and concentrations. Measuring the ∆G at different temperatures
will add more data points to the free energy of folding vs. Temperature curve
(Figure 5.8b). If a sufficient number of data points are collected, thermodynamics can be used to model the free energy of folding curve to extract
thermodynamic parameters ∆H, ∆S, and ∆C p (Figure 5.8c). Measuring the
unfolding transition at different concentrations will provide more information
about whether or not a dissociation. A concentration dependent transition
means there has been a dissociation that has taken place. This could be useful
in complimenting sedimentation velocity in identifying whether the tetramer
begins to dissociate before unfolding.

5.3.2

Investigate DSC Conditions for Reversibility

Thermal denaturation has been shown to promote protein aggregation following unfolding and hence reversibility is difficult to achieve with a monomeric
protein. Hence it is not surprising ADSL, a tetrameric protein, was not reversible by thermal denaturation. Papers have shown that additions of small
amounts of denaturant (such as Guanidine Hydrochloride) or macromolecules
(such as TMAO), make solution conditions favorable for reversibility. The
logic is the denaturant and macromolecules act as crowding agents that do
not allow unfolded units to interact with each other. This would be useful to
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Figure 5.8: Future Directions for Chemical Denaturation Experiments.
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try with ADSL protein. Thermodynamic reversibility on the DSC would best
proven by showing ∆C p is independent of scan rate as opposed to seeing the
second scan providing the same, or similar, ∆H. The later is more of a test of
thermodynamic repeatability as opposed to reversibility [73]

5.3.3

In Vivo Fluorescence Spectroscopy

Simulating the intracellular environment is not a simple task for in vitro
experiments. Currently, the best we can do is to insert inert crowding agents
into the solution. But this does not take into account the myriad of interactions that could occur with cellular transport, chaperones. To reveal the full
functionality of proteins and other biomolecules, they must be studied in the
living cell [22].

Fluorescently Tagged Proteins
We have successfully tagged all ADSL protein with RFP and GFP tags
(Figure 5.9). They express the protein and glow under the microscope. It also
appears co-transfections are possible. Very preliminary experiments have been
done on the cells to create stable cell lines and to make sure the fluorescent
tags do not change how the transfected ADSL behaves without the tag. Basic
starvation experiments were performed for cell lines with RFP and GFP tagged
ADSL (Figure 5.10). Interestingly, D87E never grew and GFP-R426H was able
to rescue the cell lines while RFP-R426H was not. The case was vise-versa for
R303C which was able to rescue the cell line when tagged with RFP and was
unable to rescue the cell line with GFP.
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Figure 5.9: Transient transfections

Figure 5.10: Starvations
These abnormalities caused by the fluorescent tags as well as the inability to
create stable cell lines with both tags (Figure 5.11 bring up the concern the tags
themselves are altering the functionality of ADSL. Overall, since the transient
cell lines seem to express fluorescent protein as well as co-transfected ADSL,
it provides promise for future experiments for ADSL trafficking, purinosome
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formation, and in vivo fluorescence stability measurements. it is possible this
method will not provide any useful information and a different method such
as immunoflourescence should be used concurrently to compare results.

Figure 5.11: Stable cell lines
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Fast Relaxation Imaging
Fast relaxation imaging (FReI; Figure 5.12) is a technique that can be used
to image fast dynamics of biomolecules in vivo [22]. It couples time-resolved
fluorescence imaging with fast temperature jump induced kinetics. It utilizes
FRET signaling to determine whether a protein is folded or unfolded Figure
5.13. ADSL is tagged on the N-terminus for both RFP and GFP tags. This
was quite fortunate because it the only two terminuses that come in close
enough contact for FRET to occur is two N-terminus of the A and D chains
(3.3 nm; Figure 5.14). Setting up this sort of experiment would be a big task
for either multiple undergraduates or new graduate student. It could also start
up collaboration with Dr. Mark Siemen’s optics lab if a FReI system need to
be “rigged up” as opposed to purchasing all new equipment.

Figure 5.12: Pictorial representation of an FReI experimental setup.
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Figure 5.13: Data you would expect to see from an FReI experiment

Figure 5.14: Approximate location for fluorescently labeled proteins. Tag
location is depicted by blue chains. Area is approximate because the first 15
amino acids do not have a specified location
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Appendix A
Materials and Methods
A.1

Materials

Chemicals, biochemicals, buffers, and solvents were purchased from SigmaAldrich Chemical Co. (St. Louis, MO), Fisher Scientific Inc. (Pittsburgh,
PA), Fluka Chemical Corp. (Milwaukee, WI), or EM Science (Cincinnati, OH).
The Centricon and Ultrafree centrifugal filter devices were obtained from Millipore Co. (Billerica, MA). Nickel-nitrilotriacetic acid-agarose, a QIAspin kit,
and high throughput crystal condition screens were purchased from QIAGEN.
Additive HT Screen was purchased from Hampton Research. QuikChange
site directed mutagenesis kit was purchased from Stratagene. SAICAR was
prepared enzymatically from AICAR purchased from Sigma-Aldrich Chemical Co. as described by Zikanova, et al [97]. Enzymes and reagents used for
molecular biology procedures were obtained from New England Biolabs, Inc.
(Ipswich, MA).
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A.2
A.2.1

Methods
Site-Directed Mutagenesis, Enzyme Expression,
and Purification

The initial WT ADSL construct was obtained from Dr. Roberta F. Colman, Department of Chemistry and Biochemistry, University of Delaware,
Newark, DE. The full description of the initial ADSL WT construct is described in Lee and Colman [47]. In short, the full length human ADSL gene
(1-484 residues) was constructed in pET-14b vector containing a 5’-end NdeI
restriction site and a 3’-end BlpI restriction site and a thrombin cleavable Nterminal histidine tag. In order to overexpress the human enzyme in E. coli,
the vector was transformed into E. coli Rosetta 2(DE3)pLysS. Introduction of
point mutations in the human ADSL plasmid was done by the QuikChange
site-direction mutagenesis. The QIAspin kit was used for cDNA extraction
and purification. DNA sequencing performed at CU Cancer Center DNA Sequencing and Analysis Core confirmed mutations.

ADSL protein was then grown in LB broth at 37◦ C until cell density
(OD600 ) reached 0.4-0.6. The cell culture was then cooled to 25◦ C and induced with 0.4 mM IPTG overnight. Cells were pelleted by centrifugation at
x2500 g. The cell pellet was resuspended in cell lysis buffer (50 mM potassium phosphate buffer, pH 8.0, 300 mM KCl, and 10% glycerol) based on 10
mL lysis buffer per gram of cell pellet. DNase (1 mg/mL) and RNase (25
mg/mL) were added to the lysis buffer at 0.001 (w/v) and 0.01 (w/v) for
DNase and RNase respectively. The pellet was freeze-thawed three times to
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rupture the bacterial cell membrane. The soluble protein fraction (crude cell
lysate) was separated from cell debris by centrifugation at x32,000 g. The
crude cell lysate was then loaded onto a Qiagen Ni-NTA column equilibrated
with lysis buffer. After loading the crude cell lysate, the Ni-NTA column was
washed with 100 mL lysis buffer, followed by 100 mL lysis buffer with 20 mM
imidazole to remove any loosely bound protein. The histidine tagged ADSL
was eluted by a column gradient or 150 mL of lysis buffer containing 20 mM
imidazole and 250 mM imidazole. ADSL was collected in 4 mL fractions with
400 µL of enzyme storage buffer (50 mM potassium phosphate, pH. 7.0, 150
mM KCL, 1 mM DTT, 1 mM EDTA, 10% glycerol). Fractions were tested
for ADSL concentration by the Bio-Rad assay. Fractions with high ADSL
concentration were pooled and concentrated using Amicon Ultra-15 (MWCO
10,000). The concentrated enzyme was dialyzed against enzyme storage buffer
overnight. Purity was assessed by SDS-PAGE Gel Electrophoresis (data not
shown). Protein Concentration was calculated by absorbance at 280 nm using
E280 1% = 7.7 [29]. After purification, protein was stored at -80◦ C.

A.2.2

Population Distribution by Static Light Scattering

Size Exclusion Chromatography-Multi-Angle Light Scattering measurements
were performed on a Wyatt miniDAWN TREOS connected to a Shimadzu
UFLC and a Wyatt WTC-030S5 size exclusion column. Samples were run in
duplicate of 350 µg of His-tagged ADSL diluted in Enzyme Storage buffer.
PBS was used as the mobile phase and flowed at .5 mL/min. Calibration
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was checked using 2 mg/mL bovine serum albumin. Data were analyzed with
ASTRA software. Values of .185 and 770 were used as the

dn
dc

value and extinc-

mL
tion coefficient ( g∗cm
) respectively. The extinction coefficient was calculated

by previously established methods [29].

A.2.3

Population Distribution by Analytical Ultracentrifugation

Sedimentation velocity (SV) experiments of the WT and mutant enzymes
were conducted using a Proteomelab XL-I analytical ultracentrifuges (Beckman Coulter, Fullerton, CA) analytical ultracentrifuge equipped with an An60Ti analytical rotor. Prior to each SV experiment, frozen samples were incubated for ∼2 hours at 25◦ C before measurements were taken. ADSL samples (
∼0.35 mg/mL) were centrifuged at 40,000 rpm at 25◦ C. The number of scans
collected in each run was adequate to capture the entire sedimentation process.
Data were analyzed using the SEDPHAT program. The density of the buffer
at 25◦ C was calculated using the SEDNTERP program. The partial specific
volume of human ASL at 25◦ C is 0.7366.

A.2.4

Secondary Structure by Circular Dichroism

The secondary structure of the WT and mutant enzymes was assessed using
CD spectroscopy. Ellipticity was measured on a Jasco - J815 spectropolarimeter from 200 to 250 nm, in 0.2 nm increments using a 0.1 cm quartz cuvette.
The samples were scanned three times and averaged, and the background from
the buffer (50 mM KPO4 buffer, pH 7, containing 150 mM KCl, 1 mM EDTA,
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1 mM DTT, and 10% glycerol) was subtracted. The mean molar residue elθ
lipticity [θ] (deg cm2 dmol−1 ) was calculated from the equation [θ]= 10∗n∗C∗`
,

where θ is the measured ellipticity in millidegrees, C is the molar concentration
of enzyme subunits, ` is the path length in centimeters, and n is the number
of residues per subunit (503 residues per monomer, including the His6 tag and
thrombin cleavage site). The WT and mutant enzyme samples were incubated
for ∼2 hours at 25◦ C before measurements were taken. The ellipticity of the
samples was measured at 25◦ .

A.2.5

Enzyme Kinetics by UV

Enzyme kinetics was performed on a UV-Vis Spectrophotometer Evolution
3000 from Thermo Scientific using 1 mL quartz cuvettes at 25◦ C. ADSL with
the His-tag intact was used for enzyme assays, as it has been shown that the
His-tag does not affect enzyme activity [47]. Experiments were run with concentrations of 0.11 mg/mL and 0.19 mg/mL for WT and R303C respectively.
Frozen samples were incubated for ∼2 hours at 25◦ C before measurements
were taken. SAMP enzyme assays of ADSL were measured at 25◦ C in 40 mM
Tris-HCl (pH 7.4) with varying concentrations of SAMP (1 - 60 µM). Specific
activity was measured from the decrease in absorbance of SAMP at 282 nm
as it was converted to AMP and fumarate. The assay was monitored over 30
seconds in a 1 mL reaction volume. The difference extinction coefficient of
10000 M−1 cm−1 between SAMP and AMP was used to calculate the specific
activity. SAICAR enzyme assays of ADSL were measured at 25◦ C in 40 mM
Tris-HCl (pH 7.4) with varying concentrations of SAICAR (1-60 µM). Specific
activity was measured from the decrease in absorbance of SAICAR at 269 nm
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as it was converted to AICAR and fumarate. The assay was monitored over 30
seconds in a 1 mL reaction volume. The difference extinction coefficient of 700
M−1 cm−1 between SAICAR and AICAR was used to calculate the specific
activity. The initial velocities (ν) and kinetic constants (Vmax , K0.5 , and

kcat
)
K0.5

were calculated by custom Mathematica templates. The initial velocity was
calculated by importing the absorbance vs. time graphs into Mathematica
where the linear portion of the graph was fit with a linear line. The change in
absorbance (∆A) was calculated for one minute from the linear fit. The initial
velocity was calculated by Beer’s Law, ∆C =

∆A
,
ε`

where ∆C is the change in

concentration over time, ∆A is the change in absorbance over time, ε is the
difference extinction coefficient, and ` is the pathlength. The initial velocity
was put in terms of specific activity (µmol min−1 mg−1 ) by dividing ν by the
total enzyme injected into the reaction volume. To determine the kinetic constants, the initial velocity data were fitted to the Hill equation, ν =

Vmax ∗[S]n
n +[S]n .
K0.5

The kcat value was calculated from Vmax and the enzyme concentration [E] via
the equation kcat =

A.2.6

Vmax
.
[E]

Enzyme Kinetics by HPLC-EC

Enzyme activity was measured by HPLC-EC analysis of AMP and AICAR
formed from SAMP and SAICAR respectively. Assays were performed at
25◦ C in 40 mM Tris-HCl (pH 7.4) with varying concentrations of SAMP and
SAICAR (0-500 µM). Experiments were run in duplicate with approximately
250-500 µg ADSL injected into 1 mL reaction volume at 100% SAMP, 100%
SAICAR, and different ratios of SAMP to SAICAR concentration: 3:1, 1:1,
and 1:3. Every minute, 100 µL of the reaction mixture was extracted into
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25 µL of 2.5 M perchloric acid on ice to stop the reaction. The solution was
neutralized by adding 25 µL of 2.5 M potassium hydroxide. Samples were
clarified by centrifugation in a Spectrafuge 16M at 14,000 rpm at -5◦ C.

Separation of SAICAR, AICAR, SAMP, and AMP was achieved by HPLCEC analysis similar to our previously described method [21]. Briefly, separation
was obtained by a reverse phase HPLC-EC with a TSKgel ODS-80Tm C-18
column (250 mm x 4.6 mm ID, 5 µM) protected by Tosoh Bioscience TSKgel
guard cartridge. A column temperature of 35◦ C was maintained throughout
the analysis. A mobile phase consisting of 50 mM lithium acetate, 2% acetonitrile, and 5 mM tetrabutyl ammonium phosphate (TBAP) at pH 4.8 was
delivered isocratically at a flow rate of 0.8 mL/min. Sample extracts and
standards were kept at 10◦ C until a 30 µL aliquot of each sample was injected
using an ESA autosampler (model 542). After injection and separation, analytes were detected using a CoulArray HPLC system (model 5600A, ESA)
with three electrochemical detector modules. Each module contains four flowthrough coulometric detectors in series. Nine EC channels were set to a range
of potentials from 0 - 900 mV in 100 mV increments. Two channels were used
for a high potential boron-doped diamond (BDD) amperometric detector set
to 1700 mV and UV detector set at 265 nm.

This HPLC-EC software allows for quantitative measurement of the amounts
of both substrates and products. Peak quantitation was done using the CoulArray software package with manual curation to assure appropriate peak calling
by the software. Standard curves of concentration versus peak area in units
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of coulombs were generated for AICAR, and AMP. For these experiments the
standard curves consisted of a concentration range of 2-150 µM for the products and fit with a linear trendline. Time points 0-5 minutes for each mixing
ratio were analyzed. AMP and AICAR concentrations were calculated from
the standard curve, plotted, and fit with a linear line. The activity was given
by the slope of the line in units of Molarity*min−1 and changed into units of
µmol*min−1 *mg−1 .

A.2.7

Resource Sharing Kinetics Model

We carried out an enzyme mixing kinetics analysis to predict the rate of
product formation when two substrates catalyzed by the same enzyme are
present in solution at different concentrations. The analysis is based on the
coupling of two independent enzymatic reactions via resource sharing. By
independent reactions, we mean two separate reactions for each substrate in
the absence of the other. However, resource sharing induces a coupling due
to the fact that if one enzyme molecule is occupied by substrate one, it is
not available for substrate two. Although the enzyme has multiple binding
sites, we assume on a given enzyme each site is occupied by substrates of the
same type thus avoiding any other possible sources of coupling that may alter
the equilibrium constant (Km ). Thus competitive binding has been enforced
in the simplest form by conserving the total number of resources between
the two substrates. This is the only source of interaction between the two
reactions in our resource sharing model. Based on work by Ray, Deaton et
al, cooperativity may play a small role in substrate binding and catalysis [70].
Therefore, for simplicity, we disregard cooperativity in the present model.
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From these assumptions, the rate of product formation for each substrate in
mixing conditions can be predicted. The analysis starts with two independent
kinetics reactions:

k1

kcat,1

−−
*
[E] + [S1 ] )
−
− [E · S1 ] −−−→ [E] + [P1 ]
k−1

k2

kcat,2

−−
*
[E] + [S2 ] )
−
− [E · S2 ] −−−→ [E] + [P2 ]
k−2

(A.2.1)

(A.2.2)

where [E ] = ADSL, [S 1 ] = SAICAR, [P 1 ] = AICAR, [S 2 ] = SAMP, and [P 2 ]=
AMP. The two independent enzyme reactions indicate that a single enzyme
molecule binds [S 1 ] or [S 2 ]. Using our assumption no cooperativity, the rate of
product formation, d[P]
, in mixing conditions can be predicted in the following
dt
manner:

Applying the Law of Mass Action to [P 1 ] and the [E · S 1 ] complex in
equation A.2.1

d[P1 ]
= kcat,1 · [E · S1 ]
dt
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(A.2.3)

d[E · S1 ]
= k1 · [E][S1 ] − k−1 · [E · S1 ] − kcat,1 · [E · S1 ]
dt
Assuming a steady-state approximation,

d[E·S1 ]
dt

(A.2.4)

= 0, leads to

[E][S1 ]
k−1 + kcat,1
=
= Km,1
[E · S1 ]
k1

(A.2.5)

Applying the same to equation A.2.2

d[P2 ]
= kcat,2 · [E · S2 ]
dt

(A.2.6)

k−2 + kcat,2
[E][S2 ]
= Km,2
=
[E · S2 ]
k2

(A.2.7)

If both substrates are present, the total enzyme concentration, [E total ], can be
written as

[Etotal ] = [E] + [E · S1 ] + [E · S2 ]

Solving for [E ] from equation A.2.5 and equation A.2.7
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(A.2.8)

[E] =

[E · S2 ]Km,2
[E · S1 ]Km,1
=
[S1 ]
[S2 ]

(A.2.9)

Utilizing equation A.2.9 to write equation A.2.8 in terms of [E · S 1 ]

[Etotal ] =

[E · S1 ]Km,1
[E · S1 ] · Km,1 · [S2 ]
+ [E · S1 ] +
[S1 ]
[S1 ] · Km,2

(A.2.10)

Solving for [E · S 1 ] from equation A.2.10

[E · S1 ] =

[Etotal ]
Km,1
[S1 ]

+

Km,1 [S2 ]
Km,2 [S1 ]

(A.2.11)
+1

Substituting equation A.2.11 into equation A.2.3

d[P1 ]
=
dt

kcat,1 [Etotal ]
Km,1
[S1 ]

+

Km,1 [S2 ]
Km,2 [S1 ]

=
+1

Vmax,1
Km,1
[S1 ]

+

Km,1 [S2 ]
Km,2 [S1 ]

(A.2.12)
+1

Since our experiment was always in saturating conditions, Km,1 << S1

d[P1 ]
=
dt

Setting x =

Vmax,1
Km,1 [S2 ]
+
Km,2 [S1 ]

[S2 ]
[S1 ]
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(A.2.13)
1

d[P1 ]
=
dt

Vmax,1
Km,1
·x+
Km,2

1

(A.2.14)

Utilizing equation A.2.9 to write equation A.2.8 in terms of [E · S 2 ], , solving
for [E · S 2 ], and substituting into equation A.2.6 results in the rate of formation
for [P 2 ]

d[P2 ]
=
dt

Vmax,2
Km,2 1
· +
Km,1 x

1

(A.2.15)

Equations A.2.14 and A.2.15 are predictions for the rate of product formation,
d[P ]/dt, as a function of substrate ratio, x. Vmax and Km values are obtained
experimentally by enzyme kinetic assays on each substrate independently.

A.2.8

Two Site, Two Substrate Model

I did not have an opportunity to really delve into this model, and it seems
pretty moot at this point to continue. But it was fun to think about and was
good practice.
(*Initial concentrations for reaction*)
i0=4; (*ADSL*)
J0=50;(*SAMP*)
P0=0;(*AMP*)
s0=50;(*SAICAR*)
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A0=0;(*AICAR*)

(*complexes*)
iJ0=0;
is0=0;
Ji0=0;
si0=0;
JiJ0=0;
sis0=0; siJ0=0;
Jis0=0;

(*rate constants*)
k1 =1;
k−1 =0;
k2 =1;
k−2 =0;
k3 =1;
k−3 =0;
k4 =1;
k−4 =0;

(*catalytic constants*)
kstoA =7.4*0.43;
kJtoP =13.5*0.052;
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(*coop and catalytic rate constants*)
α=0.97; (*coop for after J binds for another J to bind*)
β=1; (*changes in catalytic rate with two active sites filled with J*)

γ=0.94; (*coop for after s binds for another s to bind*)
φ=1;(*changes in catalytic rate with two active sites filled with s*)

θ=1; (*coop for after s binds for another J to bind*)
ψ=1;(*changes in catalytic rate with two active sites filled with s and J*)

η=1; (*coop for after J binds for another s to bind*)
=1;(*changes in catalytic rate with two active sites filled with J and s*)

(*Time constants*)
NDSolveTime=2000;(*How far out to solve the differential equations*)

solution=NDSolve[ i’[t]==-k1 * i[t] * J[t] + k−1 * iJ[t] + kJtoP * iJ[t] - k3 *
i[t] * s[t] + k−3 * is[t] + kstoA * is[t] - k2 * i[t] * J[t] + k−2 * Ji[t] - k4 * i[t] *
s[t] + k−4 * si[t], ( * + kstoA * si[t] + kJtoP * Ji[t], * )

J’[t]==-k1 * i[t] * J[t] + k−1 iJ[t] - α * k1 * Ji[t] * J[t] + α * k−1 JiJ[t] - θ * k1
* si[t] * J[t] + θ * k−1 siJ[t] - k2 * i[t] * J[t] + k−2 Ji[t] - α * k2 * iJ[t] * J[t] +
α * k−2 JiJ[t] - θ * k2 * is[t] * J[t] + θ * k−2 * Jis[t],
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iJ’[t]==k1 * J[t] * i[t] - k−1 * iJ[t] - kJtoP * iJ[t] - α * k2 * iJ[t] * J[t] + α *
k−2 * JiJ[t] - η * k4 * iJ[t] * s[t] + η * k−4 * siJ[t], ( * + β * kJtoP * JiJ[t] +
 * kstoA * siJ[t], * )

P’[t]==kJtoP * iJ[t] + β * kJtoP * JiJ[t] + ψ * kJtoP * siJ[t], ( * + kJtoP * Ji[t]
+ β * kJtoP * JiJ[t] + ψ * kJtoP * Jis[t] * )

s’[t]==-k3 * i[t] * s[t] + k−3 is[t] - γ * k3 * si[t] * s[t] + γ * k−3 sis[t] - η * k3 *
Ji[t] * s[t] + η * k−3 * Jis[t] - k4 * i[t] * s[t] + k−4 si[t] - γ * k4 * is[t] * s[t] +
γ * k−4 sis[t] - η * k4 * iJ[t] * s[t] + η * k−4 siJ[t],

is’[t]==k3 * s[t] * i[t] - k−3 * is[t] - kstoA * is[t] + k4 * s[t] * i[t] - k−4 * si[t] γ * k4 * is[t] * s[t] + γ * k−4 * sis[t] - θ * k2 * is[t] * J[t] + θ * k−2 * Jis[t], (
* + φ * kstoA * sis[t] - kstoA * si[t] + ψ * kJtoP * Jis[t], * )

A’[t]==kstoA * is[t] + φ * kstoA * sis[t] +  * kstoA * Jis[t], ( * + kstoA * si[t]
+ φ * kstoA * sis[t] +  * kstoA * siJ[t] * )

Ji’[t]==-α * k1 * Ji[t] * J[t] + α * k−1 * JiJ[t] + β * kJtoP * JiJ[t] - η * k3 *
Ji[t] * s[t] + η * k−3 * Jis[t] +  * kstoA * Jis[t] + k2 * J[t] * i[t] - k−2 * Ji[t],
( * - kJtoP * Ji[t], * )

JiJ’[t]==α * k1 * J[t] * Ji[t] - α * k−1 * JiJ[t] - β * kJtoP * JiJ[t] + α * k2 *
J[t] * iJ[t] - α * k−2 * JiJ[t], ( * - β * kJtoP * JiJ[t], * )
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si’[t]==-γ * k3 * si[t] * s[t] + γ * k−3 * sis[t] + φ * kstoA * sis[t] - θ * k1 * si[t]
* J[t] + θ * k−1 * siJ[t] + ψ * kJtoP * siJ[t],

sis’[t]==γ * k3 * s[t] * si[t] - γ * k−3 * sis[t] - φ * kstoA * sis[t] + γ * k4 * s[t]
* is[t] - γ * k−4 * sis[t], ( * - φ * kstoA * sis[t], * )

siJ’[t]==θ * k1 * J[t] * si[t] - θ * k−1 * siJ[t] - ψ * kJtoP * siJ[t] + η * k4 * s[t]
* iJ[t] - η * k−4 * siJ[t], ( * -  * kstoA * siJ[t], * )

Jis’[t]==η * k3 * s[t] * Ji[t] - η * k−3 * Jis[t] -  * kstoA * Jis[t] + θ * k2 * J[t]
* is[t] - θ * k−2 * Jis[t], ( * - ψ * kJtoP * Jis[t], * )

i[0]==i0,
J[0]==J0,
iJ[0]==iJ0,
P[0]==P0,
s[0]==s0,
is[0]==is0,
A[0]==A0,
Ji[0]==Ji0,
JiJ[0]==JiJ0,
si[0]==si0,
sis[0]==sis0,
siJ[0]==siJ0,

173

Jis[0]==Jis0,
i[t],J[t],iJ[t],P[t],s[t],is[t],A[t],Ji[t],JiJ[t],si[t],sis[t],siJ[t],Jis[t], t,0,1200]
PlotTime=25;(*How far out to plot your solution*)
Plot[Evaluate[s[t],A[t],J[t],P[t]/.solution],t,0,PlotTime,
PlotRange → All,
(*PlotRange → 0,50,0,10,*)
Frame →True,
FrameStyle →Thick,
(*FrameTicks → 0,1,2,3,4,5,6,0,0.2,0.4,0.6,0.8,1.0,,,*)
FrameLabel → ”Concentration”,” ”,”Time”,”R303C Kinetic Parameters”,
LabelStyle → FontSize → 32,
PlotStyle → RGBColor[0,0,0], Thickness[0.005], RGBColor[1,0,0],
Thickness[0.005], RGBColor[0,1,0], Thickness[0.005], RGBColor[0,0,1], Thickness[0.005]]

A.2.9

Purine Biosynthesis Pathway

This is another model I did not have time to develop further than just
starting. This model predicts the intermediate accumulation in the de novo
purine biosynthesis pathway using the principle of mass action.
(*Package for Legend*)
needs[PlotLegends‘]

(*Initial concentrations for enzymes*)
T0=0.1;(*PPAT*)
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G0=0.1;(*GART*)
B0=0.1;(*FGAMS*)
d0=0.1;(*PAICS*)
i0=0.1; (*ADSL*)
F0=0.1; (*ATIC*)
H0=0.1; (*ADSS2*)

(*Initial concentrations for metabolites*)
p0=10;(*PRPP*)
w0=0;(*PRA*)
y0=0;(*GAR*)
z0=0;(*FGAR*)
g0=0;(*FGAM*)
a0=0;(*AIR*)
c0=0;(*CAIR*)
s0=0; (*SAICAR*)
A0=0; (*AICAR*)
r0=0;(*FAICAR*)
M0=0;(*IMP*)
J0=0;(*SAMP*)
P0=0;(*AMP*)

(*Initial concentrations for complexes*)
Tp0=0;
Gw0=0;
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Gy0=0;
Bz0=0;
Gg0=0;
da0=0;
dc0=0;
is0=0;
FA0=0;
Fr0=0;
HM0=0;
iJ0=0;

(*rate constants*)
k12 =1;
k−12 =0;
k11 =1;
k−11 =0;
k10 =1;
k−10 =0;
k9 =1;
k−9 =0;
k8 =1;
k−8 =0;
k7 =1;
k−7 =0;
k6 =1;
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k−6 =0;
k1 =1;
k−1 =0;
k2 =1;
k−2 =0;
k3 =1;
k−3 =0;
k4 =1;
k−4 =0;
k5 =1;
k−5 =0;

(*catalytic rate constants*)
kptow =10;
kwtoy =10;
kytoz =10;
kztog =10;
kgtoa =10;
katoc =10;
kctos =10;
kStoA =7.4*0.43;
kAtor =10;
krtoM =10;
kM toJ =10;
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kJtoP =13.4*0.052;

(*Time constants*)
NDSolveTime=2000;(*How far out to solve the differential equations*)
PlotTime=300;(*How far out to plot your solution*)

solution=NDSolve[
T’[t]== - k12 * T[t] * p[t] + k−12 * Tp[t] + kptow * Tp[t],
p’[t]== - k12 * T[t] * p[t] + k−12 Tp[t],
Tp’[t]==k12 * p[t] * T[t] - k−12 * Tp[t] - kptow * Tp[t],
G’[t]== - k8 * G[t] * g[t] + k−8 * Gg[t] + kgtoa * Gg[t] - k10 * G[t] * y[t] +
k−10 * Gy[t] + kytoz * Gy[t] - k11 * G[t] * w[t] + k−11 * Gw[t] + kwtoy * Gw[t],
w’[t]== - k11 * G[t] * w[t] + k−11 Gw[t] + kptow * Tp[t],
Gw’[t]==k11 * w[t] * G[t] - k−11 * Gw[t] - kwtoy * Gw[t],
y’[t]== - k10 * G[t] * y[t] + k−10 Gy[t] + kwtoy * Gw[t],
Gy’[t]==k10 * y[t] * G[t] - k−10 * Gy[t] - kytoz * Gy[t],
B’[t]== - k9 * B[t] * z[t] + k−9 * Bz[t] + kztog * Bz[t],
z’[t]== - k9 * B[t] * z[t] + k−9 Bz[t] + kytoz * Gy[t],
Bz’[t]==k9 * z[t] * B[t] - k−9 * Bz[t] - kztog * Bz[t],
g’[t]== - k8 * G[t] * g[t] + k−8 Gg[t] + kztog * Bz[t],
Gg’[t]==k8 * g[t] * G[t] - k−8 * Gg[t] - kgtoa * Gg[t],
d’[t]== - k6 * d[t] * c[t] + k−6 * dc[t] + kctos * dc[t] - k7 * d[t] * a[t] + k−7 *
da[t] + katoc * da[t],
a’[t]== - k7 * d[t] * a[t] + k−7 da[t] + kgtoa * Gg[t],
da’[t]==k7 * a[t] * d[t] - k−7 * da[t] - katoc * da[t],
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c’[t]== - k6 * d[t] * c[t] + k−6 dc[t] + katoc * da[t],
dc’[t]==k6 * c[t] * d[t] - k−6 * dc[t] - kctos * dc[t],
s’[t]== - k1 * i[t] * s[t] + k−1 is[t] + kctos * dc[t],
i’[t]== - k1 * i[t] * s[t] + k−1 * is[t] + kStoA * is[t] - k5 * i[t] * J[t] + k−5 *
iJ[t] + kJtoP * iJ[t],
is’[t]==k1 * s[t] * i[t] - k−1 * is[t] - kStoA * is[t],
A’[t]==kStoA * is[t] - k2 * F[t] * A[t] + k−2 FA[t],
F’[t]== - k2 * F[t] * A[t] + k−2 * FA[t] + kAtor * FA[t] - k3 * F[t] * r[t] + k−3
* Fr[t] + krtoM * Fr[t],
FA’[t]==k2 * A[t] * F[t] - k−2 * FA[t] - kAtor * FA[t],
r’[t]==kAtor * FA[t] - k3 * F[t] * r[t] + k−3 Fr[t],
Fr’[t]==k3 * r[t] * F[t] - k−3 * Fr[t] - krtoM * Fr[t],
M’[t]==krtoM * Fr[t] - k4 * H[t] * M[t] + k−4 HM[t],
H’[t]== - k4 * H[t] * M[t] + k−4 * HM[t] + kM toJ * HM[t],
HM’[t]==k4 * M[t] * H[t] - k−4 * HM[t] - kM toJ * HM[t],
J’[t]== - k5 * i[t] * J[t] + k−5 iJ[t] + kM toJ * HM[t], iJ’[t]==k5 * J[t] * i[t] k−5 * iJ[t] - kJtoP * iJ[t],
P’[t]==kJtoP * iJ[t],

T[0]==T0,
p[0]==p0,
Tp[0]==Tp0,
G[0]==G0,
w[0]==w0,
Gw[0]==Gw0,
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y[0]==y0,
Gy[0]==Gy0,
B[0]==B0,
z[0]==z0,
Bz[0]==Bz0,
g[0]==g0,
Gg[0]==Gg0,
d[0]==d0,
a[0]==a0,
da[0]==da0,
c[0]==c0,
dc[0]==dc0,
s[0]==s0,
i[0]==i0,
is[0]==is0,
A[0]==A0,
F[0]==F0,
FA[0]==FA0,
r[0]==r0,
Fr[0]==Fr0,
M[0]==M0,
H[0]==H0,
HM[0]==HM0,
J[0]==J0,
iJ[0]==iJ0,
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P[0]==P0,
T[t], p[t], Tp[t], G[t], w[t], Gw[t], y[t], Gy[t], B[t], z[t], Bz[t], g[t], Gg[t], d[t],
a[t], da[t], c[t], dc[t], i[t], s[t], is[t], A[t], F[t], FA[t], r[t], Fr[t], M[t], H[t], HM[t],
J[t], iJ[t], P[t], t,0,NDSolveTime]

Plot[Evaluate[s[t],A[t],J[t],P[t]/.solution],t,0,PlotTime,
PlotRange → All,
(*PlotRange → 0,50,0,10,*)
Frame → True,
FrameStyle → Thick,
FrameLabel → ”Concentration (AU)”,” ”,”Time (AU)”,”R303C ADSL Metabolite Accumulation”,
PlotStyle → RGBColor[0,0,0],,Thickness[0.005], RGBColor[1,0,0], Thickness
[0.005], RGBColor[0,1,0], Thickness[ 0.005],RGBColor[0,0,1], Thickness[0.005],
LabelStyle → FontSize → 32]

A.2.10

Modeling ADSL Tetramer Formation

This is as far as I went with my code before I found the Powers paper on
tetramer formation [65].

m0=10;
d0=0;
r0=0;
e0=0;
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k1 =1;
k−1 =0;
k2 =1;
k−2 =0;
k3 =1;
k−3 =0;
k4 =1;
k−4 =0;
k5 =0;
k−5 =0;
k6 =0;
k−6 =0;

solution=NDSolve[
m’[t]==-k1 *m[t]*m[t]-k2 d[t]*m[t]-k3 r[t]*m[t]+k−1 d[t]*m[t]+
k−2 r[t]*m[t]-k6 *m[t]*m[t]*m[t]*m[t],
d’[t]==k1 *m[t]*m[t]-k−1 d[t]*m[t]-k2 d[t]*m[t]-k4 *d[t]*d[t],
r’[t]==k2 d[t]*m[t]-k3 r[t]*m[t]-k−2 r[t]*m[t],
e’[t]==k3 r[t]*m[t]+k4 *d[t]*d[t]+k6 *m[t]*m[t]*m[t]*m[t],
m[0]==m0,
d[0]==d0,
r[0]==r0,
e[0]==e0,
m[t],d[t],r[t],e[t],
t,0,100];
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Plot[Evaluate[m[t],d[t],r[t],e[t]/.solution],t,0,3,
PlotRange→ All,
AxesLabel → ”Time (sec)”,”Concentration (M)”,
PlotStyle → RGBColor[0,0,0], Thickness[0.005], RGBColor[1,0,0],
Thickness[0.005], RGBColor[0,1,0], Thickness[0.005], RGBColor[0,0,1], Thickness[0.005],
LabelStyle → FontSize → 22]

A.2.11

Thermal Denaturation

Fraction Folded by Circular Dichroism
Thermal denaturation was first tested on a Jasco-J815 spectropolarimeter
by moniroting the absorbance at 222 nm as temperature increased from 10 to
80 ◦ C at a ramping speed of 1 ◦ C/min. Samples were measured at 0.2 mg/mL
in a 0.1 cm pathlength quartz cuvette. The mean molar residue ellipticity
θ
, where
[θ] (deg cm2 dmol−1 ) was calculated from the equation [θ]= 10∗n∗C∗`

θ is the measured ellipticity in millidegrees, C is the molar concentration of
enzyme subunits, ` is the path length in centimeters, and n is the number of
residues per subunit (503 residues per monomer, including the His6 tag and
thrombin cleavage site). The WT and mutant enzyme samples were incubated
for ∼2 hours at 25◦ C before measurements were taken. The unfolding data
obtained from CD measurements were treated by linear extrapolation of the
pre- post transitions states and converted to the form of fraction folded using
the equation
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Ff =

Iexp − Iu
If − Iu

(A.2.16)

where Iu and If are the baseline intensities of the unfolded and folded signal
respectively and Iexp is the signal from the protein.
Determining ∆G, ∆H, and ∆Cp by Differential Scanning Calorimetry
Differential Scanning Calorimetry (DSC) scans for measuring the change
in excess heat capacity as a function of temperature were performed on a VPDSC by MicroCal located at the Biophysics Core facility at Anschutz Medical
Campus. DSC scans were carried out with 1 mg/mL protein, 1 mL total
volume at a scan rate of 1◦ C/min. The temperature range for thermal denaturation was 15-90◦ C. Data were analyzed with a two state, one peak model
using the ORIGIN DSC software provided by MicroCal. Testing for reversibility was not performed.

A collaboration was attempted with Colette Quinn, PhD, located at TA
Instruments. Samples were prepared and shipped to her to measure the excess heat capacity on their Nano DSC. The capillary cell design on the Nano
DSC was thought to provide better baseline, more accurate data, and better
potential for reversibility. One eppendorf tube of 0.5 mg/ mL adenylosuccinate lyase (ADSL) and one tube of 15 mL of buffer, were received on ice an
immediately stored at -20 ◦ C. The buffer and protein were thawed previous
to their use at 10 C in a controlled block heat and cooler. Initially, 600 µL of

184

buffer was loaded into the sample and reference cell. The buffer was scanned
several times, with the second scan serving as the background as the first scan
is a considered a conditioning scan, which is standard practice. The buffer was
removed from the sample cell and 600 µL of ADSL was loaded into the cell.

All of the data was fit with the NanoAnalyze Software package. The concentration used in the analysis of was 0.5 mg/mL. The enthalpy and scaling
factor (Aw) are dependent on both the molecular weight and the concentration
of the samples. The scaling factor is an integer value that is used to better fit
the data when the concentration or molecular weight might be slightly inaccurate. It is also necessary when fitting multiple unfolding events simultaneously
as in this case.

A.3

Thermal Denaturation Modeling

The math of thermal denaturation is as follows:

Z

T

Z

T

∆Cp dT − T ∆S(TR ) − T

∆G(T ) = ∆H(TR ) +

∆Cp dlnT

(A.3.1)

TR

TR

If ∆Cp is temperature independent;

∆G(T ) = ∆H(TR ) + ∆Cp (T − TR ) − T ∆S(TR ) − T ∆Cp ln
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T
TR

(A.3.2)

Simplifying and setting TR is equal to the melting temperature, Tm ;

∆G(T ) = ∆H(Tm ) − T ∆S(Tm ) + ∆Cp (T − Tm − T ln[

T
])
Tm

(A.3.3)

When T = Tm , ∆G = 0. This allows ∆S(Tm ) to be solved in terms of ∆H(Tm )
and Tm

0 = ∆H(Tm ) − Tm ∆S(Tm ) + ∆Cp (Tm − Tm − T ln[

Tm
])
Tm

(A.3.4)

∆H(Tm )
Tm

(A.3.5)

T
T
) + ∆Cp (T − Tm − T ln[ ])
Tm
Tm

(A.3.6)

∆S(Tm ) =

Substituting back into Equation A.3.3

∆G(T ) = ∆H(1 −

Theoretical Values Based on Chain Length
These equations use a different reference temperature so it is not an “apples
to apples” comparison. But it is interesting to see how close they may be and
can give us a general idea of what to expect for thermodynamic parameters.
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Table A.1: Thermodynamic Parameters from DSC and Predictions
Thermodynamic
Parameter

Experimental
Value

Tetramer
Prediction

Monomer
Prediction

∆Cp (kJ/K - mol)
∆H1 (kJ/mol)
∆H2 (kJ/mol)
∆Htotal (kJ/mol)
∆S (J/K - mol)

30
535
1157
1692
-

99
6500
6500
6500
21

25
1710
1710
1710
5.6

Comparison of experimentally measured thermodynamic parameters from Differential Scanning Calorimetry and predicted thermodynamic values based on chain length

Theoretical predictions of ∆H, ∆S, and ∆Cp based on chain length:

∆H(373.5) = (3.3N + 112)kJ/mol
∆S(385) = (10.9N + 291)J/K − mol
∆Cp = (0.051N + 0.26)kJ/K − mol

A.3.1

(A.3.7a)
(A.3.7b)
(A.3.7c)

Chemical Denaturation

Unfolding and Refolding of ADSL by Guanidine Hydrochloride
For the unfolding of ADSL, a stock solution was prepared of 1 mg/mL
protein in ESB with 0 M denaturant. The stock solution was then diluted
with ESB with denaturant concentrations, ranging from 0 to 6 M in 0.25 M
increments, for a final concentration of 0.2 mg/mL (0.9 µM). For the refolding
of ADSL, a stock solution was prepared of 1 mg/mL protein that was dialyzed
in 1 L of ESB with 6 M denaturant. The stock solution was then diluted to
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0.2 mg/mL with ESB with lower concentrations of denaturant. Samples were
allowed to equilibrate overnight before measurements were taken.

Fraction Folded by Circular Dichroism
To monitor the fraction folded, circular dichroism (CD) was used to monitor α-helical secondary structure of ADSL. CD measurements were performed
on a Jasco J-815 CD spectrometer equipped with a Peltier temperature control device that maintained the sample at 25◦ C. Changes in conformational
secondary structure of ADSL were monitored in the region between 210 and
230 nm of a 200 µL of the sample loaded in a 1 mm pathlength quartz cuvette.
The scanning speed, bandwidth, and data pitch were set to default values. Six
scans were taken and averaged for complete spectra. Samples containing no
ADSL protein were scanned identically and subtracted. Absorbance at 222 nm
θ
was recorded in mdeg and changed to ME by equation [θ]= 10∗n∗C∗`
for each con-

centration of denaturant. Baselines for completely folded and unfolded were
characterized by a linear trendline. Fraction folded curves were then produced
by

Ff =

Iexp − Iu
If − Iu

(A.3.8)

where Iu and If are the baseline intensities of the unfolded and folded signal
respectively and Iexp is the signal from the protein.
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Determining Protein State by Sedimentation Velocity
Analytical ultracentrifugation sedimentation velocity (AUC-SV) experiments were conducted in a Beckman Coulter XL-I equipped with an An-Ti 50
8-place titanium rotor. Cells were filled with 440 µL of prepared samples were
placed in the rotor and equilibrated at 25 ◦ C for approximately 30 min before
data acquisition. Data were recorded at 20 krpm and 25 ◦ C using absorbance
optics at 280 nm scanning was performed between the radial positions of 5.8
and 7.2 cm until the sample was completely sedimented. AUC-SV runs were
performed singly.

The data were analyzed using the c(s) method of SEDFIT. For the analysis, the meniscus and bottom were allowed to float with a fixed frictional ratio.
The meniscus was allow to float in a location in the vicinity of the maximum
absorbance spike. Then, the bottom and meniscus were fixed with the frictional ratio allowed to float. The sedimentation coefficient range was 1-15 or
1-30 S so no partial peaks were present at the edge. A resolution was chosen
to correspond to a step size of 0.1 S. Initial fixed frictional ratios ranged from
1.2 to 2. A regularization of 0.68 was used. The buffer density and viscosity
changed with increasing denaturant concentration and ranged from 1.01648 to
1.13316 g/ml and 0.0091562 to 0.012564 cP respectively. The partial specific
volume was changed to 0.7366 cm3 /g. Buffer density and viscosity as well as
the partial specific volume were calculated using SEDNTERP. Goodness of fit
was determined by the rmsd value, as well as no visible diagonal lines were
present on the residuals bitmap. To estimate the relative amount of different
states present in the samples, integration of the c(s) distributions was per189

formed. The percentage of ADSL monomer, tetramer, and aggregation were
calculated by dividing the corresponding peak area by the sum of all peak
areas.

Figure A.1: Sedimentation Velocity graphs from analytical ultracentrifugation

Figure A.2: Sedimentation Velocity graphs from analytical ultracentrifugation
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A.3.2

Stability Modeling

Stability models were built in Mathematica.

Two State Model - No Dissociation
Clear[ChemMelt, model, bestfit, G, m, t];
SetDirectory[ ”/Users/Stephen/Documents/research/DU/
ADSLProject/Stability/ChemicalDenature”];
ChemMelt = Take[Import[”WT25ChemDenature.csv”]];
t = 298.15; (*Temperature in kelvin*)
model = (1/(1 + eG−m∗x ));
bestfit = NonlinearModelFit[ChemMelt, model, G, m, x];
bestfit[”ParameterTable”, ”RSquared”]

G = 3.4;
m = 1.6;
fit = (1/(1 + eG−m∗x ));
Show[ Plot[fit, x, 0, 10, PlotStyle → Black, Thickness[0.005]],
ListPlot[ChemMelt, PlotStyle → PointSize[0.012], Red],
Frame → True,
FrameStyle → Thick,
FrameTicks → 0, 1, 2, 3, 4, 5, 6, 0, 0.2, 0.4, 0.6, 0.8,1.0, , ,
FrameLabel → ”Fraction Folded”, ” ”, ”GdnHCl (M)”, ”WT M4 → 4U”,
LabelStyle → FontSize → 32,
PlotRange → 0, 6, 0, 1,
AxesOrigin → Automatic]
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Two State Model - Folded Tetramer to Unfolded Monomer
For models that require an iterative process, I was unable to figure out
how to use an iterative process without equal step size in the data, which is
the case for the raw data. Therefore, the data file WTRaw.csv, has extrapolated points to fill in the spots that do not have data at certain concentrations.

SetDirectory[ ”/Users/Stephen/Documents/research/DU/
ADSLProject/Stability/ChemicalDenature”];

(*import the raw data*)
ChemMelt = Take[Import[”WTRaw.csv”]];

(*min and max values for ∆F and m value fit parameters*)

F1min = 0;
F1max = 100;

M1min = 0;
M1max = 10;

(*step size between the min and max values*)
F1incriment = 1;

M1incriment = 1;
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(*Creates an array of range of the fit parameters*)

F1 = Range[F1min, F1max, F1incriment];

M1 = Range[M1min, M1max, M1incriment];

(*calculates the number of iterations in the For loops*)

F1stop = (F1max - F1min)/F1incriment;

M1stop = (M1max - M1min)/M1incriment;

(*monomer concentration calculation*)
Subunits = 4;(*number of
monomers in the native structure*)
MonomerMolecularWeight = 228000/Subunits;(*native molecular weight in
Daltons*)
mgmL = 0.2;(*concentration of protein in mg/ml*)
Concentration = mgmL/MonomerMolecularWeight;(*sample concentration in
M
(*Concentration=1.3*10−6 ;(*If protein concentration was already in Molarity,
comment out the previous and just use this*)*)
(*min, max, and step size for denaturant concentration*)
dmin = 0;
dmax = 5.2;
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dincriment = 0.2;

dstop = (dmax - dmin)/dincriment + 1;

(*starting value for if statement to keep track of variance values*)

o = 0;
Γ = 20;

For[i = 0, i ≤ F1stop,
For[j = 0, j ≤ M1stop,

Do[If[o ≤ dstop - 1, o++, o = 1],
t = NSolve[Concentration == 4*mon4 *E(F 1[[i]]−M 1[[j]]∗d) + mon && mon > 0,
mon, Reals],
p = (4*(mon /. t)4 *E(F 1[[i]]−M 1[[j]]∗d) )/(Concentration),
Subscript[v, o] = (ChemMelt[[o, 2]] - p)2 ,
d, dmin, dmax, dincriment],
χ = Sum[Subscript[v, q], q, 1, dstop],
If[χ[[1]] ¡ Γ, Γ = χ[[1]], Print[Γ, F1[[i]], M1[[j]], ”best”], Γ]
, j++],
i++]
TimeUsed[]
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Three State Model - Folded Tetramer to Folded Monomer to Unfolded Monomer
SetDirectory[”/Users/Stephen/Documents/research/DU/
ADSLProject/Stability/ChemicalDenature”];

(*import the raw data*)
ChemMelt = Take[Import[”WTRaw.csv”]];

(*min and max values for ∆F and m value fit parameters*)

F1min = 45;
F1max = 60;

M1min = 7;
M1max = 17;

F2min = 3.1;
F2max = 3.1;

M2min = 1.5;
M2max = 1.5;

(*step size between the min and max values*)
F1incriment = 0.1;

195

M1incriment = 0.1;

F2incriment = 0.1;

M2incriment = 0.1;

(*Creates an array of range of the fit parameters*)

F1 = Range[F1min, F1max, F1incriment];

M1 = Range[M1min, M1max, M1incriment];

F2 = Range[F2min, F2max, F2incriment];

M2 = Range[M2min, M2max, M2incriment];

(*calculates the number of iterations in the For loops*)

F1stop = (F1max - F1min)/F1incriment;

M1stop = (M1max - M1min)/M1incriment;

F2stop = (F2max - F2min)/F2incriment;
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M2stop = (M2max - M2min)/M2incriment;

(*monomer concentration calculation*)
Subunits = 4;(*number of monomers in the native structure*)
MonomerMolecularWeight =228000/Subunits;(*native molecular weight in Daltons*)
mgmL = 0.2;(*concentration of protein in mg/ml*)
Concentration = mgmL/MonomerMolecularWeight;(*sample concentration in
M*)

(*Concentration=1.3*10−6 ;(*If protein concentration was already in Molarity,
comment out the previous and just use this*)*)

(*min, max, and step size for denaturant concentration*)
dmin = 0;
dmax = 5.2;
dincriment = 0.2;

dstop = (dmax - dmin)/dincriment + 1;

(*starting value for if statement to keep track of variance values*)

o = 0;
Γ = 20;
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For[i = 0, i ≤ F1stop,
For[j = 0, j ≤ M1stop,
For[k = 0, k ≤ F2stop,
For[l = 0, l ≤ M2stop,
Do[If[o ≤ dstop - 1, o++, o = 1],
t = NSolve[Concentration == (4*mon4 *E(F 1[[i]]−M 1[[j]]∗d) ) + mon
+ (mon*E−(F 2[[k]]−M 2[[l]]∗d) ) && mon > 0, mon, Reals],
p = (4*(mon /. t)4 *E(F 1[[i]]−M 1[[j]]∗d) + (mon /. t))/(Concentration),
Subscript[v, o] = (ChemMelt[[o, 2]] - p)2 ,
d, dmin, dmax, dincriment],(*end Do loop*)
χ =Sum[Subscript[v, q], q, 1, dstop],
If[χ[[1]] ¡ Γ, Γ = χ[[1]],
Print[Γ, F1[[i]], M1[[j]], F2[[k]],
M2[[l]]], Γ]

, l++](*end M2 (l) For loop*),
k++](*end F2 (k) For loop*)
, j++],(*end M1 (j) For loop*)
i++](*end F1 (i) For loop*)
TimeUsed[]

Three State Best Fit
After running the brute force code, I would use this one to see what the fit
looked like using the actual data file.
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SetDirectory[”/Users/Stephen/Documents/research/DU/
ADSLProject/Stability/ChemicalDenature”];

ChemMelt = Take[Import[”WTRaw1.csv”]];

(*monomer concentration calculation*)

Subunits = 4;(*number of monomers in the native structure*)

MonomerMolecularWeight = 228000/ Subunits;(*native molecular weight in
Daltons*)

mgmL = 0.2;(*concentration of protein in mg/ml*)

Concentration = mgmL/MonomerMolecularWeight;(*sample concentration in
M*)

F1 = 65;
M1 = 23;
F2 = 3.1;
M2 = 1.5;

dmin = 0;
dmax = 6;
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dincriment = 0.05;

dstop = (dmax - dmin)/dincriment + 1;

o = 0;

Do[If[o ≤ dstop - 1, o++, o = 1],
t = NSolve[ Concentration == 4*mon4 *E(F 1−M 1∗d) + mon + mon*E−(F 2−M 2∗d)
&& mon > 0, mon, Reals],
p = (4*(mon /. t)4 *E(F 1−M 1∗d) + (mon /. t))/(Concentration),
Subscript[a, o] = Flatten[d, p],
d, dmin, dmax, dincriment]

Show[ListPlot[ChemMelt, PlotStyle → PointSize[0.012], Red],
ListLinePlot[Table[Subscript[a, z], z, dstop],
PlotStyle → Black, Thickness[0.005]],
Frame → True,
FrameStyle → Thick,
FrameTicks → 0, 1, 2, 3, 4, 5, 6, 0, 0.2, 0.4, 0.6, 0.8, 1.0, , ,
FrameLabel → ”Fraction Folded”, ” ”, ”GdnHCl (M)”, ”WT M4 → 4M →
4U”,
LabelStyle → FontSize → 32,
PlotRange → 0, 6, 0, 1,
AxesOrigin → Automatic]
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Prediction Fraction of Tetramer and Monomer for Three State Model
(*monomer concentration calculation*)

Subunits = 4;(*number of monomers in the native structure*)

MonomerMolecularWeight = 228000/Subunits;(*native molecular weight in
Daltons*)

mgmL = 0.2;(*concentration of protein in mg/ml*)

Concentration = mgmL/MonomerMolecularWeight;(*sample concentration in
M*)

F1 = 50.8;
M1 = 12;
F2 = 3.1;
M2 = 1.5;
d = 0;

t = NSolve[ Concentration == 4*mon4 *E(F 1−M 1∗d) + mon + mon*E−(F 2−M 2∗d)
&& mon > 0, mon, Reals];
tetfrac = (4*(mon /. t)4 *E(F 1−M 1∗d) )/(Concentration) monfrac = ((mon /. t)
+ ((mon /. t)*E−(F 2−M 2∗d) ))/(Concentration)
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Hydrodynamic Radius Prediction for Three State Model
r = 2.8; (*Wilkins hyd. radius for folded*)

R = 6.02; (*Experimental hyd. radius for unfolded*)

SetDirectory[”/Users/Stephen/Documents/research/DU/
ADSLProject/Stability/ChemicalDenature”];

Radius = Take[Import[”HydRadiusAUC.csv”]];

(*monomer concentration calculation*)

Subunits = 4;(*number of monomers in the native structure*)

MonomerMolecularWeight = 228000/ Subunits;(*native molecular weight in
Daltons*)

mgmL = 0.2;(*concentration of protein in mg/ml*)

Concentration = mgmL/MonomerMolecularWeight;(*sample concentration in
M*)

F1 = 50.8;
M1 = 12;
F2 = 3.1;
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M2 = 1.5;

dmin = 0.9;
dmax = 6;
dincriment = 0.05;

dstop = (dmax - dmin)/dincriment + 1;

o = 0;

Do[If[o ≤ dstop - 1, o++, o = 1],
t = NSolve[ Concentration == 4*mon4 *E(F 1−M 1∗d) + mon + mon*E−(F 2−M 2∗d)
&& mon > 0, mon, Reals],
p = ((mon /. t))/((mon /. t) + (mon /. t)*E−(F 2−M 2∗d) ),
P = ((mon /. t)* E−(F 2−M 2∗d) )/((mon /. t) + (mon /. t)*E−(F 2−M 2∗d) ),
Subscript[R, avg] = ((r*p) + (R*P))/(P + p),
Subscript[a, o] = Flatten[d, Subscript[R, avg]] ,
d, dmin, dmax, dincriment]

Show[
ListLinePlot[Table[Subscript[a, z], z, dstop],
PlotStyle → Black, Thickness[0.005]],
ListPlot[Radius, PlotStyle → PointSize[0.02], Red],
Frame → True,
FrameStyle → Thick,
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FrameTicks → 0, 1, 2, 3, 4, 5, 6, 0, 2, 3, 4, 5, 6, 7, , ,
FrameLabel → ”Rh (nm)”, ” ”, ”GdnHCl (M)”, ”WT M4 → 4M → 4U”,
LabelStyle → FontSize → 32,
PlotRange → 1, 5, 2, 6.5,
AxesOrigin → Automatic]

A.3.3

Isothermal Titration Calorimetry

ITC experiments were conducted using a NANO-ITC system (TA Instruments, Utah, USA). Thrombin cleaved WT ADSL was dialyzed overnight
against a solution of 25 mM HEPES pH 7.0, 150 mM KCl, and 2 mM DTT.
AMP was brought to a concentration of 2.5 mM using the buffer in which WT
ADSL was dialyzed. ITC runs of WT ADSL with AMP were performed in
duplicate and comprised of one 1 µl injection followed by 24, 2 µl injections
for a total of 25 injections of 2.5 mM AMP into 0.250 mM WT ADSL. Each
injection was spaced 250 seconds apart. ITC experiments were performed in
an identical method, injecting AICAR instead of AMP into 0.225 mM WT
ADSL. In addition, AMP and AICAR were titrated in an equal manner into
0.280 mM R303C ADSL. Data sets were analyzed with NanoAnalyze software
and fit to an independent model concurrently with a blank constant model to
adjust for heat of dilution.
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Appendix B
Detailed Lab Protocol
B.1
B.1.1

Fabricating and Purifying Proteins
Day to Day Details

Day 1 - Estimated Time = 4 hours

1) Checks amount of buffer solution. If not enough see buffer page on how to
make more. Will need 1 L Lysis Buffer, ∼2 L Enzyme Storage Buffer, 1 M
Imidazole stock.
2) Make 1.5 L of LB per mutation to grow cultures in, see solutions page for
recipe.
3) Autoclave LB to sterilize using L8 cycle. Make sure to cover flasks with Al
foil and mark with autoclave tape. Autoclave takes 1.5 hours.
4) Once cycle is finished, load in incubator at 37o C. If incubator is being used,
cool LB first so you will not to kill cultures in incubator. Make 5 - 10 mL
fresh

34

Cm and

100

Ap during autoclave or take some from the - 50 C freezer
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to thaw. Best to make fresh.
5) Make 2 overnight cultures in 13 mL falcon tube.
Label with date, WT or mutation, initials.
Fill test tube with 5 mL LB and 5 µL of
34

Cm and

100

34

Cm and

100

Ap. Aloquot and freeze

Ap to use tomorrow

Find desired ADSL clone in -80o C freezer. See chart below.
Use yellow pipet tip to scoop out ADSL and place in test tube. It is also
optional to streak colonies of the mutant a day or two in advance.
Put into shaker @ 37o C for overnight.
6) Check Ni purifying column. If it does not look ok or if purifying a new
mutant, proceed to step 7.
7) To make a new column...
Cut off the top of 25 mL pipet, and put glass wool in the pipet to support
the resin (just add enough to where the resin won’t leak through). Ni-NTA
His bind resin from deli fridge. Suspend Ni resin gently and add ∼24 mL to
the pipet. Let it settle. Run about 50 mL Lysis buffer through column, label
with date and mutant it will be used for, and store in deli fridge. To store the
column, plug tip and leave 3 mL buffer on top of the resin.
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ADSL Type

Location

WT

A-9

R426H

B-8

E80D

C-8

D87E

C-9

A291V

B-7

R303C

B-6

M225T

Not Made

Day 2 - Estimated Time = 6 hours

1) Thaw

34

Cm and

100

Ap, make sure you have enough for .5 mL per flask.

Check temp of both incubators, they should be 37o C.
2) Label each flask as Control, A, B, C
Add .5 mL

34

Cm and

100

Ap, then 2 mL of overnight culture for 1:250 dilution

to each flask.
3) Put into shaker @ 37o C, 250 rpm, and record time or start timer
4) Measure OD @ λ = 600 using UV-VIS with 1 mL samples from each flask
(this measures the bacteria growth rate).
Use OD print out sheet to record data
5) Make 5 mL fresh IPTG.
6) Once OD is between .4 and .6 (aim for .5), induce 2 of the 3 flasks with 2
mL 100 mM IPTG.
Immediately turn off the shaker incubator and grow overnight
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Best to take a reading at 2 and 3 hours to get an idea of how fast the protein
is growing.

Day 3 - Estimated Time = 5 hours

1) Get water bath of 37 - 50 o C ready for Freeze-Thaw cycle. Get out DNase
and RNase from freezer to thaw.
2) Take 1 mL sample of each ADSL type and put in labeled eppie.
Will need to eventually spin down in mini-centrifuge in deli fridge, discard
supe, and freeze.
3) Get out 2 nalgene bottles per flask to pour remaining culture in.
Use wet pellet table to record empty bottle weights, then pour about 250 mL
in each bottle. Make sure the weights are within one gram of each other for
centrifugation.
4) Spin remaining culture down @ 4000 rpm in GSA rotor in the Sorvall RC-5
for 10-15 min. to pellet cells.
Colman reported a wet cell pellet of ∼ 3.7 g per 2 L cell culture
Decontaminate flasks with 10% bleach.
5) Save 200 µL supe in eppie, store in -50 C freezer and discard rest
Record weight of bottle and pellet to get pellet weight
6) Add 10 times the weight of the pellet of Lysis buffer (mL). Add 1 µg DNase
and 10 µg RNase per mL Lysis buffer added. If needed add 45 - 60 KU
lysozyme per gram wet pellet. Easy way to do this is to add the total amount
of Lysis Buffer to one bottle, resuspend pellet, and pour solution into the next
bottle of the same type of ADSL until done. DO NOT MIX DIFFERENT
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MUTANTS OR WT if purifying more than one ADSL.
7) Begin Freeze-Thaw cycle of 1 hour in -80o C freezer folowed by 10 - 15 min
in 37 - 50o C water bath.
Repeat cycle 3 times.
Leave in -80o C freezer over night. This is a potentially good break point if get
busy and can’t continue the next few days.
8) During Freeze-Thaw, make SDS-PAGE gels for diagnotic tests.
Expect ADSL monomer band at 55 kDa
See SDS-PAGE gel protocol for making gels.
9) Prep the fraction collector by loading with glass tubes. Number the tubes
with permanent marker and put 400 µL (10% total volume of fraction) of
ADSL Storage buffer with 10 mM DTT in each test tube, cover with seran
wrap and leave on counter overnight.
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Day 4 - Estimated Time = 14 - 16 hours. Bring Reading Material

1) Set water bath to 37o C if it is not already there.
Thaw lysate in -80o C freezer in 37o C water bath once it is up to temp.
2) Start washing column with Lysis Buffer
Want to flow ∼ 100 mL through before loading ADSL.
3) Once Lysate is thawed, spin for 30 min @ 12,000 (23,500 x g) rpm in GSA
rotor in Sorvall RC-5. Make sure to use the “hard” plastic nalgene bottles
because the other ones cave in from the high rpms.
4) Make 20 and 250 mM Imidazole solutions of 400 and 160 mL total volume
respectively.
5) Retrieve Lysate, pour supe into 50 mL conical tube(s). Weigh the bottles
containing cell debris and calculate percent lysis.
May want to filter ADSL supe using 4 x 4 gauze by PAGE Gel solutions.
6) Start loading column with ADSL
Once you start loading the column, IT CANNOT RUN DRY!
Save at least 200 µL of Flow through in 50 mL conical. Probably want to do
this sometime after half of ADSL has been loaded on the column.
7) Flow 200 mL Lysis Buffer though the column.
Catch at least 200 µL of flow through in 50 mL conical tube labeled Wash
Buffer 1. Catching flow through is optional, but it is always good practice just
in case purification does not work so you can trace back to where you “lost”
the protein.
8) Flow 200 mL Lysis Buffer with 20 mM Imidazole though the column.
Catch at least 200 µL of flow through in 50 mL conical tube labeled Wash
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Buffer 2.
9) Once the last 20 mL is put into the pipet, prepare column gradient.
• stirring plate
• smallest stirring rod
• large column gradient
• Lysis Buffer, Lysis Buffer with 20 mM Imidazole, Lysis Buffer with 250 mM
Imidazole
• fraction collector
Make sure the out-take tube is pinched shut and the valve connecting the inner
and outer cylinders is open.
Place the smallest stir bar in the inner cylinder and pour 150 mL 20 mM Imidazole into the inner cylinder and 150 mL 250 mM Imidazole into the outer
cylinder.
Once there is enough room to start the column gradient, open the out-put
tube slowly. Adjust the input into the pipet so it is equals the output. Put on
the connecting tube from the pipet to the fraction collector.
10) Once the column gradient is started, put the start the fraction collector
and start collecting 4 mL fractions. You will need to time out 4 mL for the
fraction collector timing.
11) Speed of output usually increases with time. May need to check on it every
half hour to hour. Once fraction 45 or 50 has been collected, equilibrate the
flow and you should be ok to leave because unless you started at 6 am, it is
going to be late.
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Day 5 - Estimated Time = 6 hours

1) Run bulk Bio-Rad without the standard to find peak of ADSL (see concentration protocol).
2) Get out resin column and run 200 mL Lysis buffer with 250 mM Imidazole
to elute any proteins left on the Ni.
Then run 200 mL of plain Lysis buffer through the resin and store in deli
fridge.
3) Run SDS-Page Gel.
See SDS-PAGE Gel protocol.
4) Stain SDS-Page Gel overnight with Commassie Blue Staining solution.

Day 6 - Estimated Time = 4 hours

1) Destain gel and take photo.
2) If data looks good, take the fractions and start filter/buffer swap sequence
All spins are for 15 min at 4,000 rpm at room temp.
Get 2 out 10,000 kDa Amni-con filters per ADSL type and spin with 3 mL
Storage Buffer
Load ADSL fractions 10 mL at a time. This may require more than one spin.
Keep retentate, dump filtrate.
Add 10 mL of Storage Buffer and spin. Do this 3 times.
Extract ADSL via pipet into 15 mL conical tube. Rinse membrane with 3 mL
Storage Buffer and place in respective conical tube.
If protein is not quite soluble, add about 1 mL Storage Buffer
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3) Soak ∼6 in of 6-8 kDa dialysing membrane per conical tube in dH2 O for 30
min.
4) After soaking, load ADSL in membrane and dialyze in 1 L of Storage Buffer
overnight.

Day 7 - Estimated Time = 5 hours

1) Put dialyzed ADSL into 15 mL conical tubes. Put 1 mL into eppie to
check concentration.
2) Check concentration with E 1% (see concentration protocol).
3) Check linearity (see kinetics protocol).
4) Protein is good for ∼3 weeks on the counter. Best to do all experiments as
soon as possible. Freeze leftover for experiments down the line.
5) ALL DONE WITH PROCESS!.
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Buffers for Fabricating and Purifying Proteins

94

2000

47

1000
70.5

23.5

500

1500

1 M K2 HPO4 (mL)

Volume (mL)

Sterile Filter when pouring into bottle

6

4.5

3

1.5

1 M KH2 PO4 (mL)

44.8

33.6

22.4

11.2

KCL (g)

200

150

100

50

Glycerol (mL)

50 mM Potassium Phosphate buffer @ pH 8.0 containing 300 mM KCl and 10% glycerol

ADSL Lysis Buffer

B.1.2
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1 M K2 HPO4 (mL)
15.4
30.8
46.2
61.6

Volume (mL)

500

1000

1500

2000

Sterile Filter when pouring into bottle

38.4

28.8

19.2

9.6

1 M KH2 PO4 (mL)

22.4

16.8

11.2

5.6

KCL (g)

200

150

100

50

Glycerol (mL)

2

1.5

1

.5

1 M DTT

4

3

2

1

.5 M EDTA

50 mM potassium phospate buffer @ pH7.0 containing 150 mM KCl, 1 mM DTT, 1 mM EDTA, and 10% glycerol

ADSL Enzyme Storage Buffer
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23.5
47

500

1000

3

1.5

1 M KH2 PO4 (mL)

22.4

11.2

KCL (g)

Volume (mL)
400
160

Final Concentration (mM)
20
250

pH with Phosphoric Acid.

40

8

1 M Imidazole (mL)

68.08

34.04

Imidazole (g)

120

392

ADSL Lysis Buffer (mL)

100

50

Glycerol (mL)

After dilution pH to 8.0. The total volume is optimal for one purification run.

20 and 250 mM Imidazole in ADSL buffer from 1 M stock

1 M K2 HPO4 (mL)

Volume (mL)

Sterile Filter when pouring into bottle

4 x stock of 250 mM, 50 x stock of 20 mM.

50 mM Potassium Phosphate buffer containing 300 mM KCl, 20 mM Imidazole and 10% glycerol

1 M Imidazole in ADSL Lysis Buffer
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1 M K2 HPO4 (mL)
23.5
47
70.5
94

Volume (mL)

500

1000

1500

2000

pH with Phosphoric Acid.

Sterile Filter when pouring into bottle

6

4.5

3

1.5

1 M KH2 PO4 (mL)

44.8

33.6

22.4

11.2

KCL (g)

200

150

100

50

Glycerol (mL)

2.72

2.04

1.36

.68

Imidazole (g)

50 mM Potassium Phosphate buffer @ pH 8.0 containing 300 mM KCl, 20 mM Imidazole and 10% glycerol

20 mM Imidazole in ADSL Lysis Buffer
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1 M K2 HPO4 (mL)
23.5
47
70.5
94

Volume (mL)

500

1000

1500

2000

pH with Phosphoric Acid.

Sterile Filter when pouring into bottle

6

4.5

3

1.5

1 M KH2 PO4 (mL)

44.8

33.6

22.4

11.2

KCL (g)

200

150

100

50

Glycerol (mL)

34.04

25.53

17.02

8.51

Imidazole (g)

50 mM Potassium Phosphate buffer @ pH 8.0 containing 300 mM KCl, 250 mM Imidazole and 10% glycerol

250 mM Imidazole in ADSL Lysis Buffer

B.1.3

Culture Solutions

LB
pH to 7.0

Volume (mL)

yeast (g)

peptone (g)

NaCl (g)

500

2.5

5

5

1000

5

10

10

1500

7.5

15

15

100 mM IPTG - Isopropl β-D-1-thiogalactopyranoside
Stuff that begins the over-expression of protein

IPTG (mg)

dH2 O (mL)

238

10

Antibiotics
34

Cm - Chloramphenicol

34 mg/mL solution in 70% ethanol
Store in eppies in -50 C freezer

Cm (mg)

70% Ethanol (mL)

170

5

340

10
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100

Amp - Ampicillin Sodium Salt

100 mg/mL solution in dH2 O
Store in eppies in -50 C freezer

Ap (g)

dH2 O (mL)

.5

5

1

10

B.1.4

Extra Solutions

DNase I
Dilute to 1 mg/mL with ADSL lysis buffer in bottle it came in. Store in -50
C freezer.

RNase A
Dilute to 10 mg/mL with ADSL lysis buffer in bottle it came in. Store in -50
C freezer.

0.5 M EDTA
Tricky to make. Dissolve given amount of EDTA with dH2 O (half total volume) first. Then add about 20 g NaOH per liter solution. Top off with dH2 O
and adjust pH, aim for 8.0.

220

Volume (mL)

EDTA (g)

NaOH (g)

500

93.05

10

1000

186.1

20

1 M DTT - Dithiothreitol

DTT (g)

dH2 O (mL)

1.54

10

B.2
B.2.1

Fabricating and Running SDS-Page Gels
Step by Step Instructions

Wear gloves while making and pouring gels and will need a camera
to take a photo of the resulting gel.
1) Compose gel molding device
Need
• large glass slide (check for previous gel residues)
• two spacers
• white divider
• white comb
• two large paper clamps
Make sure the mold is flush with the table!
2) Seal bottom of mold with agarose by pouring a straight line of agarose and
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placing the mold on top. Continue to seal with more agarose. Make sure the
white divider is on the right side when placing the mold on agarose.
3) Get out 10% Ammonium Persulfate to thaw or make fresh.
Mark glass with permanent marker at the same height as the top of the black
paper clamp.
4) Start mixing 12% resolving gel.
Using a transfer pipet, carefully run the resolving gel down one side of the
mold. Continue adding until the gel has reached the mark at the top of the
paper clamp. You may need to refill once or twice up to the mark.
Once completed, top off with .1% SDS of dH2 O to prevent oxidation. Let gel
polymerize for 30 min. Save excess gel in designated flask.
Note: The max amount you want to make at one time is 15 mL for two gels.
Otherwise the gel polymerizes before you can pour a third.
5) As the resolving gel cures, start making mixing the 5% stacking gel without
TEMED.
6) After 30 min. gently rinse out the gel mold with dH2 O. Will need to use
filter paper to soak up the excess water.
7) Place comb partially in one corner of the mold, leaving one side to pour
stacking gel.
8) Mix in TEMED, swirl around the solution and top off the gel mold. Smoothly
place comb into gel. If you do this carelessly, bubbles will form in the lanes.
The stacking gel takes 20 minutes to cure.
9) If do not need until gels until later: Wrap each mold in paper towels soaked
in 1 x Tris Glycine, then in seran wrap, and store in deli fridge overnight. On
day you need the gels, bring up to room temp before moving on.
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10) Get out SDS-Page Gel contraption and partially fill with 1 x Tris Glycine
Electrophoresis Buffer.
11) Place gels in the contraption securing it with the red clamps and mark the
center of the wells. It is easiest to do this with the comb still in. Then gently
take the comb out. Fill in wells with 1 x Tris Glycine Electrophoresis Buffer.
12) Start heating up the incubator and take out protein standards to thaw.
Fill eppies with 25 µL of SDS Buffer and 5 µL of the sample. Boil in water
bath for 3 min. Afterwards spin them down for 20 sec. May need to add 1 M
DTT (about 50 µL to SDS buffer.
13) Load outer wells with 10 µL of denatured standard. Load rest of lanes
with 10 µL of sample. Be sure to label in note book what sample goes in what
lane.
14) Let gel sit for ∼5 min after loading lanes. Then put on cover and attached
to voltage supply. Set voltage to 45 Volts. It takes ∼50 min for protein to run
through the stacking gel.
15) When protein has reached resolving gel, top off buffer in inner cavity if
needed. Crank voltage up to 80 Volts. It takes ∼1.5 hours to run through the
resolving gel. Make sure the protein runs all the way off the gel.
16) Carefully dismantle the gel apparatus, pry open the gel plates with a razor,
discard the stacking gel, cut the corner off of the top left and/or bottom left of
the resolving gel, remove the gel and place it in commassie blue stain solution.
Cover with seran wrap and place on teter-table set @ 3-4 overnight.
Note: Commassie blue staining solution is reusable up to 5 times.
Note: If do not want to wait overnight, stain for minimum of 2 hours.
17) Save what stain you can by pouring it into the beaker and mark that it
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has been used. Use a kimwipe to soak up extra stain. Set kimwipes in corners
to soak up destainer, put in enough destainer to cover the gel(s), recover with
seran wrap and put back on teter-table. Process takes ∼1.5 hours. You do
not want to destain to go too far, otherwise, you will not see any bands and
will have to restain. Check every 30 min.
18) Set on projector and take a picture.
19) Wrap in seran wrap, label with tape, and store in the deli fridge.
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B.2.2

Buffers & Gel Solutions

6% Resolving Gel
Component Volumes (mL)
Solution Components

5 mL

10 mL

15 mL

20 mL

dH2 O

2.6

5.3

7.9

10.6

30% Acrylamide Mix

1.0

2.0

3.0

4.0

1.5 M Tris (pH 8.8)

1.3

2.5

3.8

5.0

10% SDS

0.05

0.1

0.15

0.2

10% Ammonium Persulfate

0.05

0.1

0.15

0.2

TEMED

0.004

0.008

0.012

0.016

8% Resolving Gel
Component Volumes (mL)
Solution Components

5 mL

10 mL

15 mL

20 mL

dH2 O

2.3

4.6

6.9

9.3

30% Acrylamide Mix

1.3

2.7

4.0

5.3

1.5 M Tris (pH 8.8)

1.3

2.5

3.8

5.0

10% SDS

0.05

0.1

0.15

0.2

10% Ammonium Persulfate

0.05

0.1

0.15

0.2

TEMED

0.003

0.006

0.009

0.012
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10% Resolving Gel
Component Volumes (mL)
Solution Components

5 mL

10 mL

15 mL

20 mL

dH2 O

1.9

4.0

5.9

7.9

30% Acrylamide Mix

1.7

3.3

5.0

6.7

1.5 M Tris (pH 8.8)

1.3

2.5

3.8

5.0

10% SDS

0.05

0.1

0.15

0.2

10% Ammonium Persulfate

0.05

0.1

0.15

0.2

TEMED

0.002

0.004

0.006

0.008

12% Resolving Gel - used for hADSL Gels
Component Volumes (mL)
Solution Components

5 mL

10 mL

15 mL

20 mL

dH2 O

1.6

3.3

4.9

6.6

30% Acrylamide Mix

2.0

4.0

6.0

8.0

1.5 M Tris (pH 8.8)

1.3

2.5

3.8

5.0

10% SDS

0.05

0.1

0.15

0.2

10% Ammonium Persulfate

0.05

0.1

0.15

0.2

TEMED

0.002

0.004

0.006

0.008
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15% Resolving Gel
Component Volumes (mL)
Solution Components

5 mL

10 mL

15 mL

20 mL

dH2 O

1.1

2.3

3.4

4.6

30% Acrylamide Mix

2.5

5.0

7.5

10.0

1.5 M Tris (pH 8.8)

1.3

2.5

3.8

5.0

10% SDS

0.05

0.1

0.15

0.2

10% Ammonium Persulfate

0.05

0.1

0.15

0.2

TEMED

0.002

0.004

0.006

0.008

5% Stacking Gel
Component Volumes (mL)
Solution Components

1 mL

2 mL

3 mL

4 mL

dH2 O

0.68

1.4

2.1

2.7

30% Acrylamide Mix

0.17

0.33

0.5

0.67

1.0 M Tris (pH 6.8)

0.13

0.25

0.38

0.5

10% SDS

0.01

.02

0.03

0.04

10% Ammonium Persulfate

0.01

.02

0.03

0.04

TEMED

0.001

.002

0.003

0.004
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7.6
15.1
22.7

500

1000

1500

75

50

25

10% (w/v) SDS (mL)

10% SDS (mL)
2

dH2 O (mL)

5.5

.5

1

1 M Tris Gly Glycerol (mL)

1

Bromophenol Blue

50 mM Tris Cl, 100 mM DTT, 2% SDS, .1% Bromophenol Blue, 10% Glycerol

141

94

47

mM Glycine (pH 8.3) (g)

1 x SDS Gel Loading Buffer

Tris (g)

Volume (mL)

25 mM Tris, 250 mM Glycine, .1% SDS, pH 6.8

5 x Tris Glycine Electrophoresis Buffer
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1
.1

10%

1%

MetOH:dH2 O (1:1 v/v) (mL)
90
180

Coomassie Brilliant Blue R250 (g)
0.25
0.50

20

10

Glacial Acetic Acid (mL)

Careful with this, is will permanently stain clothes and turn hands blue for extended period of time

10

10

dH2 O (mL)

Coomassie Brilliant Blue R250

SDS (g)

Mass/Volume

Sodium Dodecyl Sulfate (SDS)

Destaining Solution
MetOH:dH2 O (1:1 v/v) (mL)

Glacial Acetic Acid (mL)

90

10

180

20

10% Ammonium Persulfate
dH2 O (mL)

Ammonium Persulfate (g)

10

1

Agarose Bed (2% Gel)
Bed for making SDS page gels
dH2 O

Agarose (g)

50

1

100

2

B.3
B.3.1

Enzyme Kinetics
Linearity

Need
• 200 µL and 10 µL pipets and tips
230

• 200 µL quartz cuvettes
• Range of .1, .2, .3, .4, .5 µg /mL ADSL
• 60 µM S-AMP, best to make fresh solution from 600 µM stock.
• 50 mM HEPES
• notebook and writing utensil

To check the linearity of the protein, run kinetics for 2 to 3 samples of each
ADSL dilution (see protocol below). Record change in absorbance over 1 min
period and in your lab notebook. Then transcribe the numbers into the ADSL
Characterization excel spread sheet for that mutant under the tab “Linearity”.
You should end up with a linear line. Print out graph and place in binder.

1) Make sure you have enough 60 µM S-AMP for at least 10 runs. Gather all
the needed materials and go to room 254 (Margittai and Pegan’s Lab or Dr.
Verl’s lab to use the Thermo UV Spec) and use the Varian UV/Vis Spec.
2) Turn on the Spec.
3) Open up software “kinetics” located in Cary folder on desktop.
4) Open up the method in Patterson folder for bulk runs.
5) Wash cuvettes 20 times prior to using.
6) Blank the spec with 50 mM HEPES. Keep for quality check run at beginning
and end of experiment.
8) Start run, save data in Patterson Lab folder, name data set (date, type,
linearity, ie: 042510 WT Linearity), press start until 2 min countdown starts.
9) Fill cuvette with 200 µL substrate.
10) Inject 2 µL of ADSL into the cuvette, pump once or twice, shake cuvette
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3 - 5 times to mix and place in the UV spec (cell #1 if using the cell changer),
make sure you press the cuvette all the way down. Close the chamber and
press enter for the reading to start.
11) While the sample is reading, wash any previously used cuvette.
12) Linear regression data should show up. Record the slope in notebook.
13) Remove sample (may have to use cuvette remover if cell changer platform
is in spec).
14) The next sample run will pop up on the screen.
15) Repeat steps 9 - 13 until finished.

B.3.2

Running Enzyme Kinetics

• 200 µL and 10 µL pipets and tips
• 200 µL quartz cuvettes
• ∼250 µg /mL ADSL
• 1 mL of 1, 2, 3, 4, 6, 7.5, and 10 µM S-AMP and/or SAICAR in 50 mM
HEPES
• 50 mM HEPES
• parafilm
• notebook and writing utensil
• USB

To check the kinetic behavior (cooperativity, K0.5 ) of ADSL toward either SAMP or SAICAR, run 3 samples of each S-AMP or SAICAR dilution (see
protocol below). Because the graph will not be linear over one minute, the
analysis of Vo is more complicated. Raw data will need to be saved individually
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as a .csv file and uploaded on Mathematica “Hill Plot Template”. Instructions
for uploading data onto the template are written in the mathematica file.

1) Make sure you have enough substrate for at least 3 runs each. Gather all
the needed materials and go to room 254 (Margittai and Pegan’s Lab or Dr.
Verl’s lab to use the Thermo UV Spec) and use the Varian UV/Vis Spec.
2) Turn on the Spec. If doing thermal stability, make sure cell changer is in
place and turn on temp control.
3) Open up software “kinetics” located in Cary folder on Desktop.
4) Open up the method in Patterson folder for single runs. This automatically
saves data in .csv form.
5) Wash cuvettes 20 times prior to running an experiment.
6) Blank the spec with 50 mM HEPES.
8) Start run, save data in Patterson Lab folder, name sample (date, type,
substrate, concentration, run ie:122510WTSAMP1i), press start until 2 min
countdown starts.
9) Fill cuvette with 200 µL substrate.
10) Inject 2 µL of ADSL into the cuvette, pump once or twice, shake cuvette
3 - 5 times to mix and place in the UV spec (cell #1 if using the cell changer),
make sure you press the cuvette all the way down. Close the chamber and
press enter for the reading to start.
11) While the sample is reading, wash any previously used cuvette.
12) Remove sample (may have to use cuvette remover if cell changer platform
is in spec).
13) Repeat steps 8 - 12 until finished.
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14) Save data on USB drive and then start transferring data to mathematica
template.

B.3.3

Mathematica Templates

Calculating Vo
(*User input, sets the directory*)

SetDirectory[”/Users/Stephen/Documents/research/DU/ADSLProject/
ADSLkineticsdata/012512/SAMP”];

(*User input*)

concentration = 0.15;(*concentration of enzyme used in experiment in mg/mL.*)

injvol = .01;(*Volume of injected enzyme for .2 and 1 mL substrate volumes.*)

mg = concentration*injvol;(*Amount of milligrams enzyme used during experiment for .2 and 1 mL substrate volumes.*)

mL = 1;(*Substrate volume used for 60 micromolar concentraion to preserve
sample. This produces data identical to 1 mL samples*)

[Epsilon] = 10000;(*Extinction coefficient () in M−1 cm−1 *)
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start = 9;(*the cell in the csv file that the data starts in*)

freq = 460; (*number of data points taken in 1 minute - 60 divided by time
interval in seconds*)

n = 3; (*Number of trials per concentration*)

1 µM SAMP

Trial 1

Clear[data,datum,a,b,∆A,lastpoint,V1,V2,V3]

data=Take[Import[”012512RHSAMP1i.csv”],start,.5*freq];
ListPlot[data]
lastpoint=.1;

datum= Take[data,1,lastpoint*freq];

a=LinearModelFit[datum,x,x];
a[”ParameterTable”,”RSquared”]
b=Plot[a[x],x,0,lastpoint];

Show[ListPlot[datum],b]
∆A=(a[0]-a[lastpoint])*(1/lastpoint);
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V1=(∆A*mL)/(*1000*mg)
Trial 2
data=Take[Import[”012512RHSAMP1ii.csv”],start,.5*freq];
ListPlot[data]
lastpoint=.1;

datum= Take[data,1,lastpoint*freq];

a=LinearModelFit[datum,x,x];
a[”ParameterTable”,”RSquared”]
b=Plot[a[x],x,0,lastpoint];

Show[ListPlot[datum],b]
∆A=(a[0]-a[lastpoint])*(1/lastpoint);
V2=(∆A*mL)/(*1000*mg)
Trial 3
data=Take[Import[”012512RHSAMP1iii.csv”],start,.5*freq];
ListPlot[data]
lastpoint=.1;

datum= Take[data,1,lastpoint*freq];

a=LinearModelFit[datum,x,x];
a[”ParameterTable”,”RSquared”]
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b=Plot[a[x],x,0,lastpoint];

Show[ListPlot[datum],b]
∆A=(a[0]-a[lastpoint])*(1/lastpoint);
V3=(∆A*mL)/(*1000*mg)
Average Subscript[V, 0]
Mean[V1,V2,V3]
StandardDeviation[V1,V2,V3]
√
SE= %/ n

B.3.4

Creating the Hill Plot

Clear[activity,model,bestfit,Hill,V,k,n];

(*Add on package that the fit needs*)
Needs[”PlotLegends‘”]
Needs[”ErrorBarPlots‘”]

(*User input; put in data from KineticsVoTemplate.nb*)
activity=1,1.49,2,4.26,3,4.73,4,5.60,6,6.23,7.5,6.49,10,5.61,60,6.52;

(*Model to fit Hill Plot*)
model=((V*xn )/(kn +xn ));
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(*User input; The fit is sensitive to to the max hill coefficient. If it is too high,
it won’t fit properly. So you will need to adjust the number accordingly*)
Hill=8;

(*Creates a best fit*)
bestfit=NonlinearModelFit[activity,model,V≥0,k≥0,Hill≥n≥0,V,k,n,x];

(*Creates a table of V, k, and n with standard error*)
bestfit[”ParameterTable”,”RSquared”]
(*User input; put in numbers from the above tables, V is max activity in
µmol/min/mg, k is suppose to be K0.5 in units of micromols, but it doesn’t
work out that way so have to solve for that seperately, n is the Hill Coefficient.
*)
Vmax =6.31158;
k=1.59736;
n=2.28658;

(*Defines the Hill equation with the above numbers*)
fit=((Vmax *Sn )/(kn +Sn ));

(*Solves for K0.5 , concentration where half the Vmax is reached, which is defined as S in the above equation b/c K0.5 wouldn’t work as a parameter*)
sol=Solve[fit==Vmax /2,S];
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(*Renames the answer to previous equation, the 10−6 explicitly puts answer
in micromols*)
K0.5 =(S/.sol[[1]])*10−6 ;

(*Gives all the parameters from the Hill Equation*)
Vmax ,K0.5 ,n
(*Standard Deviations of average Subscript[v, 0]*)
error1=ErrorBar[0.07];
error2=ErrorBar[0.13];
error3=ErrorBar[0.04];
error4=ErrorBar[0.25];
error6=ErrorBar[0.11];
error8=ErrorBar[0.09];
error10=ErrorBar[0.05];
error60=ErrorBar[0.05];

(*Creates a list plot from the activity data. Will have to input Subscript[V,
0] again*)
data=ErrorListPlot[1,1.49,error1,
2,4.26,error2,
3,4.73,error3,
4,5.60,error4,
6,6.23,error6,
7.5,6.49,error8,
10,5.61,error10,
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60,6.52,error60,
PlotStyle-¿Thickness[0.005],PointSize[0.012],Orange];

(*Plots the activity data and the best Hill fit together*)
Show[
Plot[fit,S,0,10,PlotStyle→Black,Thickness[0.005]],
Plot[fit,S,0,60,PlotStyle→Black,Thickness[0.005]],
data,
ListPlot[activity,PlotStyle→PointSize[0.012],Red],
Frame→True,
FrameStyle→Thick,
FrameTicks→0,10,20,30,40,50,60,0,1,3,5,7,,,
FrameLabel→”Specific Activity (µmol/min/mg)”,” ”,”SAICAR (µM)”,” ”,
LabelStyle→FontSize-¿32,
PlotRange→0,60,0,7,
AxesOrigin→Automatic]

Show[
Plot[fit,S,0,10,PlotStyle→Black,Thickness[0.005]],
data,
ListPlot[activity,PlotStyle→PointSize[0.012],Red],
Frame→True,
FrameStyle→Thick,
FrameTicks→0,10,20,30,40,50,60,0,1,3,5,7,,,
FrameLabel→”Specific Activity (µmol/min/mg)”,” ”,”SAICAR (µM)”,” ”,
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LabelStyle→FontSize→32,
PlotRange→0,10,0,7,
AxesOrigin→Automatic]
Calculating kcat and enzyme efficiency
(*User input; concentration of enzyme used in mg/mL*)
conc=.15;

B.3.5

Calculating kcat

(*User input; volume of enzyme used in the reaction in liters*)
L=2*10−6 ;

(*Tetramer weight in Daltons*)
Da=228000;

(*Seconds in a minute*)
sec=60;

(*Amount of enzyme used in mg*)
mg=(conc*L)/1000;

(*Calculates kcat in sec−1 *)
kcat =(Vmax *Da*mg)/(conc*L*sec)

241

(*Calculates the Efficiency in M−1 sec−1 . 108 -109 are the diffusion limit.*)
Efficiency=kcat /K0.5
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Solutions

dH2 O (mL)
25
50
70
100

HEPES (g)

0.30

0.60

0.84

1.2

Solution will initially have pH ∼4.3. Adjust to pH 7.4 with NaOH

50 mM HEPES

B.3.6

244
45

9

1

5

50 mM HEPES (mL)

600 µM S-AMP (mL)

For 60 µM S-AMP for Linearity

Store any extra substrate by aliquotting 1.05 mL in eppies and freeze unused aliquots of S-AMP

Dilute 1 mL 6 mM S-AMP in 9 mL 50 mM HEPES for final concentration of 600 µM S-AMP

Initially Dilute 25 mg S-AMP in bottle with 9 mL 50 mM HEPES for 6 mM S-AMP.

S-AMP
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10
10

4

3

10

60

6

1

60

7.5

10

60

10

2

S-AMP for Dilution (µM)

Final S-AMP (µM)

Dilutions for Kinetics

0.1

0.2

0.3

0.4

0.1

0.1

0.3

S-AMP (mL)

0.9

0.8

0.7

0.6

0.9

0.7

1.5

50 mM HEPES (mL)

B.4
B.4.1

Fabricating and Purifying SAICAR
Day to Day Details

Day 1
1) Day prior to starting process, turn on water bath to 37 C.
2) Remove purified ADSL from -80 C freezer and allow to warm up to room
temp (∼30 min)
3) Turn on Hot Plate, set temp to 100 C.
4) Set up reaction mixture by dilution AICAR 1:5 in SAICAR Synthesis Buffer
5) Place unmixed aliquots of ADSL enzyme and reagents in 37 C incubator
for 30 min prior to addition of ADSL to reaction mixture.
6) Add 12 µg of purified ADSL to reaction mixture and invert tube 3-4 times
to mix.
7) Immediately take a sample for the analysis by Bratton-Marshall reaction
and place tube in 37 C water bath. Start Time.
8) Get out TLC plates and pre-develop them with dH2 O. You will see a
yellowish line close to the solvent front. When they’re done, Store standing
up on the counter over night.
9) At 4 hr, Pre-run Amicon Ultra with 10,000 MWCO and spin for 30 min at
3,000 g with 10 mM Tris.
10) At 5 hr, take a sample for analysis by Bratton-Marshall reaction.
11) Add reaction mixture to Amicon Ultra and spin for 10-20 min at 3,000 g
to remove enzyme (keep the filtrate, discard the retentate). Note the volume
of retentate and filtrate as these will influence the final yield. Use either our
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centrifuge or the one in room 254 (Margittai and Pegan Lab).
12) Spin filtrate in speed vac with heater “off” to reduce total volume to about
400 µL. This takes a fair amount of time.
13) Once total volume is reduced, store in -80 C freezer for tomorrow.

Day 2
1) Set up spotting station with TLC plates, hairdryer, seran wrap, tape, and
25 µL capillary tubes.
2) Prior to spotting, draw a straight line with a pencil ∼3 cm from the bottom
of a plate to mark the start of the chromatographic separation for calculation
of RF values.
3) Spot 200 µL of reaction onto the TLC plates.
4) Fill developing tank with 200 mL 1 M ammonium acetate or 0.8 M lithium
chloride.
5) Load plates into developing tank and develop until they are 1 in from the
previous developing front.
6) Remove plates from tank and allow them to dry vertically.
7) Visualize spots onTLC plates using hand-held UV lamp located in same
drawer as tube holders. Mark location of the solvent front, SAICAR, AICAR,
and fumarate with a small tick mark on the side of the TLC plates.
8) Using the distance from the starting line to the locations, calculate RF values using the ratio of the distance traveled by the substrates and the solvent
front.
9) Using a clean razor blade, scrape SAICAR from the TLC plates into
OakRidge tubes (located on top of the incubator).
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10) Elute SAICAR from the cellulose with a total volume of 10 mL 1 N NH4 OH.
11) Remove cellulose by centrifugation in SS34 rotor in Sorvall for 30 min at
16,000 rpm (30,000 g) at 4 C.
12) Remove supernatant from cellulose pellet and discard pellet. Prepare 1
mL aliquots in 1.7 ml eppies.
13) Reduce volume by 5 - 10 fold in speed vac with heater “off”. Combine
remaining liquid in 1 or 2 eppies.
14) Remove samples for HPLC or Bratton-Marshall and store SAICAR at -80
C.

B.5
B.5.1

Determining Protein Concentration
E 1% = 7.7

This is what Roberta Colman uses for her reserach

1) Take .5 mL from stock protein and put in eppie.
2) Make serial dilutions up to 1:16 in enzyme storage buffer.
3) Find ABS at λ = 280 nm.
4) A solution of 1 mg/mL has an ABS of 0.77. Use ratio
1(mg/mL)
0.77

=

unknownconcentration(mg/mL)
measuredABS∗dilutionf actor

to find concentration of protein.
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B.5.2

Bio-Rad Assay

1) Make needed amount of 1 x Bio-Rad Dye. Will need 1 mL per sample plus
the blank.
2) Check if have 0.2 to 1.0 mg/mL dilutions of BSA to use as standards. If
not, see below for recipe.
3) Dilute ADSL to be in the range 0.2 to 1.0 mg/mL. If concentration is unknown, make serial dilutions from 1:2 to 1:8.
4) Add 980 µL of 1 x Dye to acrylic cuvettes.
5) Add 20 µL of standard or unknown ADSL, invert cuvette 3 times and incubate at room temp for 5 - 10 min.
6) Record Abs at λ= 595 nm for each sample. Blank with 1 mL 1 x Dye.
7) Record the data in Bio-Rad template in excel to make the standard curve
and calculate ADSL concentration.

BSA Standards
Dilute 100 mg BSA in 10 mL dH2 O
Final Concentration BSA (mg/mL)

BSA @ 10 mg/mL (µL)

dH2 O (µL)

0.2

20

980

0.4

40

960

0.6

60

940

0.8

80

920

1.0

100

900
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B.5.3

260-280 nm Concentration Formula

1) Fill cuvette with 2 mL Enzyme Storage buffer and place in position 1 of
UV-Vis to use as blank.
2) Make dilution of ADSL to ∼.5 mg/mL in cuvette. If unsure of concentration, or just purified ADSL, dilutions of 1:20 to 1:40 will work. Reocrd
Dilution Factor (D.F.) in printed out template.
3) Fill Positions 2 - 6 with ADSL protein as needed.
4) Blank UV-Vis at λ= 280 nm and record ADSL Abs in template.
5) Repeat for λ= 260 nm.
6) Using formula, calculate protein concentration.

Formula
ADSL [ ] (mg/mL) = (1.55×Abs280 - 0.76×Abs260 )×Dilution

B.6

How to Use the Static Light Scattering
Instrument

B.6.1

Setting Up and Running Experiments

What you need to know about your sample and mobile phase
Sample
1) Concentration in g mL−1 .
2) UV Extinction Coefficient in mol g−1 cm−1 .
3) dn/dc value. For proteins, the default value is .185.
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Mobile Phase
1) Refractive Index. If you don’t know this, there is a way to experimentally
find it. See section below that describes how to do it.

Setting up Instrument for SEC-MALS
1) Turn on the HPLC and Static Light Scattering (SLS) instruments
2) Open the HPLC and SLS software (EZStart 7.4 SP3 and ASTRA)
3) In the HPLC software, open the method “PattersonLabSECMALS” by File
→ Method → Open → PattersonLabSECMALS.
4) Change the flow rate to 0 mL/min and push “download method”. Check
to make sure the HPLC now reads 0 mL/min.
5) Connect the size injector loop you will use. Typically the 100 µL loop is
used, but smaller loops can be used. Push the injector knob down.
6) Connect the SLS to the HPLC by the two tubes located on the right side
of the HPLC. The tube with the blue stripe goes to the “Out” and the other
tube goes to the “In”. The “In” and “Out” ports of the SLS are located on
the left side of the instrument behind a door. You will need to remove two
screws before attaching the tubes.
7) Attach the column you will use to the HPLC. There are two ways to do this:
i) If you do not need to use the oven, attached the column on the left side of
the HPLC using valves 1 ii) if you do need to use the oven, attach the column
inside the oven using valves 3. The default for the method is valves 1, if you
use ii) you will have to change the valves on the software under the “Oven”
tab. When attaching the tubes to the column, make sure the mobile phase
flows in the correct direction. The left main valve is where the flow originates.
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8) Equilibrate the column by following these steps...
• Note, when changing the flowrate on the column, always to it gradually
by increasing the flowrate through the column in increments of 0.25 mL/min
using the method “outlined” in 4). This is to prevent disturbing the resin at
the top of the column by suddenly increasing the flowrate.
• First wash the column with 5 column volumes of dH2 O at 1 mL/min.
• Before switching mobile phase, check for leaks.
• Equilibrate the column with the mobile phase for the experiment. It is best
to use 15 - 20 column volumes to equilibrate the column.
• Things to keep in mind when equilibrating the column.
i) Flowrate and pressure limitation of the column.
ii) If it is ok to use your mobile phase on the column.
iii) Molecular weight range of the column.
iv) Since it takes a long time to equilibrate the column, it is best to do it
overnight.
v) Make sure you have enough buffer to equilibrate and run experiments. If
the column runs dry, you will be held responsible.
• After the column in equilibrated, you are ready to run a sample.
9) If you are using the oven, set the temperature in the HPLC software. Do
this by going to the “Oven” tab, clicking the  next to “Enable Oven”, set
the oven temperature, and push “Download Method”. It is best and easiest to
equilibrate the column with mobile phase and temperature at the same time.
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Running a Sample
Setting up the Software
EZStart
1) Under “Pumps”, set the flow rate to your desired value.
2) Under “Time Program”, change the ending controller time to the length
you need for the experimental run.
3) Under “Column Info”, the Wyatt Tech. Co. column info is the default.
Change values you need to change.
4) Hit B, name the run, hit start. The orange bar should eventually turn
purple, which means the software is waiting the auto-inject signal.

ASTRA
• Whenever you want to close a window in ASTRA, click the “OK” button at
the bottom of the window. This action should be taken every time you open
something and change it. For example, see step 5)
1) File → New → Experiment from Template.
2) This should take you to the default folder “My Templates”. Choose the
“PattersonLabSECMALS” template.
3) A new experiment will appear on the left hand side of the software.
4) Click on the + next to “Configuration”. Then click on the + next to
“Generic Pump” and “Injector”.
5) Double Click (DC) Generic Pump and change the flowrate to match the
HPLC flowrate for the experiment.
6) DC Solvent and enter your values. If you have a well known buffer (ie:
PBS), you can load its values by clicking on “...” and choose the solution you
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have. If you don’t know the refractive index and your buffer isn’t included in
the list provided by ASTRA, you will have to experimentally find it by using
BSA. To change the Refractive Index, press the + next to “Refractive Index
Model” and put in your value.
7) DC “Injector” and change the injector volume to the volume of solution
you inject.
8) DC “Sample” and change the name of sample, dn/dc (if you’re not using
a protein b/c the dn/dc value of proteins is .185), UV Extinction Coefficient,
and concentration.
9) Click the + next to “Procedures”. DC Basic Collection and change duration
if needed. Hit B to start a run. You should see “Waiting for Auto-Inject” on
the graph.

Loading a Sample
1) Make sure the injector knob is in the load position.
2) Load the appropriate amount into the injector. A good general rule would
be to inject 150% of the injector loop volume that way you will saturate the
loop with sample.
3) Press the injector knob down to inject the loop and start the run.
• Things to think about when running a sample.
i) It is always a good idea for the 1st run to be a blank of the mobile phase,
and the 2nd run to be a well known standard like BSA. That way you will
know if the injected mobile phase causes any UV or SLS signal and you will
know if the setup is working properly if the standard come out correct.
ii) You will need at least 10 min. of baseline after the last peak.
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Analyzing Data
1) See section 7 of the ASTRA manual.
2) Do not forget to save your experiment.
Running another Sample
1) Start on 4) in EZStart. You may have to hit the stop button to stop the
current run.
2) Start on 1) in ASTRA.
3) Start on 1) in Loading a Sample.
4) Analyze your data.
5) Go through steps 1- 4 above until you are all done with your samples.
Dismantling SEC-MALS
Cleaning the Column
1) Bring the flow to a stop.
2) Reverse the column direction so the flow is now backwards.
3) Clean the column with .2 M KCl @ pH ∼3. running @ 0.25 mL/min
4) Cleaning will take 10 to 15 column volumes.
5)While cleaning the column, go to the SLS and, on the interface of the instrument, press the “Tab” button until the laser is selected, press enter. This
will turn off the laser. Press “Tab” until the comet is selected, press enter.
This will turn on a vibrating mechanism to sonicate the flowcell.
6) After 10 to 15 column volumes, turn off the comet.
7) Bring the flow to a stop.
8) Orient the column so the flow is in the correct direction.
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9) Flow 5 column volumes of dH2 O .
10) Flow 5 column volumes of 20% Ethanol.
11) Stop flow and take off column. Place the plugs back and put away in its
box.
12) Reconnect the two tubes with a union.
Tidy Up
1) Disconnect the SLS and reconnect the two tubes with a union.
2) Turn off the SLS and HPLC.
3) Shut down the EZStart software.
4) Once you are down analyzing and saving your data, turn off the ASTRA
software.
5) Clean up any mess you created while using the SLS.

Find RI value for your running buffer
1) Equilibrate your column with your mobile phase.
2) Run a 100 µL sample of 2 mg/mL BSA.
3) When analyzing your data, fit all the peaks and look at the Mw . Adjust
the RI value under “Solvent” until the Mw value is close to 66 kDa. This is
your approximate RI value for your running buffer.

Advantages of SLS
1) Relatively quick to run samples - 40 to 90 minutes.
2) Detailed molecular weight and radius values.
3) Can easily look at species distribution (or stoichiometry).
4) Can use a very small amount of sample (100 µL) as long as the concentration
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is enough to generate a light scattering signal.
)The other main alternatives are Analytical Ultracentrifugation (AUC) or SDS
Gels. AUC is expensive and takes at least 5 hours to run the sample plus 3
hours of sample cell preperation. The analysis of data in non-trivial and can
give different results depending on the model you are fitting the data to. SDS
works well, but doesn’t provide near the amount of detailed information SLS
can.

Limitations of SLS
1) Particle radius must 10 nm particles to be detected.
2) Molecular weight for all peaks are averages. Therefore the better SEC you
have, the better your results.

B.7

Computer Lab Tips

For running the code to predict the folding pathway of ADSL, I used the
computer lab located in the physics building room 118. I found certain peculiarities with using these computers, namely that they “reset” the hard drive
every night so if the code needed to run longer than 24 hours, I could not
use the computers. The computers did not have a scheduled “reset” on the
hard drive, therefore I thought unplugging the ethernet cord would prevent
them from “resetting”. This gave me the intended result. However, since I
used Mathematica, the license requires the computer to be connected to the
DU network in order for Mathematica to work. So, it is possible to start the
Mathematica kernel while the ethernet cord is connected, disconnect it late at
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night so the computer does not “reset” causing you to lose all of the computations, and come back in the morning to reconnect the ethernet. Now, all of
this being said, I think it would be much simpler to use MatLab for multiple
reasons. It does not need to be connected to the DU network, therefore you
can run it overnight with the network disconnected. Mathematica is also a
memory hog for larger computations. It seems to store past solutions. So, all
this being said, I would just use MatLab or learn how to use the cluster.
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